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Abstract of Dissertation
PLATELET ENDOCYTOSIS: ROLES IN HEMOSTASIS AND INNATE IMMUNITY
Endocytosis is key to fibrinogen (Fg) uptake, receptor trafficking of integrins
(αIIbβ3, αvβ3) and purinergic receptors (P2Y1, P2Y12), and thereby for normal platelet
function. However, platelet endocytosis could potentially be critical for actively sensing
changes in vascular microenvironments and responding accordingly to what is being
taken up. This is a more dynamic view of platelets as active surveyors of the vasculature;
extending the importance of platelet endocytosis beyond granule biogenesis and
perhaps even hemostasis. The mechanistic underpinnings of endocytosis, its importance
in platelets, and the molecular machinery required and possible trafficking routes are
however understudied, in part due to a lack of experimental tools. The work presented
here, puts forth new players that regulate platelet endocytosis and mediate cargo
loading and hemostasis as well as provides a novel mechanistic understanding of how
endocytosis allows platelets to act as immune cells and become the first responders to
pathogens in the vasculature.
Previously we showed the importance of ADP-ribosylation factor 6 (Arf6), which
regulates αIIbβ3-mediated Fg uptake/storage and affects acute platelet functions e.g.,
clot retraction and spreading. To further identify elements of this endocytic machinery,
we examined the role of a vesicle-residing Soluble N-ethylmaleimide Factor Attachment
Protein Receptor (v-SNARE) called Cellubrevin/Vesicle-Associated Membrane Protein-3
(VAMP-3) in platelet function. VAMP-3 KO mice had less platelet-associated Fg,
indicating a defect in Fg uptake/storage. Loss of VAMP-3 led to a defective uptake of
fluorescently-tagged Fg and low molecular dextran in platelets though it had a greater
negative effect on receptor-mediated Fg uptake than on the fluid-phase marker uptake.
Additionally, we followed the time-dependent trafficking of Fg and dextran into
platelets using 3D-Structured Illumination Microscopy. Wild-type platelets endocytosed
both cargoes but quickly sorted them into distinct compartments with partial overlap
occurring only at early time points. Sorting was unaffected in VAMP-3 KO platelets. The
VAMP-3 loss did affect some acute platelet functions leading to enhanced spreading on

Fg and faster clot retraction compared to wild-type. Additionally, the rate of JAK2
phosphorylation, initiated through the thrombopoietin receptor (TPOR/Mpl) activation,
was affected in VAMP-3 KO platelets.
The idea that platelets can act as immune cells and contribute to innate
immunity

has

been

increasingly

gaining

ground.

Groups

have

correlated

thrombocytopenia with clinical outcomes of viremia and bacteremia. Chronic viral
infections, e.g., HIV-1, severely increase the risk of acute myocardial infarction (MI),
possibly via some level of platelet activation, contributing to increased thrombotic
potential. Platelets do endocytose viruses and bacteria, but the molecular machinery is
ill-defined. In nucleated cells, responses to HIV-1 are mediated by virus
phagocytosis/endocytosis, degradation to release Toll-like Receptor ligands, and
subsequent receptor activation. Is this process recapitulated in platelets? Here we show
that platelets indeed use VAMP-3 and Arf6-dependent pathways to endocytose HIV-1
virions, degrade retroviral particles to release TLR ligands, which initiate platelet
activation and secretion. HIV-1 uptake and subsequent activation is abolished in VAMP3 and Arf6 KO mice.
Collectively, our studies shed light on how platelets act at the early stage of
pathogen recognition and are able to process them to initiate an immune response.
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Chapter One: Introduction
Subsection One: Platelets and their roles
Platelet biology overview
While Max Schultze, in 1865, and William Osler, in 1874, were the first to discover
platelets as a “normal constituent of blood”, it was Giulio Bizzozero in 1882, who
first coined the term “blood plates” to describe platelets as “morphological elements
of blood” important for their roles in coagulation and thrombosis [1]. Mammalian
platelets are small (~2-3 µM in diameter), anucleate, circulatory cell fragments that
are derived from the cytoplasm of megakaryocytes, the only polyploid
hematopoietic cell within the bone marrow. They are the smallest blood cells and
are second only to erythrocytes in number, ranging from 150,000-450,000
platelets/µL of blood, making them the most abundant “responsive” cell type in the
bloodstream due to their ability to respond to various kinds of damage in the
circulation. The primary physiological role of platelets is to sense vascular damage
and seal the breach in the vessel endothelium to prevent blood leaks by initiating
hemostasis. Upon vascular injury, circulating platelets get exposed to collagen or
other extracellular matrix (ECM) proteins and become activated upon binding via
their myriad surface receptors and adhere to the site of injury. This resulting
activation leads to increases in cytosolic [Ca2+] levels followed by shape change
culminating into secretion from the intracellular granule stores, leading to further
platelet recruitment and activation, eventually forming the so-called “platelet plug”
at the site of injury. This, in conjunction with the activation of the coagulation
cascade and thrombin generation which converts fibrinogen to fibrin, allows
platelets to form a fibrinous thrombus which arrests blood loss. As such, platelets,
their activation and secretion, are essential for thrombosis and hemostasis. A
growing body of evidence now suggests that platelet functions extend beyond
hemostasis and thrombosis including promoting inflammatory and immune
responses [2], maintaining vascular integrity [3] and contributing to wound healing
[4]. Additionally, platelets have also been shown to contribute to pathophysiological
conditions such as atherosclerosis [5, 6], ischemic cerebrovascular diseases [7], and
angiogenesis [8-10] as well as cancer and tumor metastasis [11-13]. Platelets have a
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diverse array of granule cargo as well as several unique receptors that enable them
to oversee the aforementioned functions in health and disease. While exocytosis of
vesicular (from granules and compartments) cargo is central to a majority of platelet
functions, endocytosis of circulating exogenous cargo also occurs in platelets and is
vital to at least some functions. As vascular sentries, platelets constantly sample the
bloodstream contents and this surveillance mechanism could be mediated by
endocytosis. Uptake of small particles and solutes by human platelets was first
reported by Zucker-Franklin in 1981 [14] into a unique membrane structure called
the open canalicular system (OCS) by a phagocytosis-like process. Further studies
using electron microscopy and cytochemistry provide evidence for endocytosis of
circulating proteins such as plasma fibrinogen [15, 16] into platelets. Platelet
endocytosis is important for granule cargo loading (such as fibrinogen and VEGF) [9,
17] and contributes to thrombus formation by controlling the surface expression of
several key proteins such as the integrins, chiefly αIIbβ3, the major platelet
glycoprotein receptor [18]. Integrin trafficking modulates platelet spreading on
endothelial surfaces and clot retraction [19]. Endocytosis of purinergic receptors
such as P2Y1 and P2Y12 mediates their resensitization and response to ADP [20].
CLEC-2 and Thrombopoietin receptor (Mpl/TPOR) endocytosis regulates their surface
levels and downstream signaling responses [21, 22].
Clearly, platelets are far more multi-functional than we give them credit for. For
normal physiological responses, it is imperative for both arms of membrane
trafficking, exocytosis, and endocytosis, to occur under tight regulation. Disruption in
any of these processes leads to severe platelet dysfunction. Hyperactive platelets
cause spurious thrombosis which precipitates occlusive events such as heart attack
and stroke, which collectively accounts for 1 in 3 deaths from non-communicable
diseases, worldwide (World Health Organization, 2012 statistics). Hypoactive
platelets or platelets from patients suffering from granule biogenesis disorders have
a bleeding diathesis [23]. Thus, regulating platelet functions is crucial to developing
therapeutics to prevent cardiovascular diseases (CVD). While targeting platelet
activation and exocytosis remains the cornerstone for developing anti-platelet drugs,
understanding the mechanisms of platelet endocytosis enables us with an
2

alternative approach to load platelets with therapeutics that can then modulate
platelet responses paving the way to effectively treat cardiovascular diseases.
Platelet structures
Platelets are formed from the cytoplasm of megakaryocytes (MKs), their large
precursor cells, in the bone marrow [24]. MKs release platelets through a multi-step
and tightly regulated process involving the complex interplay of transcription factors,
signaling regulators, extensive cytoskeletal rearrangements and the bone marrow
microenvironment [25]. MKs become polyploid by endomitosis and undergoes
maturation wherein their cytoplasm gets packaged into long pseudopodial
projections, termed proplatelets [26]. Platelets form selectively at the tip of the
proplatelets and derive granule and organelle content from the MK cell body [27].
Once the proplatelets extend into sinusoidal blood vessels, they undergo fission to
release platelets into the circulation. Each megakaryocyte produces 5000-10,000
platelets. While the process of platelet production appears to be similar in mice and
humans, human platelets have a lifespan of 10 days while mouse platelets survive
for 4-5 days [28]. Mouse platelets are similar to human platelets, but they are
smaller in size (mean platelet volume ~4.7 vs. ~7.5-10 fl) and more numerous (~1.1 X
106/µL of blood) [28, 29].
In the quiescent state (see adjoining figure), platelets are a discoid shape with
smooth surfaces. Microtubules, located beneath the cell membrane of resting
platelets, together with the actin cytoskeleton, help in maintaining this discoid shape
[30, 31]. Anucleate platelets chiefly contain three major kinds of granules; dense
core granules, alpha granules, and lysosomes. These granule stores contain a
multitude of different kinds of cargo molecules that form the bulk of the platelet
secretome, upon release. Alpha granules are the largest and most abundant
secretory granule in platelets and based on electron microscopy of platelet thin
sections; there are 50-80 of these per platelet with a diameter of 200-500 nm [3235]. Alpha granules contain bioactive molecules such as growth factors (e.g. PlateletDerived

Growth

Factor

(PDGF),

Transforming

Growth

Factor

β

(TGFβ),

Thrombopoietin (TPO) etc.), chemokines (e.g. Platelet Factor 4(PF4), Regulated on
activation, normal T cell expressed and secreted (RANTES) etc.), various pro- (e.g.
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Vascular Endothelial Growth Factor (VEGF)) and anti-angiogenic molecules (e.g.
Endostatin), adhesion molecules (e.g. von Willebrand factor (vWF), P-Selectin) and
coagulation factors (e.g. fibrinogen). Some of these cargo molecules such as vWF,
PF4, and P-Selectin, a granule membrane protein, are synthesized in the
megakaryocytes while cargo molecules such as fibrinogen are endocytosed via the
αIIbβ3 integrins [17]. Some alpha granules and their precursor multivesicular bodies
(MVBs), which are present in platelets [41, 42], contain small vesicles called
exosomes, that are about 40-200 nm in range and are released upon exocytosis [36].
Dense core granules number around 5-8 per platelet [37] and contain small
molecules such as calcium, serotonin, ADP, and ATP, etc. Lysosomes are another
type of secretory granule in platelets. Though largely considered as degradative
compartments, yet there exists strong evidence suggesting the release of cargo upon
platelet activation both in vitro and in vivo [38, 39]. Platelets contain only a few
lysosomes (~2-3) [40] which contain degradative enzymes, including βhexosaminidase, cathepsins D and E, and acid hydrolases [43-45]. Platelets also
contain the lysosomal membrane proteins LAMP1, LAMP-2, and CD63 (LAMP-3) [46].
Additionally, platelets contain mitochondria as well as other organelles such as
Endoplasmic Reticulum (ER), an ER-derivative dense tubular system (DTS) and Golgi
Apparatus [48] and recent evidence suggests that cargo contained in these
organelles may also be released upon activation [49, 50].
Upon activation, rapid re-organization of the actin cytoskeleton allows platelets to
extend protrusions called filopodia to finally generate lamellipodia, resulting in a
dramatic increase in the platelet surface area [51]. It is thought that this generous
amount of extra membrane comes from a membrane reservoir, called the open
canalicular system (OCS), unique to platelets. The OCS, which is an extension and
invagination of the platelet plasma membrane, serves as the pathway for transport
of substances into the cells as well as channels for the release of granule cargo upon
activation-induced exocytosis [52, 53]. However, the exact roles of the OCS remain
controversial. While it is widely thought that alpha granules dump their cargo into
the OCS upon activation [54], recent evidence suggests otherwise. Tomographic
analysis from scanning transmission electron microscopic images of quiescent
4

platelets shows alpha granules and the closed canalicular system to be discrete
membrane-bound structures. In the early stages of platelet activation, the closed
canalicular system fuses with the plasma membrane and becomes open, while the
alpha granules fuse with the plasma membrane forming long tubular connections
[55]. It could be speculated that these OCS, are in fact, some sort of endosomal
compartments, that could get fused with the plasma membrane during platelet
activation. Recent data from our lab provides evidence for the presence of two
distinct populations of endosomes, Rab4-positive early endosomes and Rab11positive recycling endosomes in platelets [19]. These new findings suggest that
platelets are in fact more complex with what could be an extensive endomembrane
system that allows greater capacity for intracellular trafficking than previously
thought to exist, an avenue that will definitely warrant future studies.

5

Figure 1

6

Figure 1 Resting and activated platelet structures. Mature quiescent platelets are
discoid shaped and contain various cargo molecules within the different secretory
granules and ER-derived and intracellular membrane compartments as depicted in
the legends. Upon activation, platelets undergo a dramatic shape change and
become stellate, followed by granule/compartment-plasma membrane fusion drives
surface mobilization and release of luminal cargo into the extracellular space.
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Platelet surface receptors and their downstream signaling pathways: roles in
hemostasis and thrombosis
Platelets detect and respond to their external environment via a multitude of surface
receptors on their plasma membrane. The majority of the platelet surface receptors
contribute to the primary function of hemostasis; by either platelet activation or
adhesion to the damaged endothelium and in facilitating thrombus formation.
Platelets also express several other receptors that have seemingly non-hemostatic
functions namely in pathogen recognition and immunological defense. Several
transmembrane receptors span the platelet surface, including many integrins (αIIbβ3,
α2β1, α5β1, α6β1, αvβ3), leucine-rich repeats (LRR) receptors (Glycoprotein [GP] Ib-IX-V,
Toll-like Receptors), G-protein coupled receptors (GPCRs) (PAR-1 and PAR-4
thrombin receptors, P2Y1 and P2Y12 purinergic receptors, TPα and TPβ thromboxane
A2 (TxA2) receptors), proteins belonging to the immunoglobulin superfamily (GP VI,
FcγRIIA), C-type lectin receptors (CLEC-2), tyrosine kinase receptors (thrombopoietin
receptor TPOR/Mpl) and other miscellaneous receptors [56]. While platelets do
share certain receptors with other cells present in the vasculature, there are some
that are unique to platelets only, e.g., αIIbβ3. As such, they have become the hotspots
for therapeutic intervention. Most of the surface receptors, whether they are
engaged in hemostasis or non-hemostatic functions, give rise to downstream
signaling cascades that crosstalk significantly in platelets.
Platelet adhesion, recruitment and activation leading to thrombus formation at the
sites of vascular damage is dynamic and requires a series of time-dependent
concerted events that can be broadly classified as: (i) “initiation phase” when the
first layer of platelets descend on the exposed endothelium and get activated; (ii)
“extension phase” when the first activated platelets release ADP, TxA2, which act as
autocrine and paracrine agonists and help in the recruitment and activation of
additional platelets; (iii) “stabilization phase” when the forming platelet plug is
maintained to arrest blood loss and prevent its premature dislodgement until wound
healing commences [58]. Different platelet receptors come into play at each of these
phases, in an order, leading to a complex but coordinated interplay of receptor-
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ligand interactions and downstream signaling that is tightly regulated to prevent
uncontrolled thrombosis at the site of injury.
In this section, the major platelet receptors will be discussed in order of their
engagement in forming the growing thrombus.
GPIb-IX-V complex (GPIb complex)
At the vascular site of injury, the first contacts between surveilling platelets and the
damaged endothelium, underflow, is made through the interaction between the
glycoprotein (GP) Ib-IX-V complex and collagen receptors, GP VI and α2β1 integrin,
on the platelet surface, and by von Willebrand Factor (vWF) and fibrillary collagen in
the exposed endothelium [57]. This initial tethering and firm adhesion of platelets
allows further platelet recruitment and drives activation. Platelet adhesion to the
vessel wall components that are exposed to damage largely depends on the shear
rates [57]. In the microvasculature (small arteries), where platelets encounter high
shear conditions (>1000 s-1), GPIb-IX-V-mediated adhesion to the vessel wall is
chiefly vWF-dependent [59]. In the veins and larger arteries, where platelets
encounter low shear rates (~500 s-1) adhesion to the vessel wall primarily involves
binding to fibrillar collagen, fibronectin, and laminin [60]. The GPIb-IX-V complex
contains four distinct subunits that each span the lipid bilayer once: the two
disulfide-linked subunits of GPIb (GPIbα[CD42b] and GPIbβ[CD42c]), GPIX (CD42a)
and GPV (CD42d), expressed in the ration of 2:2:2:1 respectively [61]. Each subunit of
this complex has one or more leucine-rich repeats of about 24 amino acids: GPIbα
has 7 repeats, GPIbβ and GPIX have 1 each, and GPV has 15 repeats [61]. Aside from
the hydrophobic membrane-spanning segments of this complex, GPIbβ and GPIX are
palmitoylated at cysteine residues to further anchor them in the plasma membrane
[62].
In addition to vWF, GPIb-IX-V complex can also bind to P-Selectin, expressed on
activated platelets and activated endothelial cells [63], and to the integrin αMβ2
(Mac-1) expressed on leukocytes [64]. GPIbα also binds to coagulation factors from
the intrinsic pathway such as high molecular weight kininogen, FXII and FXI and
thrombin generated from the activation of the extrinsic or intrinsic coagulation
cascades [65-67]. The cytoplasmic tail of GPIbα interacts with filamin, calmodulin,
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14-3-3ζ which in turn allows it to interact with signaling proteins such as
phosphatidylinositol 3-kinase (PI-3K), focal adhesion kinase (FAK), Src-related
tyrosine kinases, GTPase-activating protein and tyrosine phosphatases (PTP1b and
SHPTP10) [68, 69]. The GPIbα-vWF interaction drives the initial platelet activation by
causing intracellular calcium transients followed by PLCγ2, ERK-1/2 and Syk
phosphorylation, TxA2 generation and ADP release from dense granules, ultimately
leading to the activation of the integrin αIIbβ3 [69].
Deficiency of functional GPIbα on human platelets causes a rare autosomal recessive
disease, called Bernard-Soulier syndrome, characterized by thrombocytopenia, large
platelets and mild to severe bleeding phenotype [70], stressing the importance of
this receptor complex in mediating hemostasis and thrombosis.
Glycoprotein VI (GPVI)
At the site of damaged endothelium, collagen is present, which facilitates the initial
platelet adhesion. Fibrillar collagen is better suited to bind to platelets than
monomeric collagen [71]. Platelets utilize GPVI, a member of the immunoglobulin
superfamily, and an integrin, α2β1, to bind directly to collagen.
Glycoprotein VI (GP VI) is a platelet and megakaryocyte-specific, a transmembrane
protein, consisting of two immunoglobulins (Ig)-like domains in the extracellular
region connected to a highly glycosylated linker, a transmembrane domain, and a
cytoplasmic tail [72, 73]. This cytoplasmic tail can bind to Fyn and Lyn Src kinases
[74]. GP VI exists as a complex with the homodimeric Fc receptor γ chain (FcRγ with a
possible stoichiometry of 2 GP VI molecules and 1 FcRγ dimer) on the platelet
surface, which bears an immunoreceptor tyrosine-based activation motif (ITAM)
acting as a signal-transducing subunit of the receptor [75]. Studies deciphering the
role of GP VI in activating platelets have often used agonist surrogates such as
Collagen-related peptide (CRP) consisting of (Gly-Pro-X)n or (Gly-X-Hyp)n sequences
organized in triple helices [76] or the snake venom C-type lectin, convulxin, [77, 78]
that are thought to work by clustering GP VI molecules on the platelet surface. When
the GP VI receptor is cross-linked by binding to collagen or CRP or convulxin, the
constitutively bound Src kinases (Fyn and Lyn) phosphorylate the ITAM sequence in
the FcR γ-chain allowing the assembly and activation of Syk and initiating activation
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of a downstream signaling pathway that has many similarities with that employed by
immune cell receptors, mainly T-cell receptors. Activation of this signaling cascade
leads to the formation of the signalosome, composed of various adaptors and
effector proteins, such as LAT (Linker for Activation of T-cells), SLP-76 (SH2 domaincontaining leukocyte protein of 76 kDa), which associates to and activates PLCγ2,
PI3K, and small molecular weight G proteins, leading to full platelet activation [7981].
GP VI blockade, or its depletion, has been shown in mice to result in complete
protection against arterial thrombosis, without significant prolongation of bleeding
time. Blockade of GP VI results in impaired platelet response to collagen and may,
therefore, present a useful antithrombotic target [82-84].
Integrin α2β1
Integrin α2β1 also called GP Ia/IIa, VLA-2 or CD49b/CD29, plays a role in the adhesion
of platelets to collagen and subsequent platelet activation [75]. Loss of α2 subunit or
β1 subunit in mice does not cause bleeding defects, although these platelets show
minor defects in platelet adhesion and aggregation to collagen [85-86]. Studies on
these knockout mice showed variable phenotypes in in vivo models of arterial
thrombosis ranging from normal thrombus formation [87] to mildly delayed, reduced
and unstable thrombi [88, 85]. Similar to other integrins, conformational activation
of α2β1 increases its affinity for collagen and requires GP VI and collagen-dependent
inside-out signaling [89]. However, combined deficiency of α2β1 and GPVI in mice
causes complete inhibition of thrombus formation while isolated deficiency of each
receptor leads to a partial defect in thrombus formation [90]. Thus, it is widely
accepted that α2β1 and GPVI function synergistically for optimal platelet adhesion
and activation by collagen.
After the initial platelet adhesion and deposition on vWF and collagen exposed
surfaces, the next step in thrombus formation is the recruitment of additional
platelets from the flowing blood to form the platelet plug, called the “extension
phase”. This process requires the localized accumulation of soluble agonists that are
secreted by adherent-activated platelets, including ADP, TxA2, epinephrine, and
thrombin. The final step is activation of αIIbβ3, causing a conformational change that
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enables it to bind fibrinogen and vWF, allowing stable bridges between platelets that
form large aggregate at the site of vascular damage. GPCRs or G-protein coupled
receptors are important seven-transmembrane spanning receptors that play crucial
roles in this extension phase.
Platelet ADP receptors: P2Y1, P2Y12, P2X1
When the adherent platelets get activated and release their cargo content, the
dense granules which are pre-docked on the plasma membrane, are the first ones to
be exocytosed [91]. ADP is stored in platelet dense granules and gets released upon
activation at the site of injury. Red blood cells also release some ADP. ADP, though
being a weak agonist, still causes the full range of platelet activation events including
intra-platelet Ca2+ influx, thromboxane A2 synthesis, protein phosphorylation, shape
change, granule secretion, and activation of αIIbβ3, and aggregation. These events are
driven by ADP interacting with two types of purinergic GPCRs namely P2Y1 and P2Y12
coupled to Gqα and Giα, respectively [92].
P2Y1 receptor
P2Y1 receptor couples with Gqα to mobilize calcium and is responsible for initiation
of platelet aggregation and shape change when ADP binds to it [93]. P2Y1 can also
couple to G12/13 and can activate platelets via Rho Kinase and Calcium [94]. A3P5PS,
a P2Y1-specific inhibitor, blocks shape change and calcium signaling in response to
2MeSADP, a stable ADP analog, without affecting cAMP downregulation
[95].Platelets from P2Y1-deficient mice are unable to aggregate in response to usual
concentrations of ADP and display defective aggregation to other agonists, while
high concentrations of ADP (together with serotonin) induce platelet aggregation
without shape change. These mutant mice do not present a bleeding diathesis but
are resistant to thromboembolic mortality induced by injecting ADP or collagen and
adrenaline [96].
P2Y12 receptor
ADP activation of P2Y12 results in amplification and sustenance of aggregation, and
secretion but plays no role in ADP-induced shape change [98]. In addition to
amplification of P2Y1-mediated platelet responses, P2Y12 plays an essential role in
potentiating platelet responses initiated by other important platelet activators such
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as thromboxane A2 and thrombin and therefore, is a critical regulator of hemostasis
and thrombosis [92]. This second ADP receptor couples to Gi to inhibit adenylate
cyclase and cause platelet aggregation [97]. Activation-based signaling downstream
of the P2Y12 receptor potentiates agonist-induced dense granule release as well as
alpha granule release of P-selectin [99, 100]. P2Y12 coupling to Gi also leads to
activation of PI3K, Akt, Rap1b and potassium channels [99]. Both Rap1b and Akt are
signaling mediators that contribute to platelet aggregation and are activated in a
PI3K-dependent manner. Inhibiting P2Y12 receptor reduces thrombus formation
without affecting its stability [101, 102]. In P2Y12-deficient mice, ADP does not induce
aggregation and platelet responses to other agonists are dramatically reduced; these
mice have a bleeding phenotype as well as reduced thrombus formation and
resistance to thromboembolism [102, 104]. While congenital P2Y12 receptor
deficiency is a rare autosomal recessive disorder, it presents with a bleeding
diathesis, though the severity of it varies from patient to patient [103].
Given its well-established importance in hemostasis and thrombosis, the P2Y12
receptor is the target of a host of anti-platelet drugs such as the thienopyridine class
of drugs (ticagrelor, clopidogrel, cangrelor, elinogrel, and prasugrel) [105]. These
antagonists bind to the receptor irreversibly and reduce platelet function. Some of
these are already in use as antithrombotic while others are in development. These
drugs are routinely used together with aspirin which inhibits TxA2 synthesis in
platelets and thus provides additional benefits of reducing platelet function. Of these,
clopidogrel, marketed as Plavix, remains the most widely used anti-thrombotic to
prevent vascular events in patients with cardiovascular diseases, especially in the
case of coronary stent insertion.
An important aspect of both the P2Y1 and P2Y12 receptors is their ability to become
desensitized to ADP. This serves to regulate platelet reactivity and control thrombus
formation. Once initially activated by ADP, there is a transient loss of platelet
responsiveness to a second stimulation by ADP by selective desensitization of the
P2Y1 receptor [106]. The P2Y12 receptor remains functional and conserves its ability
to amplify the platelet aggregation induced by other agonists, suggesting that the
two receptors are regulated differently [107]. Platelets, at the site of vascular injury,
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use receptor desensitization as means to regulate responses when ADP, released
from red blood cells, is the sole agonist in the medium, a situation when P2Y1 comes
to play. Then, when platelets become refractory to ADP, P2Y12 still remains viable
and can respond to other agonists thus ensuring platelets’ responsiveness and
preserves the hemostatic function of the platelets [92]. Furthermore, surface levels
of P2Y receptors and consequently ADP responsiveness is regulated through
endocytic trafficking [148]. Endocytic trafficking of P2Y receptors allows platelets to
be desensitized and resensitized to ADP. It has been shown that P2Y1 and P2Y12,
upon ADP stimulation, rapidly desensitize in a kinase-dependent manner [149].
Endocytosis of P2Y1 is dependent on protein kinase C (PKC) activity, whereas P2Y12
requires G protein-coupled receptor kinase (GSK). After removal of agonist, P2Y
receptors recycle back to the cell surface, a process that is called resensitization.
ADP-ribosylation factor 6 (Arf6), a small GTPase that is present in platelets and is key
for integrin recycling [19], has been suggested to be important for P2Y12
internalization by regulating Nm23-H1, an NDP (nucleoside diphosphate) kinase
which facilitates dynamin-dependent fission of clathrin-coated vesicles [150].
P2X1 receptor
In addition to P2Y1 and P2Y12 receptors, platelets express a third purinergic receptor
P2X1. This receptor is actually an ATP-gated cation channel [108] that is unable to
trigger platelet aggregation by itself, but under high shear conditions acts as a
positive regulator of platelet responses to collagen and thus plays a significant role in
thrombus formation [109]. P2X1-deficient mice have normal bleeding times but are
resistant to thromboembolism upon collagen-epinephrine injection as well as to
localized laser-induced injury of the vessel walls of mesenteric arteries [109].
Conversely, mice overexpressing the human P2X1 receptor are more prone to
increased systemic thrombosis [110]. The P2X1 antagonist NF449 [111] inhibits
platelet function ex vivo and in vivo thrombus formation [112]. Together, these data
strongly suggest the effectiveness of P2X1 antagonists as potent anti-thrombotic
drugs especially in patients with severe stenosis where shear forces are high.
Amongst the soluble agonists secreted at the site of injury, thromboxane A2, is one
of the key prostanoids secreted by activated platelets through the sequential
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activities of cyclooxygenase (COX) and TxA2 synthase enzymes [117]. TxA2, an
unstable arachidonic acid metabolite, is a vasoconstrictor and a potent platelet
activator causing shape change, phosphoinositide hydrolysis, calcium mobilization,
protein phosphorylation, secretion and aggregation [113]. Once synthesized, it
diffuses through the plasma membrane and activates other recruited platelets, thus
allowing the platelet plug formation. The receptor that TxA2 binds to on platelets is
the thromboxane A2 receptor TP [114].
Thromboxane A2 (TP) receptor
TP exists in two splice variants (TPα and TPβ) which differ mostly in their C-terminal
cytoplasmic domains though their ligand-binding properties are the same. TPα was
cloned from the placenta [115] while TPβ was cloned from endothelial cells [116].
Platelets contain both these isoforms [118]. TPs in platelets couple to Gqα and G12α
activating pathways, but not to Giα, activating the phosphoinositide hydrolysis
(leading to IP3 formation), mobilization of calcium and activation of Rho GTPases
when activated by the thromboxane A2 analog, U46619 [119, 120]. Mice deficient in
TP are unable to respond to TxA2 analogs, have reduced response to collagen and
have prolonged bleeding times as well as altered vascular responses to arachidonic
acid a TxA2 [121]. Blocking TxA2 synthesis using antagonists/inhibitors especially
those that inhibit cyclooxygenase enzymes and thromboxane A2 synthase, such as
aspirin (irreversibly inhibits COX-1 and modifies the enzymatic activity of COX-2)
have been used for decades to manage high cardiovascular risk [122]. Aspirin still
remains one of the most widely used drugs for preventing and managing
cardiovascular diseases. Aspirin’s importance was honored when John Robert Vane,
a British pharmacologist, won the Nobel Prize in Physiology or Medicine in 1982, for
his landmark discovery in showing the inhibitory effects of aspirin on thromboxane
and prostaglandin production, essentially being one of the most important antiplatelet drugs to be discovered.
The next major and a most important agonist that comes into play at promoting and
stabilizing the growing thrombus at the site of damage under all shear conditions is
thrombin [58]. Thrombin is a multifunctional serine protease that has both
anticoagulant and procoagulant properties, being the only one of all the coagulation
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cascade proteins to have the ability to regulate normal hemostasis and spurious
uncontrolled thrombosis [147]. Thrombin is generated by the action of several
members of the coagulation cascade on the surface of the platelets, namely tenase
complex (FIXa in complex with FVIIa, which activate FX) and by the prothrombinase
complex (FXa in complex with FVa, which activate FII) [123]. These coagulation
factors together with the activated platelet surface which provides exposed
phosphatidylserine, creates a procoagulant surface that allows thrombin generation
to occur [124].
Thrombin is the most potent platelet activator and generates full blown platelet
activation in terms of platelet shape change, secretion, TxA2 generation, Ca2+
mobilization, protein phosphorylation and aggregation [58, 56]. Even low
concentrations of thrombin (0.1 nM) can activate platelets [56]. Thrombin can
efficiently couple to PLCβ activation, leading to rapid increase in cytosolic Ca2+ levels,
triggering downstream events such as activation of PLA2 [125]. The thrombininduced platelet responses are mediated partially by the GPIb-IX-V complex [126,
127, 68-69]. However, thrombin acts on platelets mainly through the action of two
protease-activated receptors (PARs), PAR-1 and PAR-4 in humans and PAR-3 and
PAR-4 in mice [128].
Protease-activated receptors (PARs)
PARs belong to the seven transmembrane domain containing G-protein coupled
receptors that are present on the surface of platelets and are sufficient to activate
platelets by themselves in the presence of thrombin. To date, four PAR receptors
have been identified and characterized, three of which PAR-1, PAR-3, and PAR-4 are
substrates for thrombin while PAR-2 is activated by mast cell tryptase, trypsin and
factor Xa but not by thrombin [134-140]. There are four PAR members on platelets,
PAR-1 and PAR-4 in human platelets while PAR-4 is the major mouse platelet PAR
receptor with PAR-3 acting as a co-receptor [129]. Since thrombin generation
requires some level of platelet activation (usually ADP, TxA2-mediated), PARmediated activation occurs after platelet adhesion and activation.
PAR-mediated activation requires irreversible proteolytic cleavage within the first Nterminal extracellular loop of the seven transmembrane domain receptors that
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contain a putative thrombin cleavage site LDPR/S [130]. Upon cleavage by thrombin,
a new N-terminus is exposed that now serves as a tethered ligand. Studies were
done on PAR-4 knockout mice, PAR-4 being the major thrombin receptor in mouse
platelets, showed prolonged bleeding times and were protected in the FeCl3 injury
model of arterial thrombosis; the platelets from these mice were unresponsive to
thrombin, even at higher concentrations, with no observed shape change, ATP
release from dense granules or aggregation [131]. In PAR-3 knockout mice, thrombin
responses were abnormal as in low levels of thrombin did not elicit any response in
terms of ATP release and aggregation, while higher concentrations elicited markedly
delayed responses; bleeding times were normal in these mice [132]. Interestingly,
platelets from PAR-3 knockout mice responded normally to a PAR-4 activating
peptide mimetic, suggesting that while PAR-3 is necessary for normal responses, it is
not the major thrombin receptor in mouse platelets. Furthermore, it leads to a dualreceptor model for platelet activation by thrombin that has important implications
for developing anti-thrombotic drugs.
Understanding the role of the thrombin receptors on human platelets becomes key
to developing therapeutic strategies against myocardial infarction and stroke. Similar
to mice, a dual-receptor system for thrombin-induced platelet activation is also
present in humans, mainly through the actions of PAR-1 and PAR-4. PAR-1 is the
major thrombin receptor in human platelets [134]. The PAR-4 activating peptide can
also activate human platelets suggesting that PAR-4 also plays a secondary but
important function. Blockade of PAR-1 with antibodies or specific antagonists ablates
platelet function even at low concentrations of thrombin, whereas similar blockade
of PAR-4 at low thrombin concentrations has no inhibitory effect [133]. Blocking or
inhibiting both PAR-1 and PAR-4 receptors results in complete ablation of platelet
response to even very high concentrations of thrombin [133]. Further support for
this dual receptor model in human platelets can be gleaned from studies on
intracellular cytosolic calcium transients using PAR agonists and antagonists. Human
platelets have a biphasic calcium response, the first phase being a rapid phase where
intracellular cytosolic calcium levels spike in response to PAR-1 activation (by
thrombin) and the second more sustained phase of calcium transient is maintained
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by PAR-4 activation [141]. Studies using PAR-1 knockout mice revealed that
disruption of the murine PAR-1 gene causes 50% embryonic lethality at E9-10 days,
while the other half of mice developed normally with no hemorrhagic diatheses.
PAR-1 knockout platelets normally respond to thrombin and have normal hemostasis,
mainly because PAR-3 and PAR-4 thrombin responses are unaffected. However,
these mice have defective vasculogenesis in their yolk sac and cardiovascular
collapse leading to early embryonic lethality [142]. While PAR-3 and PAR-4 knockout
mice are protected against thrombosis and demonstrate defective thrombus
formation, direct PAR-1 inhibition in primate models also abolishes arterial
thrombosis [131, 143-144]. PARs provide an important link between hemostasis and
inflammatory pathways [145] due to the pro-inflammatory nature of thrombin. PARs
have been implicated in thrombin-mediated activation of endothelial cells by
triggering release of vWF from the Weibel-Palade bodies (granules that store vWF
within the endothelial cells) and surface expression of P-selectin that facilitates
rolling and adhesion of platelets and leukocytes on the endothelial surface as well as
release of interleukins-6 and 8, thereby mediating inflammation [128, 145-146].
PARs have also been implicated in atherothrombosis [128].
After thrombin-mediated PAR activation and engagement in the formation of the
growing thrombus, the last phase that finally leads to a stable thrombus at the site of
injury to arrest blood loss, is called the “stabilization phase”. In this phase, activated
platelets within the developing platelet plug come into close contact with each other,
aided by fibrin fibers that form bridges closing the gap between nearby platelets and
facilitating the formation of the thrombus. Once aggregation has started, a series of
late signaling events sets in to consolidate the stable thrombus and prevent its
embolization. These contact-dependent signaling events that drive this late phase of
thrombus formation is mainly mediated by the outside-in signaling through the
platelet integrins, particularly αIIbβ3.
Integrins
The integrins are a major class of adhesive and signaling receptors that are present
on most cell types consisting of two subunits, α subunit and β subunit [151].
Vertebrates have 18 α subunits and 8 β subunits, generating 24 heterodimers that
18

are non-covalently associated [152]. Integrins have a large extracellular domain, a
single transmembrane domain from each subunit, and small cytoplasmic tail,
although α and β subunits have distinct domain structures. Both subunits contribute
to the ligand-binding site in their extracellular domain, with specific binding ligand
for individual integrin. Integrins exist in two affinity states, low and high, which are
altered by cytoplasmic signaling and phosphorylation of their cytoplasmic domains
[153].
Platelets express integrins from three families (β1, β2 and β3) and in total six different
integrins: α2β1, α5β1, α6β1, αLβ2, αIIbβ3, and αvβ3 [154].
β3 family (αIIbβ3 and αvβ3)
Integrin αIIbβ3
αIIbβ3, or the GPIIb-IIIa complex, is the only integrin that is exclusively expressed on
platelets and megakaryocytes [155]. There are about 80,000 copies of αIIbβ3 on the
surface of quiescent platelets and additional heterodimers in the membranes of
platelet granules are translocated to the surface during platelet activation [156-157].
αIIbβ3 is the major receptor for fibrinogen, vWF, fibronectin and vitronectin and is
essential for platelet aggregation [158]. As a result, absence or deficiency of αIIbβ3
prevent platelet aggregation and leads to sever bleeding disorder called Glanzmann’s
thrombasthenia [159]. Conversely, the thrombi formed during arterial circulation
result from αIIbβ3-mediated formation of platelet aggregates [160].

Given the

importance of αIIbβ3 in mediating hemostasis and thrombosis, it is one of the most
studied integrins and most targeted receptor for anti-thrombotic therapies.
Integrin αvβ3
This integrin is present in platelets in small amounts (several hundred copies per
platelet) and is known to mediate platelet adhesion to osteopontin and vitronectin in
vitro [161-162]. Integrin αvβ3 supports adhesion on fibronectin and promotes the
formation of filopodia but not lamellipodia or downstream focal adhesion kinase
(FAK) phosphorylation [163]. However, the in vivo role of integrin αvβ3 is unknown.
β1 family (α2β1, α5β1 and α6β1)
Integrin α2β1
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Also known as GPIa-IIa and on lymphocytes as VLA-2, it is the second most important
integrin after GPIIb-IIIa on platelets [164]. There are 2000-4000 copies per platelet
and is the major collagen receptor on platelets as well as other cell types.
Integrin α5β1
The extracellular matrix protein, fibronectin, is the major ligand for the integrin α5β1
and supports static platelet adhesion on fibronectin [163, 165]. Soluble fibronectin
binds to integrin αIIbβ3 on thrombin-activated platelets and this binding is not
observed with platelets from Glanzmann’s thrombasthenia patients that lack αIIbβ3.
However, these platelets can still retain the ability to bind to fibronectin-coated
surfaces as adhesion to fibronectin does not require platelet activation and is in fact
inhibited by soluble fibronectin [166]. Another hallmark of platelet-fibronectin
interactions is that it is shear stress-dependent and as a result platelet adhesion to
fibronectin is thought to occur in large arterioles where the shear stress is
considerably less [167].
Integrin α6β1
α6β1 is thought to be the principal laminin receptor on platelets and has a
supplementary role in platelet adhesion at injury sites [170, 174]. Platelet adhesion
to laminin strongly depends on the presence of divalent cations like Ca2+ and Mg2+
and low shear rates (about 800/s) but does not lead to aggregation although
filopodia and lamellipodia formation does occur [168-169]. Laminin stimulates
platelet spreading through α6β1-dependent activation of the collagen receptor, GPVI
[174]. Lamellipodia formation on laminin is completely inhibited in the absence of
GPVI, while filopodia formation remains viable and is thought to be mediated via
α6β1 [174].
β2 family (αLβ2)
Integrin αLβ2
Quiescent platelets express low to variable expression levels of the integrin αLβ2, also
known as CD11a/CD18 (LFA-1). However, activation of platelets leads to a marked
increase in the levels of this integrin, suggesting that this integrin is expressed on
granule membranes, which upon granule fusion with the plasma membrane gets
exteriorized, in a manner similar to the alpha granule marker, P-selectin [171].
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Studies done on mice further revealed that stimulation of thrombocytopoiesis
(production of new platelets) leads to loss of β2, but not β1 or β3 integrins, from the
newly released platelets and there appears to be a selective loss of β2 integrin from
platelets in circulation [172]. Further studies using the β2 integrin knockout mice,
demonstrated that β2 modulates caspase activation and consequently platelet life
span and response to inflammatory cytokines such as Tumor Necrosis Factor (TNF)
[173].
Platelet outside-in signaling, mainly mediated through fibrinogen binding to αIIbβ3,
triggers key events for thrombus growth and stabilization, such as cytoskeletal
reorganization, formation and stabilization of large platelet aggregates, development
of a procoagulant surface and clot retraction that helps in bridging the gaps between
platelets and increase the local concentration of soluble platelet agonists [175]. At
the heart of this growing thrombus, where the concentrations of the soluble agonists
(mainly thrombin) is highest is called the core and consists of fully activated platelets,
while the surrounding region is overlaid by what is called the shell comprising of
minimally activated platelets [176-178]. While the integrins are the main players in
promoting the continued growth and stability of the hemostatic thrombus, other
participants include cell adhesion molecules (junctional adhesion molecules, JAM-A
and JAM-C) that provide cohesive and signaling interactions between adjacent
platelets and leukocytes favoring thrombus stabilization [179]; receptor tyrosine
kinases such as the Ephrin family of kinases (EphA4, EphB1, and ephrinB are present
in human platelets) that cluster to cause platelet adhesion on fibrinogen [180];
secreted agonists and protein fragments that are shed from the surface of activated
platelets such as CD40 ligand (CD40L, CD154). CD40L is shed from activated platelets
to produce a soluble form, sCD40L that can bind to αIIbβ3 through the Arg-Gly-Asp
motif and favors outside-in signaling that drives thrombus growth and stability [181].
Receptors involved in the negative regulation of platelet activation and thrombus
growth
To prevent uncontrolled thrombus growth at the site of injury that grows into an
occlusion that covers the entire blood vessel, several negative regulators or
passivators of platelet activation exists. Chief among them are nitric oxide (NO) and
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prostacyclin (PGI2). PGI2, produced by the vascular endothelium, is a labile
metabolite of arachidonic acid and acts as a potent vasodilator in coronary
circulation as well as dampens platelet activation by inhibiting platelet adenylyl
cyclase and preventing formation of cAMP [182]. Endogenous nitric oxide has been
shown to inhibit platelet adhesion to the vascular endothelium and protects against
platelet aggregation in stenosis and endothelium-injured arteries [183-184]. Platelet
activation can also be blocked by the adhesion molecule, platelet endothelial cell
adhesion molecule, PECAM-1 or CD31, a member of the Ig superfamily that contains
an immunoreceptor tyrosine-based inhibitory motif (ITIM) that gets phosphorylated
upon platelet activation. PECAM-1 plays a vital role in attenuating thrombus
formation involving GP VI, GP Ib, thrombin-mediated activation of platelets as well as
αIIbβ3-mediated platelet activation [185-187]. Another mechanism to arrest
unregulated thrombus growth is by the action of the matrix metalloprotease
ADAMTS13, which cleaves highly adhesive large vWF multimers that are formed on
the surface of the growing thrombus. ADAMTS13 works as an anti-thrombotic by
down-regulating both platelet adhesion to damaged endothelium and thrombus
formation in injured arterioles [188].
Platelet exocytosis
Activation-dependent platelet exocytosis, also called the “platelet release reaction”,
is at the core of several physiological and pathophysiological processes such as
thrombosis, wound healing, angiogenesis, and inflammation among others [245].
Activated platelets release their granule contents that consist of ADP from dense
granules (activates other platelets in the immediate vicinity in a paracrine manner),
fibrinogen and vWF from alpha granules that modulates thrombus formation and
stability, various cytokines, chemokines and growth factors that allows
communication with other cell types (endothelial cells, leukocytes etc.) as well as
several lytic enzymes from lysosomes that are thought to modulate clot remodeling.
Platelet secretion, its kinetics, extent, and release composition, appears to have no
functionally thematic pattern, with only agonist potency driving these parameters
for the release reaction [91]. However, there are distinct kinetic patterns or waves in
cargo release with dense granule cargo being the fastest and most important in
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mediating hemostasis, followed by the secondary wave of alpha granule release and
then by lysosomal release being the slowest. Distinct kinetic patterns of the granule
releasates allow platelets to control their microenvironment. Platelet granule
secretion provides a concentrated release of key effector molecules at the site of
injury that allows platelets to carry out their functions. Secretion of more than 300
proteins and bioactive small molecules [189-190] from activated platelets requires a
cascade of complex protein-protein interactions that are tightly regulated and
govern this release reaction. The Soluble N-ethylmaleimide Sensitive Fusion Protein
Attachment Protein Receptor (SNARE) proteins are the core machinery [194] that
drives the process of granule-plasma membrane fusion in platelets, using
mechanisms similar to those found in other secretory cells such as neurons,
chromaffin cells, mast cells, neutrophils etc. Platelet exocytosis involves the
movement of granules to juxtapose with the plasma membrane, leading to granuleplasma membrane fusion, and release of intracellular contents. Within the platelet
itself, granule-granule fusion may occur in a process called compound fusion which
may or may not precedes fusion with the plasma membrane [191-192]. SNAREs can
be classified into two groups based on their location, v-SNAREs for the ones residing
on the granules and vesicles, t-SNAREs for target-membrane localization. Extensive
sequence analysis led to a further classification of the SNAREs based on amino acids
present within their SNARE motifs, called the QabcR system [193]. All SNAREs
contain 1-2 amphipathic, heptad-repeat-containing cytosolic domain called the
SNARE motif consisting of 60-70 amino acids. Cognate v- and t-SNAREs interact with
each other by binding to these SNARE domains. Specificity of binding is conferred by
a highly conserved 16 amino acids stretch which lay up- and down-stream of an ionic
“zero” layer. This zero layer invariably consists of three glutamines (Q) and an
arginine (R) residue. The v-SNAREs also called Vesicle-Associated Membrane Proteins
(VAMPs) make up the majority of the R-SNAREs while the t-SNAREs are mostly QSNAREs. The t-SNAREs can be subdivided into two classes of proteins; the Syntaxins
(Qa-SNAREs) and the Synaptosome Associated Proteins (SNAP-25/23 proteins) (Qbc
SNAREs) [195-196]. SNARE-driven exocytosis in platelets proceeds in conformation
to the SNARE hypothesis which states that members of the v- and t-SNAREs form
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cognate pairs on the basis of binding specificity and should be essential and
sufficient for vesicle docking in vivo [197]. Accordingly, four SNARE motifs, one each
from Qa and R and two from Qbc families form a functional four-helical complex that
undergoes a cis to trans conformational change that brings the granule membrane
and plasma membrane in close physical apposition and drives fusion [197].
Previous studies done by our lab and others have established the importance and
contribution of several of these platelet SNARE proteins and their contributions to
hemostasis and thrombosis.
Platelet v-SNAREs
SNAREs were first reported by our group when NSF, SNAP and Syntaxin-2 and
Syntaxin-4 were detected in platelet lysates [198]. Platelets contain multiple
isoforms of the VAMPs (VAMP-2,-3,-4,-5,-7,-8), based on data gleaned from
proteomic analyses and quantitative Western blotting [199-200]. In terms of a
number of copies per platelet, VAMP-8 and VAMP-7 are the most abundant in
human platelets while VAMP-8, VAMP-2, and VAMP-3 are the major ones in mouse
platelets. VAMP-8 which is the most abundant in both mouse and human platelets is
the primary v-SNARE to mediate secretion. Loss of VAMP-8 attenuates secretion
from all three granules, causes defective thrombosis (thrombus growth is slower and
lessened in comparison to WT) with no bleeding diathesis [199, 201]. Loss of VAMP-3
by itself had no defect in secretion and hemostasis proceeded normally as measured
by tail bleeding assay [202]. Loss of VAMP-2 is embryonic lethal [201]. Treatment of
tetanus toxin which specifically cleaves VAMP-2 and VAMP-3 showed that platelet
secretion is unaffected as long as VAMP-8 and VAMP-7 are present [201]. Loss of
VAMP-7 does not lead to a bleeding diathesis or defects in platelet accumulation at
sites of injury in the laser injury model of arterial thrombosis, although alpha granule
secretion is attenuated in these platelets [203]. Collectively, these data implies there
appears to be an order of ranking amongst the isoforms in mediating secretion with
some amount of redundancy. VAMP-8 is primary with VAMP-2 and VAMP-3 playing
secondary roles. VAMP-7 on the other hand may be less involved in secretion but
mainly play a part in platelet spreading due to its interactions with the actin
cytoskeleton via VPS9-domain Ankyrin-repeat containing protein (VARP) and Arp2/3
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[203]. Immunofluorescence studies have shown VAMP-7-dotted structures to be
localized to the platelet periphery while VAMP-8 and VAMP-3 have been shown to
be more centrally localized within the granulomere in spread platelets [204]. The
central localization of VAMP-3 concurs with studies done in our lab where we
reported the intracellular punctate staining of VAMP-3 containing structures that
resist being targeted to the plasma membrane during thrombin activation [205].
These could very easily be VAMP-3 positive endosomes in platelets. Additionally,
VAMP-8 and VAMP-7 could potentially mediate differential cargo release or may be
differentially responsive to various kinds of agonists. However, future studies need
to be done to parse this distinction.
Platelet t-SNAREs
While SNAP-25 is the major Qbc SNARE in neuronal cells, most hematopoietic cells
including platelets rely on SNAP-23 as the functionally relevant t-SNARE [206-207].
Platelets also contain SNAP-25 [200] and SNAP-29 [208] but to lesser amounts.
Platelets contain Syntaxins 2, 4, 6, 7, 8, 11, 12, 16, 17 and 18 based on proteomic
analyses and functional studies [200]. Of the Syntaxins or Qa-SNAREs, Syntaxin 11, is
the most important for platelet secretion. Platelets isolated from Familial
Hemophagocytic Lymphohistiocytosis type 4 (FHL4) patients, which lack Syntaxin 11,
were deficient in secretion from all three granules [209]. Co-immunoprecipitation
analyses showed that upon stimulation, Syntaxin 11, complexed with SNAP-23 and
VAMP-8 to form the fusogenic SNARE complexes. While previous secretion studies in
permeabilized platelets using inhibitory antibodies and peptides showed the
importance of Syntaxin 2 and 4 in platelet secretion [206-207, 210-212], both
Syntaxin 4 single knockout mice and Syntaxin 2/4 double knockout showed no
secretion defect [209, Ye unpublished data]. The previously reported incorrect
results were due to the original Syntaxin 2 antibodies cross-reacting with Syntaxin 11
to inhibit secretion [209]. As mentioned before, Syntaxin 8 is present in platelets and
has been shown to regulate dense core granule release, platelet aggregation and
thrombus stability [213].
SNARE regulatory proteins
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Several regulatory proteins affect the functions of the SNAREs by controlling their
fusogenicity either temporally or spatially. Some of these SNARE regulators either
function as chaperones or tethering/docking factors or modulate the SNAREs via
post-translational modifications.
SNARE chaperones
Munc18b: Members of the Sec1/Munc 18 (SM) gene family regulate interactions
between the various SNAREs. The Sec1/Munc 18 proteins bind to the Syntaxins and
form a Syntaxin-Munc18 complex that regulates vesicle priming and potentially
modulates the conformation of the SNARE proteins [214-215]. Platelets contain
Munc18a, Munc18b, Munc18c (STXBP1, 2, 3) with Munc18b being the most
abundant of these three [216]. Platelets isolated from Familial Hemophagocytic
Lymphohistiocytosis type 5 (FHL 5) patients, which have defective Munc18b, had
severe secretion deficits showing the importance of Munc18b in mediating secretion
from all three different granules [216]. In platelets, Munc18c has been shown to
interact with Syntaxin 4 and thereby contribute to platelet secretion [217]; however,
platelets from heterozygous Munc18c mice showed normal secretion indicating that
Munc18c loss does not affect secretion to a great extent [218]. Munc18s have also
been reported to be phosphorylated in platelets and this is thought to affect their
interactions with Syntaxins [219-220]. Platelets also contain Vacuolar Protein
Sorting-associated protein 33A and B, VPS33A and VPS33B, which are members of
the SM family and are important for dense and alpha-granule biogenesis respectively
[221-222]. VPS33B has been recently shown to bind to the integrin β subunit and can
modulate αIIbβ3-mediated fibrinogen endocytosis, platelet activation, aggregation,
spreading, clot retraction and in vivo thrombosis and hemostasis [223].
STXBP5/Tomosyn 1: Syntaxin Binding Protein 5 or Tomosyn 1 is a t-SNARE regulator
that interacts with the t-SNARE heterodimers (e.g., Syntaxin 11/SNAP-23) through its
v-SNARE-like domain, and is thought to be a “place-holder” for the t-SNAREs [224225]. In platelets, STXBP5 binds only to t-SNAREs and loss of this protein causes
platelet secretion in mostly alpha granules and lysosomes, with a little defect in
dense granule secretion. STXBP5 knockout mice also have a severe bleeding defect
[226].
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Tethering/docking factors
Rab27: Platelets contain both the isoforms of Rab27, Rab27a, and Rab27b, which are
small GTPases that mediate granule docking and tethering in secretory cells [227].
Loss of Rab27a in mouse platelets does not cause any bleeding defects. When these
mice were crossed with a Rab27b knockout, both the double knockout and the
Rab27b single knockout mice had a robust bleeding phenotype as well as a reduced
secretion from dense granules. Additionally, the number of dense granules per
platelet and the serotonin content within the dense granules was reduced in these
Rab27b and Rab27a/b double KO strains suggesting a role for Rab27 in dense granule
packaging at the megakaryocyte level [228]. Rab27a could partially compensate for
the secretion deficit but not the reduced granule number, indicating there exists
some level of compensation between these two homologs within platelets.
Munc13-4: Protein unc-13 homolog D, commonly known as Munc13-4, belongs to a
family of multi-domain proteins that contain the Munc Homology Domain (MUN)
domain and two calcium/lipid-binding C2 domains and act as “priming or docking
factors” in driving SNARE-mediated fusion. Munc13-4 is highly expressed in cells of
the immune system and platelets where it acts as a Rab27a-binding protein that
regulates dense-core granule release [229]. Munc13-4 was the first identified
priming factor that promotes Ca2+-dependent SNARE complex formation and SNAREmediated liposome fusion [230]. Cytotoxic T lymphocytes deficient in Munc13-4
from familial hemophagocytic lymphohistiocytosis type 3 (FHL3) patients fail to
exocytose docked cytotoxic granules, suggesting a role for Munc13-4 in granule
priming [231]. Munc13-4 knockout platelets have a robust secretion defect as well as
severe bleeding phenotype and acts as a limiting factor in driving fusion of docked
granules [232]. Loss of Munc13-4 has a more pronounced effect on dense granule
release than on alpha granules and lysosomes. Furthermore, the addition of ADP has
shown to override the apparent alpha granule secretion deficiency in Munc13-4
knockout platelets [233], implicating the role of ADP as an autocrine factor that
modulates alpha granule and lysosome release.
NSF and SNAPs: N-ethylmaleimide-sensitive factor (NSF), an AAA+ ATPase, and its
adaptor proteins, Soluble NSF attachment proteins (SNAPs), are proteins that
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disassemble spent SNARE complexes for recycling [234-237]. NSF and SNAPs are
present in platelets [198]. Inhibitory peptides and antibodies that block alpha-SNAPstimulated ATPase activity of NSF impede secretion from permeabilized platelets
[238]. Nitric oxide inhibits platelet secretion partly by the reversible S-nitrosylation
of NSF [239]. Since platelet secretion is a terminal event with no discernible need to
recycle exhausted SNARE complexes, the role of platelet NSF is unclear. However, in
light of new studies that depict platelets to be more proficient at intracellular
trafficking and membrane fusion, especially in the context of autophagy and
endocytic trafficking, NSF and SNAPs may certainly become more relevant and
functional than previously thought [240, 19].
Post-translational modifications of SNAREs: Of the platelet SNAREs, SNAP-23 has
been shown to be phosphorylated by both Protein Kinase C in vitro [241] and by IκB
Kinase β (IKKβ or IKK2) [242]. Our group has shown that IKKβ, but not PKC, is the
proximal kinase that drives SNAP-23 phosphorylation in platelets both in vivo and invitro. IKKβ-mediated phosphorylation affects SNARE complex formation and
platelets from either IKKβ knockout mice or those treated with IKKβ inhibitors shown
severe secretion deficiency from all three granule types and robust bleeding
phenotype [242]. Agonist-induced activation causes SNAP-23 to get phosphorylated
at serine 95 and serine 120 by IKKβ in platelets. Data generated in this thesis shows
that this phosphorylation event holds true for most platelet agonists (thrombin,
convulxin, ADP, etc as well as immune agonists such as Toll-like Receptor ligands)
implicating that this is an essential step that precedes granule secretion. PhosphoSNAP-23 can thus be used as readout for activation-induced secretion in platelets.
Acylation is another common post-translational modification of SNARE proteins.
Thioester-linked fatty acids attached to cysteines present within several platelet
proteins have been reported in proteomic analyses [243] and this active acylation
appears to be agonist-induced and important for platelet function and in vivo
thrombus formation [244]. Two potential SNAREs that could be acylated in platelets
are Syntaxin 11 and SNAP-23. Both are membrane-anchored and yet lack classical
transmembrane domains. The presence of a cysteine-rich domain at their C-terminus
that can get readily acylated, allows them to be appropriate candidates for using
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acylation to tether to the plasma membrane and disruptions in acylation leads to
defects in platelet secretion and aggregation [Zhang J, in prep, 2017].
Signaling events during activation-exocytosis coupling
Platelets exocytosis is uniquely coupled to signaling events triggered by activation.
Resting platelets contain cis-SNARE complexes that prevent the non-specific release
of cargo in the absence of any activating stimulus. However, when platelets are
activated by agonists such as thrombin, collagen, ADP, thromboxane A2,
phosphatidylinositol-4, 5-bisphosphate (PIP2) present in the platelet membranes gets
cleaved to form diacylglycerol and inositol-1, 4, 5-trisphosphate (IP3). Diacylglycerol
(DAG) activates several forms of Protein Kinase C while IP3 increases the intracellular
Ca2+ concentration, triggering platelet secretion [246-249]. Increases in intracellular
Ca2+ are sufficient to induce platelet secretion but PKC also plays a key role, both
being critical second messengers in this process and use of PKC inhibitors has been
shown to block secretion [250]. How calcium regulates platelet secretion still
remains a mystery, simply because no definite calcium sensors (Synaptotagmins)
haven been detected in platelets. Although several proteins containing calciumbinding C2 domains (synaptotagmin-like domains) are present and can potentially
work as calcium sensors, yet definitive studies are yet to be done.
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Subsection Two: Intracellular trafficking in platelets
Eukaryotic cells are surrounded by a plasma membrane that serves as a partition
between the inside of the cell and its outside. Membrane-bound compartments
within the cells can transport cargo molecules (proteins and lipids) both into and out
of the cell at the plasma membrane interface in order to communicate with their
external environment. This process of cargo trafficking is key to the normal function,
growth, and survival of cells. These membrane-bound compartments or vesicles
traffic cargo via two major pathways: the outwards or the exocytic pathway that
carries intracellular contents to the outside, and the inwards or endocytic pathway,
that allows uptake/internalization of cargo from the external environment to the
inside of the cell. Vesicular transport, thus, is a major process by which
compartments within the cell, communicate with each other and connect the cell
with its external environment. Cargo-loaded vesicles can form at a donor
compartment with the help of specific coat and adaptor proteins (e.g., COPI, COPII
and clathrin), and then targeted to their appropriate acceptor compartments,
followed by tethering and vesicle fusion to said compartments, using an expansive
array of proteins including the SNAREs that oversee this highly regulated process. As
proposed by the SNARE hypothesis [197], intracellular membrane fusion reactions
require a specific set of SNARE proteins from one membrane (donor) to bind to their
cognate SNARE proteins associated with the other acceptor membrane, to drive this
process. Although there are several regulatory proteins that participate in this
collaborative process, it is widely accepted that the membrane-bridging SNARE
complexes are the main drivers of the cellular fusion machinery [251].
Platelets are secretory cells that release their cargo contents, upon activation, to
oversee their primary functions of hemostasis and thrombosis. In light of this,
platelet exocytosis has been extensively studied, with the SNAREs being the major
players executing the platelet release reactions. Platelet endocytosis, on the other
hand, has been largely recognized in the context of cargo loading into granules, and
receptor-mediated uptake of fibrinogen and it's biological ramifications in the
context of platelet cell biology and function. The role of SNAREs in mediating platelet
endocytosis, though implicitly acknowledged given its necessity, remains largely
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understudied. My thesis project aims to make important inroads into this facet of
SNARE-mediated endocytic trafficking in platelets.
General overview of endocytosis
The routes that carry cargo inside a cell from the cell surface start with the process
of endocytosis, by which cells internalize macromolecules, particulates and in some
cases even dead cells and pathogens. Small portions of the cell membrane invaginate
and engulf the material to be endocytosed, pinching off to form endocytic vesicles
that allow internalization of said material. Two main types of endocytosis are
distinguished on the basis of the size of the endocytic vesicle formed. Phagocytosis
or “cell eating”, involves the ingestion of large particles such as microbes or dead
cells via large vesicles called phagosomes (generally >250nm in diameter) [252]. The
other process is called pinocytosis or “cell drinking” and involves ingestion of fluid
and solutes via small pinocytic vesicles (about 100nm in diameter) [253]. Pinocytosis
is generally thought to be a constitutive process with cells ingesting small solutes and
fluids continually. The third kind of endocytosis, which allows uptake of specific
macromolecules from the extracellular fluid, is called receptor-mediated endocytosis.
In

this

process,

specific

macromolecules

bind

to

their

complementary

transmembrane receptor proteins, accumulate in coated pits, and then enter the cell
as receptor-macromolecule complexes in coated vesicles [254].
The pathways of endocytosis
Phagocytosis
Phagocytosis involves ingestion of large particles such as invading microbes or dead
cells and is a critical mode of response of the innate immune system. Phagocytosis in
eukaryotic cells serves to provide nutrition and is required for clearing apoptotic
bodies, which is key for maintaining cell turnover, tissue homoeostasis and
remodeling [255]. Phagocytosis of foreign bodies and microbes such as bacteria,
fungi, and viruses can be cleared from infection sites by professional phagocytesmacrophages, neutrophils, and dendritic cells, thus forming the first line of defense
against infection. Phagocytosis is central to innate immunity; however, professional
phagocytes can present processed/degraded phagocytosed antigens to the lymphoid
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cells and initiate an adaptive immune response [256-258]. While the immune
phagocytes can engulf microbes and initiate a pro-inflammatory response,
phagocytosis by other non-professional phagocytes such as fibroblasts, epithelial
cells, and endothelial cells mount an anti-inflammatory response. These cells,
however, cannot ingest microbes, but they contribute in clearance of apoptotic
bodies and help in clearance of dead cells and thereby serve to contain tissue
damage [259]. Phagocytosis is a receptor-mediated event and as such numerous
receptors are present on the cell surface that can engage with foreign bodies and
mediate uptake. Some of the key receptors are the pattern recognition receptors
that detect unique pathogen-associated molecular patterns (PAMPs) on microbes
that are never found in higher eukaryotes (e.g., mannose receptor CD206, dectin-1,
CD114, scavenger receptor CD204, CD36 etc.), opsonic receptors that allow
opsonization of microbes (e.g., FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa receptors that bind to
the different IgGs), apoptotic corpse receptors that bind to apoptotic bodies and
help clear them (e.g., TIM-1 and TIM-4, CD36 receptors etc.) amongst others [255].
The presence of FcγRIIa on platelet surface enables platelets to be uniquely capable
of doing phagocytosis. This receptor is crucial for immune complex clearance and
platelets have been shown to phagocytose immune complexes in a FcγRIIadependent manner [260-261]. Platelets can phagocytose bacteria such as P.
gingivalis [262] and S. aureus [263-264] and it is usually thought to be inside a
membrane-bound compartment or the OCS. Platelets respond to phagocytosed
bacteria by generating antimicrobial peptides (defensins) that could potentially kill
the bacteria. Nevertheless, what happens to phagocytosed bacteria remains far from
clear. Theories have been put forth suggesting that the bacteria remain trapped
within these membrane-bound compartments but remain viable [265]. This is could
be a potential mechanism to evade the immune system and may play a role in
disease pathogenesis.
Platelets can also phagocytose inert molecules such as latex beads that cause
platelet aggregation due to the release of ADP [266]. Interestingly, longer
incubations of platelets with latex beads led to the loss of granule integrity [266],
though the mechanism of this is not clear.
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Macropinocytosis
Another regulated form of endocytosis that mediates the non-selective uptake of
solutes, nutrients and antigens. It is one of the clathrin-independent endocytosis
processes and is an actin-dependent process initiated from surface membrane
ruffles that give rise to distinct heterogeneous endocytic vesicles called
macropinosomes that are much larger than clathrin-coated vesicles [253].
Macropinocytosis is important for cell motility which becomes key in the case of
tumor metastasis due to its role in Actin-dependent membrane ruffling [267]. In the
immune system, micropinocytosis becomes a way for dendritic cells and
macrophages to sample their microenvironment and endocytose antigens that are
then processed and presented with major histocompatibility complex (MHC) class II
or class I molecules to T cells to mount an adaptive immune response [268-270].
Data generated in this thesis and others [271] have shown that platelets present
antigen in the context of MHC class I. Though there are no definite reports of
micropinocytosis occurring in platelets, platelets acting as antigen presenting cells
could potentially utilize an endocytic mechanism similar to micropinocytosis to
engulf pathogens and respond accordingly.
Clathrin-mediated endocytosis
Clathrin-mediated endocytosis also called receptor-mediated endocytosis is the most
ubiquitous endocytic pathway and it requires the use of clathrin, a coat protein,
which plays a major role in the formation of coated vesicles [272]. Clathrin forms a
triskelion-shaped structure composed of three heavy chains and three light chains.
The three heavy chains form the structural backbone of the clathrin lattice while the
three light chains are thought to regulate the formation and disassembly of the
polyhedral clathrin lattice. The clathrin lattice builds around the small vesicles where
cargo is transported from the outside to the inside of the cell. These vesicles are
called clathrin-coated vesicles (CCVs) and are formed at specialized domains of the
plasma membrane called the clathrin-coated pits (CCPs) [273-274].
Based on ultrastructural and cell biology data, CCV formation occurs in five stages:
initiation, cargo selection, coat assembly, scission, and uncoating. Several adaptors
and accessory proteins are involved in the process. In the first stage of vesicle
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budding, or nucleation, a clathrin-coated pit, in the form of a membrane invagination
if formed and is triggered when the highly conserved adaptor protein 2, AP2, is
recruited to the plasma membrane [275]. AP2 can bind to the cytoplasmic tails of
receptors for the specific cargo being endocytosed and plasma membrane specific
lipids such as phosphatidylinositol-4, 5-bisphosphate (PtdIns (4,5)P2) and facilitates in
cargo selection [276, 279-280]. Nucleation promotes polymerization of clathrin into
curved lattices which aid in the formation and constriction of the vesicle neck,
bridging the two membranes at the neck into close apposition. The F-BAR domain of
the FCH domain only containing proteins (FCHO) proteins, which come into play
during nucleation, provides the membrane-bending activity that is needed to
generate curvature at the neck for the membrane to bridge close to each other [277].
Cargo selection is mainly mediated by AP2 at the plasma membrane, while other
isoforms such as AP1, AP3, and AP4 are found to aid in cargo selection at the internal
membranes [278]. AP2 binds clathrin and most other accessory proteins and helps
in the maturation of the forming clathrin-coated vesicle. During the assembly
process, clathrin triskelia get recruited at the pits where AP2 concentrations are
higher. The absence of clathrin recruitment at these sites prevents maturation of the
coated vesicle [277]. After the mature coated vesicle has formed, Dynamin, a small
molecule GTPase, is recruited to this site by BAR-domain-containing proteins such as
amphiphysin, endophilin, and sorting nexin 9 (SNX9), which have SRC homology 3
(SH3) domains that bind to the proline-rich domains of Dynamin [278-285]. Dynamin
forms a helical polymer around the neck, constricting it. Clathrin polymerization
facilitates a conformational change in Dynamin powered by GTP hydrolysis which
mediates scission of the mature coated vesicle [286-289]. The clathrin-coated
vesicles are subsequently released by proteins such as the ATPase heat shock
cognate 70 (HSC70) and its cofactor, auxilin, that allows the uncoated vesicle to now
travel

to

its

targeted

endosome

[290-291].

Additionally,

alterations

in

phosphoinositide composition of the clathrin-coated vesicles mediated by the
phosphatase, synaptojanin, are required for the uncoating process [292]. Eventually,
uncoating allows disassembly of the clathrin machinery and its adaptor proteins
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from the membrane back to the cytosol for recycling in subsequent rounds of
clathrin-dependent endocytosis.
Clathrin-independent endocytosis
Several endocytic pathways have now been identified that traffic cargo inside cells
without using clathrin and these are collectively grouped under the clathrinindependent endocytic pathways. These pathways can be further classified based on
their use of Dynamin. Some clathrin-independent (CI) pathways use Dynamin, such
as those involving caveolae and Rho families of GTPases, while there are others that
use members of the CDC42 and ADP-ribosylation factor (Arf) families of small
GTPases to mediate vesicle scission, which is central to subsequent vesicle
internalization [293].
Of the Dynamin-dependent CI pathways, caveolae-mediated endocytosis is the most
studied process. It utilizes formation of caveolae at the plasma membrane, which is
50-80nm flask-shaped membrane invaginations marked by the Caveolin family of
proteins [294-295]. Caveolae are enriched in cholesterol, sphingolipids, signaling
proteins and glycosyl phosphatidylinositol-anchored proteins (GPI-APs) [296, 297].
Cargo transported by caveolae includes lipids, proteins, and lipid-anchored proteins.
The second type of Dynamin-independent CI pathways utilizes the GTPase, RhoA, as
noted in internalizing transmembrane receptors such as the interleukin-2 receptor β
chain in fibroblasts and immune cells [298]. It is thought that the actin machinery is
recruited through the actions of RhoA, to mediate this type of endocytosis [295].
Dynamin-independent CI pathways use either the Rho family member CDC42 or the
Arf family of small GTPases, chiefly Arf6. Most GPI-anchored proteins are
transported via this process using CDC42 [299]; while Arf6 mediates endocytosis of
class I MHC, β1 integrins, carboxypeptidase E, E-cadherins and some other GPIanchored proteins [300-301].
How cargo enters cells through the different CI pathways is not clear when
compared to clathrin-mediated processes, simply because no well-defined adaptors
or accessory proteins have been identified yet. Ubiquitination of cargo has been
suggested as a possible mode to tag cargo proteins for entry via this pathway, for
example, receptor tyrosine kinases such as epidermal growth factor (EGF), by the E3
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ubiquitin ligase c-Cbl, preferentially enters cells via the caveolae [302]. Flotilin-1 and
-2, are integral membrane proteins that mediate endocytosis of GPI-anchored
proteins and cholera toxin b (CtxB) in cells that lack Caveolin [303] and can form
dynamic punctate structures that allow endocytosis at sites that are distinct from
clathrin and Caveolin sites at the plasma membrane [304]. Despite the discovery of
many proteins that mediate the different CI pathways, the exact mechanisms are still
poorly understood.
The components of the endocytic pathway
In mammalian cells, distinct membrane-bound compartments called endosomes,
serve as carriers of internalized cargo molecules. They shuttle cargo from the plasma
membrane to the inside (early endosomes) or recycle internalized cargo back to the
cell surface (recycling endosomes), or sort them to degradative compartments such
as the late endosomes or lysosomes.
Early endosomes: It is the starting point for cargo entry into the cell [305]
irrespective of the endocytic route used (clathrin-dependent, -independent, caveolar,
or Arf6-dependent pathways) [293]. They are small and have a characteristic
tubulovesicular structure ranging up to 1µm in diameter and patrol the cell
periphery close to the plasma membrane along microtubules [306]. The limiting
membrane of early endosomes contains various subdomains that vary in their
composition and function [307]. Early endosomes are identified by the presence of
Rab5, Rab4 GTPases, with Rab5 being key in maintaining organelle identity, together
with its effector molecule VPS34/p150, a phosphatidylinositol 3-kinase (PI3K)
complex that generates phosphatidylinositol-3-phosphate (PtdIns3P) [307-308].
Rab5 oversees early endosomal maturation and eventually becomes the main
regulator for conversion of early endosomes to late endosomes. Early endosomes
are weakly acidic in nature (pH 6.8-5.9) [309] and contain low levels of Ca2+ within
them [310]. The subdomains located in the tubular extensions of the early
endosomes are the epicenters for molecular sorting and generate vesicles either
targeted to the other cell organelles or the plasma membrane, recycling endosomes,
late endosomes or the Trans-Golgi network (TGN) [311].
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Recycling endosomes: Endocytic uptake and recycling are key to ensure the plasma
membrane composition. Cargo that is endocytosed faces one of two fates; either
they are targeted to the lysosomes for degradation or they are recycled back to the
cell surface [311]. Most peripheral early endosomes are capable of recycling cargo;
however, most cells have a distinct subset of endosomes, called the recycling
endosomes or endosomal recycling compartment (ERC), located along the
perinuclear microtubule-organizing center (MTOC) [312]. These recycling endosomes
have a slightly higher pH of ~6.4 [315] and are incredibly heterogeneous in
morphology and composition due to dynamic trafficking to and fro between early
endosomes and plasma membrane [313-314]. Rab11 is the most important GTPase
that adorns recycling endosomes [316]. Rab11 interacts with the Ral/Exocyst
complex (made up of RalA/B GTPases and the exocyst complex comprising of Sec5,
Sec6, Sec8, Sec10, Sec15 and Exo70 proteins), a multi-protein complex, that is
essential for polarized targeting of vesicles in most cells including epithelial cells
[317-319]. Recycling back to the cell surface occurs either through the faster Rab4dependent short-loop (allows trafficking back to the plasma membrane) or the
slower Rab11-dependent long loop (where cargo moves from early endosome to
endosomal recycling compartment (ERC) and then recycles back to the plasma
membrane) [320]. Arf6, a small GTPase belonging to the mammalian Arf family of
proteins, has a distinctive plasma membrane and peripheral localization that plays a
key role in endocytic recycling back to the plasma membrane [321].
Late endosomes: Cargo that is destined to the lysosome passes through the late
endosomes en route, arriving either from early endosomes, trans-Golgi network, or
the phagosome. Mature late endosomes are round or oval shaped with a diameter
of 250-1000 nm and their pH ranges from 6.0-4.9 [309]. Limiting membranes of
these endosomes contain several lysosomal membrane glycoproteins such as LAMP1 and numerous acid hydrolases are present in their lumen. Late endosomes localize
to the perinuclear region of the cell and can sometimes fuse with each other to form
larger late endosomes or can fuse with the lysosomes or with endosomes to form
hybrid endolysosomal organelles [322]. Rab7-positive late endosomes are derived
from the vacuolar domains of the early endosomes and starts with the generation of
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a Rab7 domain in a process facilitated by Rab5-GTP [323]. Post GTP hydrolysis, the
Rab5-to-Rab7 switch occurs with the GDP-bound Rab5 dissociating with its effectors
from this newly formed late endosome. Rab5 (early) and Rab7 (late) are the master
regulators of the endocytic pathway and provide the most important organelle
identity markers for their respective compartments. Rab7 and its effector molecules
determine the functions of late endosomes and lysosomes [324].
Lysosomes: They are the final and largest compartment, sized at 1-2 µM, of the
endocytic pathway where cargo is degraded. Lysosomes utilize a host of acid
hydrolases to accomplish the process of cellular waste turnover to generate new
building blocks for the cell. Inside the lumen of the lysosomes, the pH drops to ~4.5
[309]. Lysosomes are also important in energy metabolism, plasma membrane repair,
cell signaling and secretion [325].
Multivesicular bodies: An intermediate intracellular organelle that incorporates
cargo that gets sorted for degradation and operates in the endosome-to-lysosome
route of endocytosis. Multivesicular bodies (MVBs) arise during maturation of the
early to late endosome process. Cargo that is destined for lysosomal degradation is
ubiquitinated and then incorporated into the intermediate intraluminal vesicle (ILV)
that buds from the limiting membranes of the early endosome, giving rise to the
MVB, which can eventually fuse with or mature into lysosomes [368-369]. Cargo
trafficking to MVBs provides a mechanism for damaged or misfolded proteins to be
degraded, especially plasma membrane receptors (e.g., EGFR) [370] that undergo
downregulation or clearing from the cell surface as part of their regulation. MVBs
perform diverse functions within the cell. They are the major sorting hub for
damaged proteins as well as serve as signaling nodes within the cell. MVBs recruit
ubiquitinated cargos, with Ubiquitin serving as a positive sorting signal for MVBdirected degradative pathway, using the endosomal sorting complexes required for
transport (ESCRT) machinery made up of cytosolic protein complexes: ESCRT-0,
ESCRT-I, ESCRT-II, and ESCRT-III, together with a host of accessory proteins including
the AAA-ATPase vacuolar protein sorting-associated 4 (Vps4) and endosome-specific
phosphatidylinositol-3-phosphate (PtdIns3P) [371-372]. In addition to degradation,
MVBs also function as non-degradative storage organelles as seen when von
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Willebrand Factor (vWF) gets packaged into the lumen of alpha granules in platelets
[41-42] or the Weibel-Palade bodies of endothelial cells [373]. Proteins such as the
transferrin receptor, which are recycled back to the plasma membrane postinternalization, are incorporated into the MVBs for secretion at the cell surface [374].
Numerous cell types including neurons, epithelial cells, mast cells, tumor cells,
melanocytes, platelets as well as other cell types within the hematopoietic lineage
are known to generate extracellular vesicles called exosomes, which are derived
from MVBs [375]. MVBs have a slightly acidic pH of 6.0-5.0 [309].
Role of endocytosis in platelets
As mentioned earlier, platelet endocytosis has been largely studied in the context of
granule cargo packaging and αIIbβ3-mediated uptake of fibrinogen. Uptake of small
particles and solutes by human platelets was first reported by Zucker-Franklin in
1981 [14] into a unique membrane structure called the open canalicular system (OCS)
by a phagocytosis-like process. Further studies using electron microscopy and
cytochemistry provide evidence for endocytosis of circulating proteins such as
plasma fibrinogen [15, 16] into platelets. The integrin αIIbβ3-mediated endocytosed
fibrinogen eventually ends up in alpha granules [340]. Platelet endocytosis is
important for granule cargo loading (such as fibrinogen and VEGF) [9, 17] and
contributes to thrombus formation by controlling the surface expression of several
key proteins such as the integrins, chiefly αIIbβ3, the major platelet glycoprotein
receptor [18]. Integrin trafficking modulates platelet spreading on endothelial
surfaces and clot retraction [19]. Endocytosis of purinergic receptors such as P2Y1
and P2Y12 mediates their re-sensitization and response to ADP [20]. CLEC-2 and
Thrombopoietin receptor Mpl/TPOR endocytosis regulates their surface levels and
downstream signaling responses [21, 22].
Coated vesicles and membranes are central to intracellular trafficking and clathrinmediated endocytosis in almost all eukaryotic cells. The first report of the presence
of such coated vesicles in platelets came from studies done on aldehyde-fixed
human platelets back in the early 1980s. The concomitant addition of alcian blue and
tannic acid to human platelets during glutaraldehyde fixation allowed for the
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visualization of coated membranes within platelets [326]. These coated membranes
were found either as coated pits or vesicles or dotted around the plasma membrane
and the secretory granules (alpha granules and lysosomes). Further evidence using
fluid-phase markers showed that the coated pits are lined with the plasma
membrane and open canalicular system (OCS) where the coated vesicles either
existed by themselves or fused with the secretory granules [327]. These studies first
demonstrated that an active endocytosis and intracellular trafficking process occurs
in platelets. Following that, a series of experiments done by Bainton and colleagues
provided evidence for endocytosis of plasma proteins such as albumin, IgG and most
importantly αIIbβ3 receptor-mediated uptake of fibrinogen into both megakaryocytes
and platelets, thereby laying the groundwork for platelet endocytosis and its
importance [15-17, 328-329]. In support of these studies, transmission electron
microscopy of antibody-stained ultrathin frozen sections of platelets showed that
plasma proteins such as fibrinogen and von Willebrand factor (vWF) are taken up
and translocate to storage granules (alpha granules in this case) [330]. Klinger et al.
used post-embedding immunocytochemistry on platelets using the acrylic resin, LR
white, to first show the presence of clathrin-coated vesicles colocalizing with
fibrinogen, vWF, fibronectin on the cytoplasmic faces of the alpha granules, open
canalicular system and the plasma membrane [331]. Morphological studies on
quiescent platelets using fibrinogen-stabilized colloidal gold as a receptor-mediated
endocytosis marker and acid phosphatase as a lysosome marker demonstrated that
both clathrin-dependent and clathrin-independent endocytic pathways occur in
platelets [332]. While fibrinogen uses a clathrin-mediated route to enter the alphagranules, acid phosphatase uses a clathrin-independent degradative endo-lysosomal
route to reach the lysosomes. This report also proposes the presence of a lysosomal
autophagy system that is tasked with degradation in platelets and could be linked to
platelet senescence [332]. Many platelet surface receptors such as integrin αIIbβ3,
glycoprotein Ib are internalized and cycle back to the plasma membrane [334-338].
In unstimulated platelets, an internal storage pool of these receptors exists which
can be targeted to the plasma membrane upon platelet activation, thereby
increasing their surface expression. Stimulation by agonists such as thrombin or ADP
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often leads to re-distribution on the plasma membrane as can be noted in the case
of glycoprotein IV (CD36) [339]. ADP-stimulation causes an enhancement in
fibrinogen internalization in platelets [333]. Megakaryocytes but not platelets can
endocytose plasma-derived factor V, a member of the coagulation cascade, via a
clathrin-dependent and most likely receptor-mediated process [342], although factor
V is a known to platelet protein part of the alpha granule repository, where it
colocalizes with fibrinogen [341].
Quantitative proteomic analyses have shown platelets to carry most of the proteins
that are part of the clathrin-mediated endocytic machinery, including all three
isoforms of the mechanochemical small GTPase Dynamin, Dynamin1 (DNM1),
Dynamin2 (DNM2) and Dynamin3 (DNM3) [200, 343]. Human platelets contain all
three isoforms, DNM1, DNM2 and DNM3 while mouse platelets predominantly
express DNM2. Dynamin plays a key role in clathrin-coated vesicle fission.
Interestingly they have been shown to play a role in megakaryopoiesis, especially
DNM3 [344-345]. DNM3 co-localizes to the demarcation membrane system (DMS),
which serves as a membrane reservoir during proplatelet formation in the
megakaryocytes [345]. In several human macrothrombocytopenia disorders, the
nonmuscle myosin IIA (MYH9) protein important for cytoskeletal reorganization,
appears to be mutated [346] and DNM3 has been shown to bind MYH9 [345]. In vitro
use of pan-Dynamin inhibitor such as Dynasore in megakaryocytes impaired
proplatelet formation [347]. In fact, GWAS studies corroborate the importance of
DNMs in regulating platelet size and formation when a single nucleotide
polymorphism (SNP) within the DNM3 gene promoter was detected to be associated
with variable mean platelet volume in humans [347].
Platelets have an abundance of DNM2 [200] and mutations in DNM2 have been
associated with thrombocytopenia and hematopoietic diseases, most notably
Charcot-Marie-Tooth disease [348-349]. Using platelet-specific DNM2 knockout mice,
the role of DNM2 in thrombopoiesis was determined by Bender et al. [22]. These
mutant mice had severe macrothrombocytopenia with giant platelets but increased
clearance from circulation leading to low platelet counts. Bone marrow
megakaryocytes had altered demarcation membrane system packed with
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abnormally high numbers of clathrin-coated vesicles in addition to increased
emperipolesis (presence of intact nucleated cells within the MK cytoplasm).
Compared to control MKs, the clathrin-mediated endocytic pathway was also
impaired in this DNM2-null MKs as noted by mislocalization of early endosomal
markers such as Early Endosomal Antigen 1 (EEA1) and Adaptor protein,
Phosphotyrosine interacting with PH domain and Leucine Zipper 1 (APPL1).
Proplatelet formation from DNM2-null MKs was also impaired as was
Thrombopoietin receptor (TPO/Mpl) endocytosis in DNM2 null platelets leading to
constitutive phosphorylation of downstream Janus Kinase 2 (JAK2). Constitutive JAK2
signaling is consistent with defective endocytosis that is seen in these platelets.
Additionally,

DNM2

null

mice

developed

MK

hyperplasia,

myelofibrosis,

extramedullary hematopoiesis and splenomegaly with a concomitant increase in
hematopoietic stem progenitor cells [22].
DNM1 levels are very low in platelets and it is mainly expressed in the brain where it
functions in synaptic vesicle endocytosis [350].
Dynamin-related protein-1 (Drp1) belongs to the Dynamin family of small GTPases
and plays a key role in mediating fission and fusion during mitochondrial biogenesis
[352]. Platelets contain Drp1, which gets phosphorylated upon activation [351]. Drp1
plays a key role in fusion pore stability and granule exocytosis. Inhibition of Drp1
affects platelet accumulation during thrombus formation in vivo. Any role of Drp1 in
mediating endocytic events in platelets is currently unknown.
Disabled-2 (Dab2) is a clathrin, AP-2, and cargo binding adaptor protein that is
involved in endocytic trafficking of many cell surface receptors and modulating
intracellular signaling [353]. Alternate splicing generates two isoforms, p82-Dab2 and
p59-Dab2 [354]. Dab2 is present in megakaryocytes and platelets and plays a key
role in facilitating megakaryocytic differentiation [355, 358] with p82-Dab2 mainly
expressed in human platelets while p59-Dab2 is predominant in mouse platelets
[356]. In human platelets, p82-Dab2 is present in the cytosol and alpha granules and
interacts with the cytoplasmic tail of αIIbβ3, gets phosphorylated by thrombin and
upon thrombin stimulation of platelets, gets secreted but remains tethered to the
αIIb subunit, regulates fibrinogen binding and platelet aggregation [357]. In mouse
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platelets, p59-Dab2 is required for platelet aggregation, fibrinogen uptake, RhoAROCK activation, secretion of ADP and αIIbβ3-mediated platelet activation [356].
Platelet-specific Dab2-deficient mice have a bleeding diathesis and defective
thrombus formation in vivo [356]. Dab2 is a key modulator of integrin inside-out
signaling in platelets and plays key roles in fibrinogen uptake; however the exact
mechanistic underpinnings of how Dab2 acts, which proteins of the clathrinmediated endocytic pathways it interacts within platelets, remains unknown and
needs to be further explored.
ADP-ribosylation factor 6, Arf6, is a small GTPase from the ARF family of proteins
that oversee endocytic trafficking and receptor recycling and has been shown to be
involved in several steps of trafficking such as recruitment of coat proteins, coated
pit assembly, vesicle fission, and vesicle route [359, 366]. Our group was the first to
show the presence of Arf6 in platelets [360]. There are six members of the Arf family,
with Arf1, Arf3, and Arf6 being present in platelets [200, 360]. In platelets, ASAP1, a
member of the family of ArfGTPase-activating proteins (Arf-GAPs), proteins that
induce hydrolysis of GTP bound to Arf, was detected and shown to be recruited to
peripheral focal adhesions via CrkL, an SH2 and SH3 adaptor protein for WASP, Syk
and STAT5 [361, 364, 367]. Previous work by our group has shown that in resting
platelets, Arf6 is present in the GTP-bound form, and upon platelet activation, Arf6GTP is quickly converted to Arf6-GDP [360]. This transition is regulated by two waves
of platelet signaling pathways, primary signaling (e.g. PAR receptor, GPVI) and
contact-dependent signaling (e.g. αIIbβ3 integrin) [363]. This was in corroboration to
previous studies showing the involvement of Arf6 in regulating integrin function in
platelets [361-362]. Blocking integrin αIIbβ3 outside-in signaling could partially
reverse the loss of Arf6-GTP, suggesting a regulation of Arf6 by signaling downstream
of integrin αIIbβ3. Arf6 is downstream of several key platelet kinases, like PLC, PI3K,
PKC, and Syk, indicating its importance in platelet signaling [364]. Using an inhibitory,
myristoylated Arf6 N-terminal peptide, loss of Arf6-GTP could be blocked in human
platelets, probably due to the inhibition of the Arf6 GAP activity by the peptide.
Pretreatment with this peptide inhibited platelet aggregation, adhesion and
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spreading on the collagen-coated surface, and activation of Rho family members,
suggesting the central role of Arf6 in platelet activation [363].
The endocytic trafficking function of Arf6 has been widely recognized in other cells
[366]. In platelets, Arf6 was suggested to be involved in P2Y12 receptor
internalization required for receptor desensitization and resensitization to ADP. It
was shown that P2Y activation by ADP could stimulate Arf6 activation, and activated
Arf6 stimulates Nm23-H1, a nucleoside diphosphate kinase, which in turn promotes
dynamin-dependent internalization of P2Y receptors [150]. It was also proposed that
Arf6-GTP in resting platelets is maintained by cytohesin-2, an Arf–guanosine
exchange factor (Arf-GEF) protein, and upon platelet activation, PKC-mediated
phosphorylation of cytohesin-2 decreases the interaction between Arf6-GTP and
cytohesin-2, leading to loss of Arf6-GTP and platelet secretion [365]. However, it
should be noted that these studies used Myr-Arf6 peptide and pharmacological
inhibitors, and the dynamics of Arf6-GTP changes were not consistent with previous
reports.
To better understand the role of Arf6, a platelet-specific (PF4-Cre)-Arf6 conditional
knockout mice were generated [19]. Arf6 null platelets have defective αIIbβ3mediated fibrinogen uptake in vitro and in vivo. Although resting and activated levels
of αIIbβ3 were unchanged, Arf6 null platelets demonstrated enhanced spreading on
fibrinogen-coated surfaces and the rate of thrombin-induced clot retraction, in the
presence of fibrinogen, was faster than controls. Arf6 null platelets had no overt
morphological defects, no secretion defects or aggregation defects. Tail bleeding
times were normal and no occlusion defect was noted in the FeCl3-induced carotid
artery injury model of arterial thrombosis. Taken as a whole, the noted defects in the
Arf6 null mice could be largely attributed to altered integrin trafficking and serves as
a viable model to study endocytic trafficking in platelets and megakaryocytes. While
Arf6-mediated integrin trafficking largely affects platelets’ roles in acute platelet
functions such as clot retraction and spreading, it remains to be seen what other
platelet functions are influenced by Arf6.
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Role of integrin trafficking in platelets
As mentioned previously, integrins are one of the major platelet receptors and their
function is essential for hemostasis and thrombosis. While trafficking of integrin
heterodimers between the plasma membrane and the intracellular endosomal
compartments is a key aspect of regulating integrin function [376], most notably in
the context of cell migration [382-383], how much of this process occurs in platelets,
what are the regulators for said process and the potential biological ramifications of
integrin trafficking in platelet function still remains to be fully explored.
Mechanistically, integrin endocytosis occurs both in a clathrin-dependent and a
clathrin-independent manner. α5β1 and αvβ3 integrins endocytose via both clathrindependent endocytosis [377-379] and caveolin-dependent endocytosis [380] while
αIIbβ3 mainly prefers a clathrin-dependent endocytic pathway [381]. After
internalization, integrins are recycled back to the plasma membrane via two
temporally and spatially distinct mechanisms, a short-loop and a long-loop recycling.
After reaching early endosomes, integrins such as αvβ3, selected for short-loop
recycling are sorted to particular subdomains of these endosomes and then rapidly
returned to the plasma membrane in a Rab4-dependent manner [385]. Alternatively,
integrins β1, αvβ3, and α6β4 may pass from EEs to the recycling endosomes, from
where they return to the plasma membrane under control of the Rab11 GTPase,
referred as long-loop recycling [384]. These trafficking routes are under the control
of several regulators such as Arf6 and signaling kinases such as PKB/Akt, GSK3β as
well as several isoforms of Protein Kinase C [384].
Integrin trafficking plays an important role in cell adhesion and migration. As such,
inhibition of long-loop recycling events by targeting Rab11, Arf6 etc., impairs cell
migration and motility in a number of different cell types [386]. Selective inhibition
of the short-loop recycling of integrin αvβ3 by using dominant-negative Rab4 leads to
impaired spreading on vitronectin-coated matrices in an ERK1-dependent manner
[387]. Additionally, it has been demonstrated that treating cells with primaquine
inhibits receptor recycling and leads to accumulation of integrins within endosomes
with the consequent detachment of cells from the substratum [385]. Integrin
trafficking also plays a key role in tumor cell invasiveness with several reports of
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regulators such as Arf6 and Protein Kinase D1 abounds in the invadopodia of
aggressive tumor cells [388-389].
In platelets, studies regarding integrin recycling have been mainly focused on how
αIIbβ3 is trafficked in and out of platelets. While the concept of αIIbβ3 transiting back
and forth between the plasma membrane and intra-platelet compartments has been
largely recognized for close to three decades, the mechanistic understanding is still
far from complete. Fibrinogen, part of the alpha granule repository in platelets,
enters via binding to αIIbβ3, transits through the multivesicular bodies and ends up in
alpha granules [17, 41]. Therefore, fibrinogen content in α-granules is a good
indicator of trafficking of integrin αIIbβ3. This has been exploited to determine the
intricacies of the process of integrin αIIbβ3 trafficking in platelets. One of the first
insights into this process came from the studies using the molecule c7E3 Fab
fragment, an antagonist of integrin αIIbβ3, commercially available as abciximab [390].
One of the startling findings of this study was that trafficking of αIIbβ3 in platelets is
very fast where they showed that abciximab or c7E3 Fab, could be detected within 3
hours post-infusion into a patient. Consistently, it requires much shorter time for
abciximab to be detected in vitro after incubation with washed platelets. Open
canalicular systems (OCS) were stained as early as 1 min showing that indeed
trafficking of αIIbβ3 is very fast. This is in agreement with the widely held theory in
the platelet field that the open canalicular system, which serves as a membrane
reservoir for platelets, is the entry site for the endocytosis of various exogenous
substances [391]. Studies using monoclonal antibody AP6, which binds to integrin
αIIbβ3 only when the receptor is occupied by intact fibrinogen, suggested the
presence of a pool of ligand-bound αIIbβ3 within the α-granules [392]. Platelet
activation by ADP or thrombin receptor activation peptide (TRAP) significantly
increases the actin cytoskeleton-dependent internalization of αIIbβ3 [335]. Studies
using an anti-Ligand-induced binding site (anti-LIBS) antibody, which activated αIIbβ3
by directly binding to it, showed that enhanced integrin internalization directly
modulates platelet aggregation [393]. Our recent studies have now added to this
growing body of integrin trafficking and its importance in platelet function. Arf6, a
Ras-like, small guanosine triphosphate (GTP)-binding protein called adenosine 5’46

diphosphate ribosylation factor 6 (Arf6), which is important for intracellular
trafficking of integrins and membrane receptors, mediates fibrinogen endocytosis
and trafficking of αIIbβ3 in platelets [19]. Loss of Arf6 leads to defective fibrinogen
uptake and storage which manifests in enhanced platelet spreading and clot
retraction. This could potentially be due to faster short-loop recycling of αIIbβ3, which
could explain why αIIbβ3-bound fibrinogen resides for less time (compared to
wildtype) within the intra-platelet compartments that are manifested as lower
fibrinogen content of Arf6 KO platelets. Altered dynamic routing of αIIbβ3 could lead
to enhanced surface presence of the integrins which may allow more areas of
contact with fibrinogen-coated matrices corresponding to enhanced spreading. This
coupled with faster thrombin-induced clot retraction could predispose Arf6 KO mice
to become hyper thrombotic in nature. While this hyper thrombotic phenotype
could not be detected in standard models of arterial thrombosis due to technical
redundancies of the assays involved, it does shed some light on the global
importance of integrin trafficking and recycling on hemostasis and thrombosis. Arf6
KO mice do not have a secretion defect or a bleeding phenotype, yet altered integrin
trafficking leads to defective cargo uptake and a predisposition to hyperthombosis
(though this remains to be confirmed yet). In summary, Arf6-mediated integrin αIIbβ3
trafficking occurs constitutively in platelets and appears to play an important role in
the deposition of α-granule cargo, like fibrinogen, and in the modulation of other
integrin-mediated platelet functions, like spreading, clot retraction. In my thesis,
Arf6 null mice are used as a model system to understand how endocytosis and
potentially integrin trafficking influences other platelet functions e.g., mediating
innate immune responses against pathogens.
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Figure 2
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Figure 2 Potential platelet endocytic routes. Cargo can enter platelets either via
clathrin-dependent endocytosis, requiring GTP hydrolysis by Dynamin and using
specific surface receptors (e.g., αIIbβ3-mediated fibrinogen entry) or via clathrinindependent endocytosis that may require Dynamin (via caveolin- or RhoAdependent pathways) or may not (via Arf6- or Cdc42-dependent pathways).
Internalized cargo then transits through Rab4 GTPase-positive early endosomes,
where it can be sorted to recycling endosomes (Rab 11-positive) for a return to the
plasma membranes or to multivesicular bodies and ultimately into α-granules for
storage (e.g., fibrinogen, vWF, thrombospondin-1). Alternatively, cargo can move
into late endosomes, either directly from early endosomes or through multivesicular
bodies. Cargo from late endosomes can transit into dense granules or into lysosomes
where it may be degraded or stored. The complexity of these pathways in platelets
has not been studied in sufficient detail.
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Table 1: Endocytic and sorting machinery in platelets.
Full name of Protein*

Abundance (copies per human platelet)&

Aliases/Identifiers

Clathrin-mediated endocytosis
Clathrin Heavy Chain 1, 2

CLTC1; CLTC2

13,600; 4,300

Clathrin Light Chain A, B

CLTA; CLTB

2,800; 2,100

AP-2 complex (α, β, σ, μ)

AP-2

ND; 7,900; ND; 4,800

AP-3 complex

AP-3

3,500

AP-4 complex

AP-4

1,400

Dynamin 1 , 2, 3

DNM1, DNM2, DNM3

5,200; 6,100; 3,600

Endophilin A2, B2

Endo A2; Endo B2

3,500; 2,900

Sorting Nexins (1, 2, 3, 4, 5,
6, 7, 8, 9, 24, 29, 30)

SXN

1,500; 5,100; 8,500; 1,400; 1,700; 2,300; 1,400; 730; 1,900;
1,800; 810; 1,100.

Clathrin-independent endocytosis
Ras-related C3 botulinum
toxin substrate 1, 2

Rac1; Rac2

32,900; 27,900

Cell division control protein
42 homolog

Cdc42

27,900

ADP-ribosylation Factor 1, 3,
4, 5, 6

Arf1, Arf3, Arf4, Arf5,
Arf6

49,800; 44,300; 33,300; 36,200; 6,400

Flotillin-1, 2

FLOT-1; FLOT-2

7,500; 6,000

Rab GTPases
Rab 1A, 1B, 2A, 2B, 3, 4, 5,
6A, 6B, 7, 8A, 8B, 9, 20, 21,
30, 31, 32, 33, 35, 37, 38

27,700; 26,000; 11,600; 7,400; 11,200; 23,200; 7,700; 20,900;
27,500; 18,800; 17,900; 16,100; 2,500; 1,500; 5,600; 4,700;
2,200; 8,900; 2,000; 5,600; 9,200; 4,400

Protein Sorting Complexes
Vacuolar Protein Sortingassociated protein 4A , 4B,
11, 13A, 13B, 16, 26A, 26B,
28, 29, 33A, 33B, 35,

VPS 4A; VPS 4B; VPS11;
VPS 13A, VPS 13C; VPS
16; VPS 26A, VPS 26B;
VPS 28; VPS 29; VPS 33A;
VPS 33B; VPS 35; VPS 36;
VPS 37A; VPS 37B; VPS
41; VPS 45; VPS 52

2,900; 4,300; 1,100; 2,000; 1,600; 1,500; 1,100; 3,100; 3,600;
4,800; 1,700; 2,100; 4,600; 2,500; 2,900; 1,900; 810; 2,200;
900;

Neurobeachin-like 2 protein

NBEAL2

3,000
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Other
Early Endosome Antigen-1

EEA-1

1,700

Lysosomal Associated
Membrane Protein-1, 2

LAMP-1; LAMP-2

3,000; 2,000

Vacuolar Protein Sortingassociated protein 33B
Interacting Protein

VIPAR

1,200

Calreticulin

CALR

20,300

Calnexin

CANX

10,400

Calmodulin

CaM

15,600

*Listed are human platelet proteins that may contribute to endocytosis and/or subsequent
cargo-sorting events.
&

Included are copy numbers, estimated based on quantitative proteomic analyses [200] .

ND= Not determined.
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Subsection Three: Vesicle-associated membrane protein 3 (VAMP-3/Cellubrevin)
VAMPs in platelets
Platelets contain multiple isoforms of the Vesicle-associated Membrane Proteins or
VAMPs (VAMP-2,-3,-4,-5,-7,-8), based on data gleaned from proteomic analyses and
quantitative Western blotting [199-200]. In terms of a number of copies per platelet,
VAMP-8 and VAMP-7 are the most abundant in human platelets while VAMP-8,
VAMP-2, and VAMP-3 are the major ones in mouse platelets. VAMP-8 which is the
most abundant in both mouse and human platelets is the primary v-SNARE to
mediate secretion. Loss of VAMP-8 attenuates secretion from all three granules,
causes defective thrombosis (thrombus growth is slower and lessened in comparison
to WT) with no bleeding diathesis [199, 201]. Loss of VAMP-3 by itself had no defect
in secretion and hemostasis proceeded normally as measured by tail bleeding assay
[202]. Loss of VAMP-2 is embryonic lethal [201]. Treatment of tetanus toxin which
specifically cleaves VAMP-2 and VAMP-3 showed that platelet secretion is
unaffected as long as VAMP-8 and VAMP-7 are present [201]. Loss of VAMP-7 does
not lead to a bleeding diathesis or defects in platelet accumulation at sites of injury
in the laser injury model of arterial thrombosis, although alpha granule secretion is
attenuated in these platelets [203]. Collectively, these data imply that there is a
ranking amongst the isoforms in mediating secretion with some amount of
redundancy. VAMP-8 is primary with VAMP-2 and VAMP-3 playing secondary roles.
VAMP-7 on the other hand may be less involved in secretion but mainly play a part in
platelet spreading due to its interactions with the actin cytoskeleton via VPS9domain
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Immunofluorescence studies have shown VAMP-7-dotted structures to be localized
to the platelet periphery while VAMP-8 and VAMP-3 have been shown to be more
centrally localized within the granulomere in spread platelets [204]. The central
localization of VAMP-3 concurs with studies done in our lab where we reported the
intracellular punctate staining of VAMP-3 containing structures that resist being
targeted to the plasma membrane during thrombin activation [205]. These could
very easily be VAMP-3 positive endosomes in platelets. Additionally, VAMP-8 and
VAMP-7 could potentially mediate differential cargo release or may be differentially
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responsive to various kinds of agonists. However, future studies need to be done to
parse this distinction.
VAMP-3 and its cellular localization
Synaptobrevins are small, highly conserved integral membrane proteins that are part
of the Vesicle-Associated Membrane Protein (VAMP) family and are abundantly
found in synaptic vesicles within the brain [394-395]. VAMP-3 is a type of
synaptobrevin that is ubiquitously expressed in all cells and was thus named
cellubrevin as the cellular homolog of synaptobrevins [396]. Like synaptobrevins,
which are targets of clostridial neurotoxins such as tetanospasmin, a protein from
Clostridium tetani, and botulinum toxin, from Clostridium botulinum [397-398],
cellubrevin/VAMP-3 is also cleaved by tetanus toxin substrate [396]. Using
immunofluorescence and subcellular fractionation techniques, VAMP-3 was shown
to be intracellularly localized to all parts of the cell with a localized concentration in
and around the Golgi complex. Using transferrin receptor (Tfn-R) as a marker for a
recycling receptor, it was shown that while all transferrin-positive vesicles stained for
VAMP-3, not every VAMP-3-positive vesicles stained for transferrin [396]. This
suggested that VAMP-3 is a component of receptor-mediated endocytosis pathway
and is present on coated vesicles that recycle transferrin as well as other similar
vesicles. In Chinese hamster ovarian (CHO) cells transfected with synaptophysin,
VAMP-3 was shown to colocalize with synaptophysin, which in turn associated with
the transferrin receptor and is targeted to the receptor-mediated endocytic pathway
[396, 399-400]. VAMP-3 was also shown to reside in insulin-sensitive GLUT4 glucose
transporter vesicles in 3T3-L1 adipocytes and is a part of the insulin-regulated
membrane trafficking pathways [401]. Furthermore, subcellular fractionation of
pancreatic acinar cells revealed VAMP-3 to be present on the smooth microsomal
fraction consisting of small vesicles and condensing vacuoles that originate from the
Golgi complex, indicating a possible role in the maturation of secretory granules
within these cells [402]. Transferrin receptor recycling has been instrumental in
shedding light regarding the subcellular localization of VAMP-3. Following the entry
routes of Tfn-R in CHO cells using immunofluorescence microscopy, showed that
upon internalization, Tfn enters the early endosomes that stain positive for both
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VAMP-3 and Rab4, which marks early endosomes. Soon after that, Tfn moves into a
subset of pericentriolar cluster or tubules and vesicles that are now referred to as
the recycling endosomes, which stain positive for VAMP-3 but not Rab4. These
endosomes instead stained positive for another Rab GTPase called Rab11. These
Rab11-VAMP-3 double positive vesicles transiently accumulate Tfn inside the cells on
its route back to the plasma membrane [403].
Role of VAMP-3 in receptor trafficking
VAMP-3 has been shown to be concentrated in vesicles which recycle transferrin
receptors but its role in membrane trafficking and fusion was demonstrated by the
use of tetanus toxin, a metallo-endoprotease that cleaves VAMP-3 (and VAMP-2)
which partially blocked transferrin release in CHO cells [404]. Like Tfn-R, the
intracellular glucose transporter 4 (GLUT4)-containing vesicles dock and fuse with
the plasma membrane to facilitate insulin-controlled glucose uptake in muscle and
fat cells. GLUT4 colocalizes with both VAMP-3 and VAMP-2 (both synaptobrevin type
vesicle SNAREs that are tetanus toxin-sensitive) and tetanus toxin treatment
inhibited insulin-stimulated GLUT4 translocation to the plasma membrane [405].
Furthermore, overexpression of VAMP-3, but not VAMP-2, in HL-1 atrial
cardiomyocytes, prevented lipid-induced inhibition of insulin-stimulated GLUT4
translocation from the intracellular stores to the plasma membrane, in an in vitro
model of cardiac insulin resistance [406].
VAMP-3 has also been implicated in the trafficking of a host of other plasmalemma
receptors such as translocation of Na+/K+/2Cl- co-transporter (NKCC2) to the apical
surface of the renal cells of the thick ascending limb in kidney and is required for
NaCl absorption and regulation of blood pressure [407]. VAMP-3 regulates recycling
of glutamate transporters in mouse cortical astrocytes, which express VAMP-3 but
not VAMP-2, and as a result, plays a key role in Ca2+-independent recycling of these
receptors to the surface and glutamate uptake by astrocytes [408]. VAMP-3, in
association with the small GTPase, Rab8, regulates recycling of T-cell receptors (TCR)
by interacting with IFT20, a component of the intraflagellar transport (IFT) system
that modulates ciliogenesis and immune synapse assembly in non-ciliated T cells
[409]. In dendritic cells, cross-presentation of peptides derived from phagocytosed
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microbes, infected cells, or tumor cells to CD8+ T cells requires the action of VAMP3/VAMP-8/Rab11-positive endosomal recycling compartments that carry major
histocompatibility complex I (MHC class I) receptors to fuse with phagosomes, which
drives Toll-Like Receptor activation in response to infection [410]. Endosomal TLRs
such as TLR7 and TLR9 that bind viral nucleic acids traffic to distinct endomembrane
systems, namely VAMP-3-positive and LAMP-positive endosomes, for signaling [411].
This bifurcation of the TLRs to separate compartments allows for cytokine and type I
interferon gene induction. Studies in RAW264.7 cells showed the involvement of the
phosphatidylinositol 3P 5-kinase, PIKfyve, to mediate selective trafficking of TLR9 to
VAMP-3 positive endosomes. Blocking PIKfyve activity of disruption of VAMP-3 by
tetanus toxin, lead to a reduction in trafficking of TLR9 and consequent reduction in
type I interferon induction [412].
Role of VAMP-3 in vesicle trafficking
As discussed earlier, VAMP-3 dots the early and recycling endosomes and is essential
for recycling of several plasma membranes and endomembrane receptors. On the
same vein, VAMP-3 is also crucial for targeting of vesicles to specific locations within
the cell. Autophagosomes are specialized double-membraned organelles where
degradation of intracellular macromolecules, RNA and protein turnover as well as
damaged organelles takes place [413]. Cargo that is destined for the
autophagosomes passes through the sorting hubs or the Multivesicular bodies
(MVBs) and several reports have shown that these MVBs can fuse with
autophagosomes to form a pre-lysosomal hybrid organelle called the amphisome
[414]. A mature amphisome can then fuse with the lysosome to form the
autolysosomal organelle where the actual degradation of cargo occurs. Several
SNAREs have been implicated in mediating one or more steps of these concerted
vesicle trafficking. Key among those is VAMP-3 that oversees fusion of the MVBs
with the autophagosomes to generate the mature amphisome. VAMP-7, another key
v-SNARE involved in vesicle trafficking, comes into play after amphisome formation
step and is responsible for fusing the amphisome to the lysosome. VAMP-3, however,
does not play any role in this step [415].
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Role of VAMP-3 in phagocytosis
Phagocytosis or the engulfment of pathogens is an important immune response. This
mode of entry of cargo (pathogens) can be receptor-mediated as it is in
macrophages and require membrane expansion at the site of phagocytosis and
several key intracellular trafficking steps. Not only is membrane trafficking in
macrophages required for pathogen phagocytosis but it also stimulates
proinflammatory cytokine secretion. VAMP-3 heads a trafficking pathway that
oversees both these actions thereby ensuring efficient immune responses in
macrophages; this pathway follows tumor necrosis factor α (TNF-α) being trafficked
from the Golgi complex to the VAMP-3-positive recycling endosomes. TNF-α
containing recycling endosomes are then targeted to the plasma membrane where
the phagocytic cup forms allowing the concomitant rapid release of TNF-α and
expansion of the membrane to engulf the pathogen [416]. VAMP-3 has also been
shown to play a role in phagosome maturation which causes phagosomes containing
pathogens to fuse with the lysosomes to form the phagolysosomes, using
Mycobacterium tuberculosis var. Bovis BCG, an organism that causes phagosomal
maturation arrest upon entering phagosomes. This allows the bacterium to evade
lysosomal degradation. Inhibition of VAMP-3 leads to disruption in mycobacterial
phagosomes, overcoming this arrest and thereby causing degradation of the
pathogen in the lysosomes and protecting against mycobacterial infection [417]. In a
process similar to phagocytosis, bacterial invasion of cells, also involves membrane
expansion at the host cell plasma membrane where the bacteria invade. In
Salmonella typhimurium infections, VAMP-3 has been shown to accumulates at sites
on the plasma membrane where the bacteria invades and this accumulation leads to
membrane protrusions in an N-ethylmaleimide-sensitive factor (NSF)-independent
manner [418]. Though VAMP-3 does indeed play a role in phagocytosis and recycling
of receptors, bone-marrow derived macrophages (BMM) from VAMP-3 null mice
showed no defects in phagocytosis of IgG-beads, complement-opsonized particles,
or latex microspheres although zymosan internalization was found to be significantly
slower than wild-type [419]. In fact, in primary mouse embryoblast isolated from
VAMP-3 null mice, rates of transferrin internalization (endocytosis), transferrin
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release (recycling) and horse-radish peroxidase (HRP) uptake (pinocytosis) were
essentially unchanged compared to wild-type [420]. Insulin-dependent glucose
uptake in isolated primary adipocytes as well as insulin-, hypoxia-, and exercisestimulated glucose uptake in isolated skeletal muscle cells from VAMP-3 null mice
were unchanged compared to wildtype [420]. Taken as a whole, it appears that
VAMP-3 is necessary for phagocytic uptake of pathogens as well as cargo
(receptors/macromolecules) in some cells while in others, other VAMPs such as
VAMP-2 can play compensatory roles to tide over any possible defects caused by loss
of VAMP-3.
Role of VAMP-3 in exocytosis
VAMP-3, being a v-SNARE, partners with cognate SNAREpins such as the t-SNAREs
(SNAP-23/SNAP-25 and syntaxins) to mediate vesicle fusion during intracellular
trafficking events as well as during granule/vesicle exocytosis. VAMP-3 usage for the
sake of release of granule cargo varies from cell to cell. Some cells require VAMP-3
for exocytosis while others do not. In mast cells, VAMP-7 or VAMP-8, but not VAMP3 or VAMP-2, are required for high-affinity IgE receptor-mediated histamine release
[421]. Trafficking and secretion of matrix metalloproteinases (MMPs) determine
cellular remodeling of the extracellular matrix (ECM). Studies done in invasive human
fibrosarcoma cell lines HT-1080 showed that inhibition of SNAP-23 and VAMP-3 by
using dominant-negative forms of these SNAREs, RNAi treatment or Tetanus toxinmediated cleavage of VAMP-3 leads to a reduction in the secretion of MMP2 and
MMP9 as well as impaired trafficking of membrane type I MMP to the cell surface
[422]. Blocking of these SNAREs also led to less invasiveness of the HT-1080 cell lines
on gelatin substrates in vitro.
In endothelial cells, Weibel-Palade Bodies (WPB) are the storehouses of the
thrombogenic glycoprotein von Willebrand Factor (vWF). At the site of damage,
endothelial cell activation triggered by thrombin or histamine leads to Ca2+-, and
SNARE-dependent exocytosis of WPBs to release vWF into the vessels that in turn
leads to platelet adhesion via the GPIb-IX-V complex and thrombus formation. Both
VAMP-3 and VAMP-8 are present on WPBs; yet only VAMP-3 is required for forming
stable SNARE complexes with plasma membrane syntaxin 4 and SNAP-23 to drive
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membrane fusion of WPB to release vWF. Using mutant VAMP-3 and VAMP-8
comprising of the cytoplasmic domains of the proteins, it was noted that only VAMP3 but not VAMP-8 inhibits with vWF release in permeabilized endothelial cells [423].
Cytotoxic granules containing granzymes and perforin are important for killing viral
infected and transformed host cells by natural killer (NK) cells. The release of
inflammatory cytokines such as TNF-α and IFN-γ is also mediated by exocytosis of
these cytotoxic granules through SNARE-mediated pathways. Studies in NK cells have
shown that granules that contain perforin and granzymes are different from the
ones that contain cytokines such as TNF-α and IFN-γ. The vesicles that contain these
cytokines are actually recycling endosomes and release of cytokines from these is
mediated by Rab11 and VAMP-3 [424]. Inactivation of recycling endosomes or
mutating Rab11 or inactivating VAMP-3 by tetanus toxin treatment or mutant
versions of VAMP-3 impaired TNF-α and IFN-γ release from NK cells. VAMP-3,
together with SNAP-23, has also been shown to be involved in the release of IL-6 and
TNF-α in an SNARE-dependent, IL-1β-stimulated exocytosis event from human
synovial sarcoma cell lines SW982 [425].
Role of VAMP-3 in cell migration
Cell migration is a highly-regulated pathway of cell polarization that involves both
endocytosis and exocytosis to drive membrane protrusion at the leading edge of the
cell, adhesion of the leading edge and de-adhesion at the cell body and rear end
followed by cytoskeletal contractions to pull the cell and move it in the direction of
the stimulus. As with any membrane trafficking/fusion events, SNAREs play a key
role in mediating membrane trafficking in cell migration. Inhibiting SNARE-mediated
membrane traffic by using a dominant-negative form of the enzyme NSF and Tetanus
toxin-mediated cleavage of VAMP-3 leads to reduced serum-induced migration of
CHO-K1 cells in transwell migration assays with a concomitant reduction in cell
surface α5β1 integrins [426]. This study was closely followed by Thierry Galli’s group
who also showed that Tetanus toxin-mediated cleavage of VAMP-3 impairs epithelial
cell migration and β1 integrin-dependent cell adhesion [427]. Tetanus toxin cleavage
of VAMP-3 also led to enhanced adhesion of epithelial cells (CHO cells) to collagen,
laminin, fibronectin and E-cadherin matrices with altered spreading on collagen58

coated surfaces due to impaired recycling of β1 integrins. siRNA-induced silencing of
VAMP-3 in CHO cells also leads to a similar reduction in chemotactic cell migration
without affecting cell proliferation [428] agreeing with previous reports. Recycling of
adhesion receptors is crucial for lamellipodia formation at the leading edge of a
migrating cell. VAMP-3 containing recycling endosomes is incorporated into the
leading edge to bring about the expansion of the lamellipodia membrane in an
SNARE-dependent membrane fusion event that also requires SNAP-23 and syntaxin 4.
Inhibition of VAMP-3 by tetanus toxin showed that fusion of recycling endosomes is
necessary for lamellipodia formation and delivery of the α5β1 integrins present on
the recycling endosomes to the cell surface necessary for efficient cell migration
[429]. VAMP-3 together with SNAP-23 and syntaxin 4 has also been shown to
regulate the formation of ring-like podosome structures that accumulate in the
leading edge of spreading cells such as macrophages migrating on fibronectin.
Lowering VAMP-3 levels or disrupting VAMP-3 function (or SNAP-23 or syntaxin 4)
leads to disrupted trafficking of the recycling endosomes to the plasma membrane,
impaired polarization of these podosome structures at the leading edge and reduced
adhesion and spreading on fibronectin [430]. Since integrins are the major adhesion
receptors, VAMP-3 mediated trafficking of integrins plays an essential role in
regulating cell migration and by extension proliferation and survival. Surface
expression of integrins is controlled by SNARE-mediated endo-exocytic recycling.
While VAMP-3, by virtue of being present on recycling endosomes, does play a key
role in this process, what determines the specificity of regulating one integrin
trafficking event versus another often depends on the t-SNARE partners it pairs with.
This also determines whether a particular integrin recycles directly back to the
plasma membrane from the recycling endosomes or traverses through the transGolgi network (TGN) before it reaches its cell surface destination. For example,
syntaxin 6, a t-SNARE located in the trans-Golgi network, pairs with VAMP-3 to
mediate trafficking of α3β1 integrins from the recycling endosomes to the TGN
before being recycled to the plasma membrane surface in epithelial cells [431].
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VAMP-3 and its role in platelets
The presence of VAMP-3 in human platelets was first reported by our group [205].
Termed as human Cellubrevin (Hceb) was present in detergent-solubilized platelet
membranes and participated in α-SNAP-dependent 20S SNARE complex formation
and ATP-dependent 20S SNARE complex disassembly thereby functioning as a vSNARE in human platelets. Immunofluorescence microscopy showed an intracellular
punctate staining in human platelets, megakaryocytes and HEK-293 cells agreeing
with previous reports of how cellubrevin/VAMP-3 is located on endosomes/vesicles
within the cell. This was confirmed when thrombin-stimulated human platelets
resisted targeting of these Hceb-positive punctate structures to the plasma
membrane even though all dense core and most alpha granules had been released.
This was the first indication showing that VAMP-3 could be present on an endosomal
organelle that is not part of the exocytic pathway in platelets. This was further
corroborated by immunogold labeling which showed that almost 80% of VAMP-3 in
resting human platelets was localized to platelet granule membranes including alpha
granules [206]. The role of VAMP-3 in mediating platelet secretion was first
monitored by introducing anti-VAMP-3 antibody in streptolysin-O-permeabilized
platelets which resulted in a 50% reduction of Ca2+-induced alpha granule secretion,
an effect that could be reversed by using a VAMP-3 blocking peptide [206]. These
studies were further expanded upon by others to demonstrate the role of VAMP-3 in
mediating secretion in human platelets. VAMP-3 and VAMP-8 were both shown to
coimmunoprecipitate with syntaxin 4 and SNAP-23 in human platelets using
microcapillary

reverse-phase

high-performance

liquid

chromatography-nano-

electrospray tandem mass spectrometry [433]. Introducing soluble recombinant
VAMP-3 into streptolysin-O-permeabilized platelets led to a dramatic reduction in Pselectin exteriorization from alpha granules as measured by flow cytometry and C14serotonin from dense granules as measured by radioactivity. This led to the idea that
VAMP-3 together with SNAP-23 and syntaxin forms fusogenic SNARE complexes that
drive granule secretion in human platelets.
Insulin largely recognized for its role in glucose homeostasis, acts as a vasodilator in
the vasculature in a nitric oxide synthase (NOS)-dependent manner, in part by
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enhancing platelet-endothelial NOS activity [434]. Insulin works by inducing ATP,
adenosine, and serotonin release from dense granules in an NO-dependent manner,
a response that is abolished in NOS null platelets [433]. Similarly, insulin stimulation
of human platelets requires SNAP-23/syntaxin t-SNARE heterodimers to associate
with VAMP-3 to form the functional SNARE complexes that drive ATP release from
dense granules via an NO-G kinase-dependent signaling cascade that is independent
of αIIbβ3 activation [433].
Surprisingly, platelets isolated from VAMP-3 null mice showed no defect in secretion
from all three granules (dense core, alpha granules, and lysosomes) tested in
response to thrombin and collagen in both kinetic (time-course) and dosage assays
[202]. Additionally, loss of VAMP-3 did not cause any change in levels of other SNARE
proteins. Agonist-induced platelet aggregation was also unchanged in the VAMP-3
null platelets as was bleeding time measurements. Collectively, these data suggests
that there is some level of heterogeneity in VAMP usage in mouse platelets versus
human platelets; VAMP-3 is essential for secretion in human platelets while VAMP-3
plays a subordinate role and is not required for platelet secretion in mice. However,
what other roles VAMP-3 plays in mouse platelets needs further exploration.
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Subsection Four: Role of platelets as immune cells
Overview
Platelets have been classically studied for their roles in hemostasis and thrombosis.
What has become increasingly clear is that platelets are, in fact, multifunctional and
can carry out several important physiological and pathophysiological processes e.g.,
wound healing, inflammatory and immune responses. From an evolutionary
perspective, lower invertebrates such as birds, reptiles, amphibians, and fishes,
which have an open vasculature, only contain a single primordial cell type called
thrombocytes or hemocytes. Hemocytes are nucleated and perform both hemostasis
and innate immune responses within the hemolymph [435]. Invertebrate hemocytes
mediate immune responses by virtue of bearing Toll-like Receptors (TLRs) on their
surfaces which allow pathogen recognition, phagocytosis, and secretion of
antimicrobial peptides [436]. They can also mediate wound healing and induce
hemolymph coagulation and clotting at sites of tissue damage in a process that is
similar to how mammalian platelets form clots. It is thought that as vertebrates
climbed higher up the evolutionary tree, their hemocytes lost the nuclei, retained
most of their hemostatic and thrombosis functions and evolved into the modern-day
mammalian platelets, while the immune-related functions were taken over the
professional immune cells. As recent studies over the past decade bring to light more
immune-related functions of platelets, it essentially solidifies this concept of
platelets being the evolutionary link between the coagulation and immune
responses, two key facets of the vascular system. How mammalian platelets mediate
immune responses will be covered in the following sections.
Platelet Toll-like Receptors (TLRs)
Pathogen-sensing and subsequent innate immune responses are carried out by a
specialized class of pattern-recognition receptors (PRR) that recognize molecules
called pathogen-associated molecular patterns (PAMPs) broadly expressed by
pathogens distinct from host molecules (see Table 1) and are expressed on immune
cells such as dendritic cells, monocytes/macrophages, neutrophils, T and B
lymphocytes. Toll-like receptors are type I transmembrane proteins possessing:
leucine-rich repeat (LRR) ectodomains folded into beta sheets, enabling PAMPs
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recognition, a transmembrane domain and a cytoplasmic Toll-Interleukin-1 receptor
(TIR) domain that does signal transduction [437]. To date, 10 TLRs in humans and 13
TLRs in mice have been identified that can recognize PAMPs such as lipids,
lipoproteins, proteins or nucleic acids derived from pathogens (viruses, bacteria,
parasites, fungi etc.) or from endogenous sources, either at the cell surface or within
intracellular compartments (endosomes, lysosomes, and endolysosomes), triggering
distinct downstream signaling cascades based on the PAMP recognized [438].
Several reports have demonstrated the expression of TLR1-9 in both human and
mouse platelets [439-442] and have shown that some of these TLRs (TLR2, TLR4,
TLR7, and TLR9) are functional and can modulate platelet responses during infection
and thus, will be discussed in depth.
TLR2
TLR2 primarily resides on the plasma membrane and can recognize bacterial
lipopeptides, peptidoglycans, and lipoteichoic acid from Gram-positive bacteria,
mycobacterial lipoarabinomannan, yeast zymosan, and viral hemagglutinin [437].
TLR2 can heterodimerize with TLR1 to form TLR2/1 complexes that bind triacylated
lipopeptides or with TLR6 to form TLR2/6 that preferentially binds diacylated
lipopeptides [437]. Platelet TLR2 binds to the adaptor protein MyD88 to trigger its
downstream signaling cascades. In platelets, TLR2 engagement using triacylated
lipopeptides such as Pam3CSK4 leads to activation of the PI3K/Akt signaling pathway
[444-445] and platelet αIIbβ3 activation, aggregation, adhesion, membrane
expression of P-selectin from alpha granules and platelet-neutrophil aggregates
formation [443, 446]. These responses can be blocked by treatment with PI3K
inhibitor, LY294002, or using anti-TLR2 antibodies or TLR2 knockout mice [447].
Platelet TLR2 stimulation by Pam3CSK4 also leads to increases in cytosolic Ca2+
concentrations, the release of ATP and TxA2 generation [443]. Platelet TLR2 has also
been implicated in enhanced phagocytosis of periodontopathogens such as P.
gingivalis by neutrophils with a concomitant increase in TLR2-activated plateletneutrophil aggregates and CD40L expression in platelets [448-449]. Platelet TLR2 has
also

been

implicated

in

platelet-viral
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interactions

chiefly

with

human

cytomegalovirus. Human cytomegalovirus interacts with platelets via TLR2, giving
rise to pro-inflammatory cytokine production by platelets [450].
A pivotal study by the Freedman group using the TLR2 ligand, Pam3CSK4, was the
first to shed light on the concept of differential stimulation of platelets. Platelets
have been traditionally thought to be fast responders to any kind of damage though
thrombotic damage which leads to hemostasis has only been extensively studied.
However, when platelets encounter immune damage such as those related to TLR
activation, the response generated is both slower and more gradual than the rapid
and maximal thrombotic stimulation of platelets [447]. Stimulation of platelets by
Pam3CSK4 leads to a more gradual phosphorylation kinetics of Akt, p38, and ERK
that are present downstream of TLR2 in platelets; compared to rapid and substantial
phosphorylation kinetics of the same under thrombin stimulation. This differential
stimulation of platelets that we have provisionally termed “hemostatic” versus
“immune-activation” agrees with data generated in my thesis and supports this
shifting view of platelets being more diverse in their response curves to various
stimuli than the originally held idea of rapid activation and maximal release of cargo
to all kinds of stimuli from platelets.
TLR4
TLR4 is the most abundant Toll-like receptor on platelets [441] and binds to
lipopolysaccharides (LPS), a major component of the cell membrane of Gramnegative bacteria. TLR4, in a complex with an adaptor protein MD-2, binds to LPS, in
the presence of CD14 and LPS-binding protein (LBP) [451].
LPS-induced thrombocytopenia and tumor necrosis factor-α (TNF-α) production in
vivo is mediated by platelet TLR4-dependent pathways [439]. LPS induced a 60%
reduction in platelet counts as early as 4 hr post-injection in wildtype mice compared
to a 20% reduction in TLR4 KO mice. Drop in platelet counts is often due to the
formation of platelet-neutrophil and platelet-monocyte aggregates that get trapped
in the lungs and are thus removed from the circulation [475]. Another possible
mechanism by which platelet numbers drop during inflammation is due to increased
platelet destruction caused by phagocytosis [453].
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LPS-induced TLR4-dependent functions of platelets have been largely studied in the
context of bacterial sepsis. Endotoxin-induced or bacterial-induced sepsis often leads
to severe thrombocytopenia [476]. Platelet activation during sepsis contributes to
disseminated intravascular coagulation (DIC) or the formation of microthrombi,
which impedes blood flow to vital organs causing death by multiple organ failures
[477]. Platelet activation during sepsis leads to the production of both pro- and antiinflammatory cytokines, which triggers immune responses in the circulation [478].
Increased platelet and leukocyte activation, often times correlate with severity of
DIC-induced multiple organ failures during sepsis [479]. To further probe the role of
platelets in endotoxin-induced sepsis, experimental thrombocytopenia was induced
in mice by the in vivo administration of anti-glycoprotein Ibα monoclonal antibody
[480] in LPS-induced endotoxemia and a bacterial infusion mouse sepsis model [481].
This caused increased plasma levels of pro-inflammatory cytokines such as TNF-α
and IL-6, followed by widespread organ failure in the liver, lungs, and spleen and
increased mortality, an effect that could be reversed significantly by transfusion of
healthy platelets in these septic mice [481]. This was the first detailed and conclusive
study that showed that platelets protect from septic shock, via a mechanism that
involves inhibiting the macrophage-dependent inflammation via the cyclooxygenase
1 signaling pathways. In another similar study the role of platelets and specifically
how thrombocytopenia affects the outcomes in sepsis was determined [493]. It was
shown that thrombocytopenia caused, led to worsened outcomes that manifested as
increased mortality strongly correlating with increased bacterial burden [493].
Titrating platelet counts by in vivo GPIbα administration to mice showed the diverse
effects caused on Klebsiella pneumoniae-induced sepsis; when platelet counts were
reduced to 5 X 109/L in blood of mice infected with Klebsiella through the airways,
they showed impaired survival with increased bacterial burden in lungs, blood and in
distant organs such as liver as well as causing severe hemorrhaging at primary sites
of infection. However, this led to increased cytokine production which exacerbated
the pro-inflammatory sepsis caused by Klebsiella. On the other hand, when platelet
counts were titrated to 5-13 X 109/L, hemostasis could be maintained even within
the infected lungs. Taken together, these studies showed the threshold platelet
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counts required to maintain hemostasis in a mouse model of Klebsiella-induced
sepsis.
Another possible mechanism by which platelets provide protection during severe
sepsis is by activating the neutrophil extracellular traps (NETs) in a TLR4-dependent
mechanism that trap bacteria in septic blood [482]. Activated neutrophils release
granule proteins and chromatin material from their nucleus in vivo that form these
mesh-like extracellular DNA fibers containing histones and antimicrobial proteins
and effectors called neutrophil extracellular traps (NETs) that bind and kill Grampositive and Gram-negative bacteria [484]. NET formation is called NETosis. In a
series of imaging experiments in liver sinusoids and pulmonary capillaries, platelets
were shown to bind activated neutrophils via their TLR4 to release NETs to entrap
the bacteria [482-483]. The complex interactions between platelets and neutrophils
in the context of NETs were also shown to be important for thrombus formation
[485]. NETs caused platelet activation, adhesion, and aggregation by providing a
scaffold that triggers thrombus formation. DNase treatment which degrades the
meshwork of DNA fibers that form the NETs or treatment with the anticoagulant
heparin can disrupt pre-formed NETs and thus inhibit thrombus formation.
Furthermore, markers of NETs including histones were found to be inside thrombi
within veins that also contained red blood cells, giving rise to red thrombi. This led to
further studies showing the importance of NETs in the propagation of deep vein
thrombosis [486-487]. In neutrophils, peptidyl arginine deiminase 4 (PAD4) mediates
citrullination of histones, a process that is required for chromatin decondensation
that releases the DNA fibers and NETs formation [488]. Studies using PAD4 KO mice
showed that only 10% of these mice formed venous thrombi 48 hr after inferior vena
cava stenosis compared to 90% of wild-type mice that formed venous thrombi,
suggesting that PAD4-mediated chromatin decondensation in neutrophils is
responsible for pathological deep vein thrombosis.
Another key NET mediator is platelet P-selectin. NET formation by neutrophils
induced by thrombin-activated platelets can be inhibited by anti-P-selectin
glycoprotein ligand-1 (PSGL-1) inhibitory antibody or by the use of anti-P-selectin
aptamers. The NET formation is also abolished when platelets from P-selectin KO
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mice are used to induce neutrophils [489]. Platelet-induced NET formation by
neutrophils has now become an increasingly growing field of research, providing new
insights into how NETs promotes tumor growth and contribute to cancer-associated
thrombosis [490-491].
While platelet TLR4 is essential in mediating inflammatory responses by platelets in
vivo, reports elucidating the exact mechanism of how LPS stimulates TLR4 in ex vivo
and in-vitro assays have been confusing.

Platelets lack CD14, an essential co-

receptor that engages with LPS-bound TLR4 to initiate proper downstream signaling.
While all other TLR4-expressing cells have both CD14 and LPS-binding protein, LBP,
unless added otherwise in the form of free plasma or recombinant versions of CD14
and LBP to washed platelets, platelets do not respond to LPS [492]. This has led to
controversial reports where some suggest that LPS does not stimulate platelet
activation when measuring P-selectin expression [441] while others have reported
otherwise [454]. However, since platelets express MyD88, the adaptor protein that is
required for TLR4 signaling, in amounts similar to those found in leukocytes [454],
platelets do seem to share signaling kinases that are common to TLR4 signaling
pathway in immune cells. These include TBK-1, IRAK-1, JNKs, MAPKs, TRAF3, TRAF6,
IRF-3, IKK complex, NF-κB p65, Akt among others [452, 492]. LPS has also been
shown to initiate splicing of mRNA encoding IL-1β in a TRAF6-Akt-JNK activationdependent manner [492].
LPS has also been shown to increase in vivo thrombopoietin (TPO) levels by
influencing megakaryocyte TLR4, this led to a concomitant increase in circulating
reticulated platelets (young platelets) and enhanced platelet-neutrophil aggregates
[494]. LPS via TLR-4 also induced bone marrows to produce more TPO leading to
more platelet production [495-496].
TLR7
One of the key viral sensors as part of the host’s innate immune defenses is the
endosomal Toll-like Receptor 7 that binds to single-stranded RNA [497]. TLR7
stimulation by ssRNA causes a type I interferon (IFN) response. Many ssRNA viruses
(HIV-1, VSV, and influenza viruses) bind to cell-surface receptors and gain entry into
the cell via endocytosis. Once the viruses get trafficked to an endosome, it fuses with
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the endosomal membrane to release its capsid, followed by endosomal acidification
that causes degradation of the envelope via TLR7-MyD88 dependent signaling
cascade to cause IFN production; both steps being required for effective responses
[498-499]. TLR7, being an endosomal TLR7, has been studied in the context of selfvs-non-self-recognition of PAMPs; with ssRNA not being a part of the host, but
clearly abundant in pathogens such as ssRNA-containing viruses that infect hosts.
Endosomal localization may be a strategy to prevent recognition of self-nucleic acids,
a feature that is common to most nucleotide-sensing endosomal TLRs such as TLR8,
TLR9 and TLR3 [499]. ssRNA engagement of TLR7 initiates MyD88-dependent
responses that signal via an IRAK4/IRAK1-TRAF3/TRAF6 pathway that leads to
activation of the IRF7 transcription factors that cause interferon production [500].
In platelets, the first report about the presence of TLR7 was shown by the Freedman
group. TLR7, which resides in an intracellular compartment and recognizes singlestranded RNA, was found to be present in platelets [411, 437, 472]; and is required
for mediating platelet counts and host survival in a mouse model of
encephalomyocarditis virus (EMCV) infection. Viruses such as EMCV, HIV-1, and
influenza virus as well as small guanosine analogs such as Loxoribine and Imiquimod
(R837) have been shown to activate TLR7 signaling pathways [437]. EMCV-induced or
Loxoribine-induced TLR7 activation led to PI3K/Akt, p38-MAPK phosphorylation
events in platelets and these effects were largely abolished in the TLR7 KO platelets.
In this dissertation, the role of the endosomal TLR7 in platelets and how it affects
platelets responses to ssRNA-containing viruses is further explored.
TLR9
Like TLR7, TLR9 is also an endosomal TLR that senses unmethylated 2’-deoxyribose
cytidine-phosphate-guanosine (CpG) DNA motifs that are present in bacteria, viruses
and other pathogens [501]. In platelets, TLR9 is present both intracellularly and on
the plasma membrane [442] and increased expression of the receptor occurs upon
CpG ODN stimulation of human platelets [502]. It was reported that in both human
and mouse platelets, TLR9 is present in a specific platelet granule, called the T
granule, which is different from the other kinds of granules present within platelets
(namely dense, alpha and lysosomes) [502]. In fact, TLR9 transcripts are upregulated
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during proplatelet formation in the megakaryocytes [503]. Within the T granules,
TLR9 has been shown to colocalize with protein disulfide isomerase (PDI) and is
associated with either VAMP-7 or VAMP-8. These v-SNAREs allow targeting of the T
granules to the plasma membrane during platelet activation and is thought to put
TLR9 on the surface. However, recent studies have shown that PDI is located in an
ER-type compartment within platelets, present near the inner surface of the platelet
plasma membrane, which is different from the secretory granules found in platelets
[47]. These compartments are targeted to the plasma membrane via an actin
polymerization process and are independent of SNARE-mediated vesicle fusion. TLR9
resides in the endoplasmic reticulum of resting dendritic cells and macrophages [505]
and gets trafficked in COPII coated vesicles to an endo-lysosomal organelle [504].
CpG DNA, on the other hand, enters the cells through the early endosomes and has
to be trafficked to a TLR9-containing organelle, where it partners with MyD88 for
proper signal transduction to be initiated [504]. Hence, in platelets, given that PDI is
present in ER-like compartments and TLR9 colocalizes with PDI, these T granules
could very easily be ER-remnants instead of being a specialized separate
compartment as previously thought.
In platelets, TLR9 has been shown to bind to derivatives of polyunsaturated fatty
acid oxidation such as carboxy-alkyl-pyrroles (CAPs), generated during oxidative
stress, and activates platelet via the PI3K-Akt pathway leading to aggregation and
secretion [506].
While CpG motifs bearing oligonucleotides have been used as activators of TLR9 in
dendritic cells and macrophages, a recent study, discovered an unexpected new
mechanism of how CpG ODNs activates platelets [507]. When oligonucleotides were
first discovered as potent therapeutics, measures had to be taken to prevent rapid
degradation of these short single-stranded DNA molecules from cellular and plasma
nucleases, to ensure pharmacostability of the drugs inside the host system. One such
way was to introduce a phosphorothioate modification where the nonbridging
oxygen molecules are replaced by sulfur [508]. This phosphorothioate modification
of TLR9 agonists causes GP VI-dependent activation, adhesion, and aggregation of
platelets, a response that was unchanged in TLR9 KO platelets, suggesting that this
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mechanism of activation of platelets proceeds in a TLR9-independent manner [507].
These findings stress the importance of developing novel alternative chemical
modifications of oligonucleotides used as drugs, such that they do not have spurious
platelet activation side-effects.
Platelet cytokines/chemokines
Platelets store several different kinds of cytokines and chemokines within their
secretory granules (mostly alpha granules) such as Platelet Factor 4 (PF4), RANTES, βthromboglobulin, MIP-1α, TGF-β [91]. Transforming growth factor-β (TGF-β) is a
potent immunomodulatory molecule and platelets contain large amounts of it within
their granules [509] and have been shown to regulate blood levels of TGF-β. In
patients with immune thrombocytopenia (ITP), levels of TFG-β were markedly
reduced and only reached normal levels upon platelet transfusions [510-511]. The
release of cytokines and chemokines by platelets allows them to modulate their
microenvironments in the vasculature. Platelets are the largest source of PF4, which
can render monocytes apoptosis-resistant and induce differentiation into
macrophages [512]; enhance neutrophil adhesion on endothelial surfaces and
degranulation [513] among others. Platelet-derived CXC chemokines such as βthromboglobulin, that is stored in platelet alpha granules and released upon
activation, can be stimulatory or can be inhibitory as in the case of neutrophil
function [514]. Platelets release the chemokine Macrophage Inflammatory Protein-α
(MIP-α) upon activation which can then stimulate granulocytes such as basophils and
mast cells to release histamines [515]. CCL5 or RANTES, the second-most abundant
chemokine after PF4, is released from platelets upon activation and can stimulate
proplatelet production by the megakaryocytes [516].
One of the most important inflammatory mediators expressed by platelets is CD40L
or CD154 that can bind to CD40, the costimulatory protein found on antigen
presenting cells [517]. Membrane-anchored CD40L is expressed by platelets and
upon activation, release most of it in its soluble form, as sCD40L; which makes up for
the majority of circulating sCD40L in the plasma [518].
One of the key functions of platelet-derived CD40L has been in linking the innate
immunity with adaptive immunity by enhancing CD8+ cytotoxic T cell responses in
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response to Listeria monocytogenes infection [519] as well mediating CTL-induced
liver damage in response to Hepatitis B infection [520]. Platelets have been shown to
bind dendritic cells (DC) in a CD40L-dependent manner to suppress DC
differentiation, downregulate pro-inflammatory cytokine production of TNF, IL12p70 while upregulating IL-10 production [521]. In addition to affecting dendritic
cells, platelet-derived CD40L can modulate B cell differentiation and antibody class
switching [522]. Taken together, platelet-derived cytokines, chemokines and
immune mediators such as CD40L allow platelets to modulate the effector functions
of other immune cells, thereby forming an important link between immune systems
and the coagulation cascades [523].
Platelet-bacterial interactions
In addition to the Toll-like receptors, which are the premier innate immune
receptors to interact with bacteria and bacterial products, platelets express a wide
range of potential receptors such as complement receptors, FcγRII as well as the
conventional hemostatic receptors such as αIIbβ3, GPIbα, which allow bacteria to
directly or indirectly interact with platelets via fibrinogen, fibronectin, complement
C1q, vWF among others [524]. Bacteria can interact with platelets in three ways: (i)
direct binding of bacteria to platelet receptors, (ii) direct binding of bacterial
products or toxins to platelet receptors, and (iii) indirect binding of bacteria to
proteins that are ligands of platelet receptors. Of the hemostatic receptors that are
known to bind bacteria either directly or indirectly by binding to their cognate
ligands bound to bacteria, αIIbβ3 and GPIbα, are the most important. Staphylococci
express surface proteins that can bind to fibrinogen and fibronectin, ligands for αIIbβ3
[525-527]. Protein A from Staphylococcus aureus can bind to vWF, which in turn
interacts with GPIb β, allowing the bacteria to adhere to platelets [528-530].
Platelets also express members of the complement factor receptors such as gC1q-R,
the receptor for the complement factor C1q, which allows opsonization of C1q
complement-coated bacteria [531]. This occurs during platelet activation when there
is an increase in C1q-R surface expression. P-selectin, which is expressed upon
platelet activation on the surface, has been shown to bind to the complement C3b
that can act as an opsonin for bacteria [532].
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Platelets also express the immune receptor, FcγRII, which recognizes the Fc domain
of IgG and enables pathogen phagocytosis and engulfment of immune complexes
[533]. Heparin is often administered to patients as a potent anticoagulant. However,
this occasionally leads to thrombocytopenia, which predisposes these patients
towards thrombosis. This is the basis of heparin-induced thrombocytopenia (HIT), a
condition where autoantibodies are generated by the body against heparin-platelet
factor 4 complexes. Heparin acts as a hapten and thus can be recognized by IgG
antibodies in the bloodstream. It complexes with PF4 in circulation to form PF4heparin complexes that can then bind to FcγRIIA on the platelet surface, leading to
strong platelet activation, followed by internalization of these platelet-bound
complexes by phagocytes leading to increased clearance of activated platelets [534535].
Platelets have been shown to harbor bacterial pathogens such as Staphylococcus
aureus within their vacuole-like compartments [263] that are separate from the OCS.
These compartments could be potential endosomes, though this has not been
confirmed yet. Porphyromonas gingivalis has also been similarly found within
platelet vacuoles [536]. IgG-mediated opsonized particles or bacteria can be
internalized by human platelets via FcγRIIA, resulting in activation and degranulation
of sCD40L and RANTES, in a process that requires actin cytoskeletal rearrangements
[537].
What happens to bacteria that have been internalized by platelets? While this
remains an active area of ongoing research, some insights are available [538].
Bacteria such as Streptococci and Staphylococci that bind via αIIbβ3 or to GPIb via vWF,
activate platelet aggregation, release ATP from dense granules and generate TxA2
[539]. Streptococcus sanguinis has been shown to activate platelets via ERK and p38
MAPK phosphorylation [540]. An interesting feature of note in the context of
bacteria-induced platelet activation is the difference in kinetics of responses as
compared to hemostatic responses [538]. Bacteria-induced platelet aggregation
proceeds after a lag time, dependent on the bacterial density that lasts between 320 min, as compared to thrombin or ADP-mediated hemostatic responses which
reach maximal activation in less than 3 min. This harks back to this overarching
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hypothesis that platelets do indeed interpret different stimuli and respond
accordingly. Thus, there exists a differential response in reacting to “immuno
agonists” vs “hemostatic agonists”. Data generated in this thesis further consolidates
this idea.
Platelet-viral interactions
As in the case with severe bacteremia, thrombocytopenia is commonly associated
with viral infections. Platelets get activated by viruses in the circulation, present due
to the ongoing viremia, leading to a platelet-leukocyte aggregate formation that
causes sequestration of platelets from the circulation, possibly by macrophages that
contribute to lowering the platelet counts. Viruses have also been found inside
platelets, with the first electron micrographs of platelets containing influenza virus,
is the first evidence that platelets can indeed internalize viruses [541]. Since platelets
can internalize FcγRIIA-bound complexes, viruses that can bind to FcγRIIA are often
found inside platelets [535]. Platelets isolated from patients infected with viruses
such as HIV-1 [263], influenza [469], dengue virus [471] and hepatitis C virus [470],
have been shown to harbor viral particles. Some of these cause functional responses,
while for others the same is yet to be discovered.
Human Immunodeficiency Virus-1 (HIV-1)
HIV-1 is a lentivirus containing single-stranded RNA belonging to the Retroviridae
family. It causes HIV infection that eventually becomes Acquired Immunodeficiency
Syndrome (AIDS) over time. AIDS is a cohort of immune dysfunction related
conditions that happens when HIV infection has significantly impaired the immune
system to the point where opportunistic pathogens wreak havoc in an already
immunocompromised individual. This creates infections to become life-threatening
as well as increased propensity for cancers to thrive. In total, death is often caused
due to one or more complications arising from this plethora of infections in HIV+
individuals than due to the actual HIV infection. HIV-induced AIDS is a global killer
with estimates of over 22 million people worldwide having been killed by this disease
ever since its discovery in the 1980s.
The first report of platelets and megakaryocytes internalizing HIV-1 was obtained
from electron micrographs [542] suggesting that direct infection of these cells could
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perhaps play a role in the disease progression of HIV-related AIDS. Youssefian et al.
have previously shown that platelets isolated from HIV-AIDS patients with severe
thrombocytopenia contain virions inside endocytic vesicles lying close to the plasma
membrane [263]. This observation was further clarified using genetically modified
non-replicative HIV and vesicular stomatitis virus (VSV), which were found to be
present within endocytic vesicles in platelets [543]. Electron micrographs showed
that these virus-containing vesicles colocalized with alpha granules markers and
were trafficked to the surface-connected canalicular system (SCCS) where
degradation of the lentiviral particles occurred when in contact with alpha granule
proteins. In cultured megakaryocytes, lentiviral particles were also found in
endocytic

vesicles

and

then

trafficked

into

acid-phosphatase-containing

Multivesicular bodies (MVBs).
HIV-1 entry into platelets is mediated by a host of surface receptors. While
megakaryocytes express CD4, which is the main receptor for viral entry,
megakaryocytes also express other co-receptors such as CXCR1, 2, 4, and CCR3 [544545]. HIV-1 viruses can be transferred from CXCR4+ megakaryocytes to CXCR4- cells,
aiding in viral dissemination [546]. Platelets, on the contrary, do not express CD4 but
only express CXCR1, 2, 4 and CCR1, 3 and 4 [546-549]. HIV-1 can also bind the
dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DCSIGN/CD209 and the C-type lectin-like receptor 2 (CLEC-2) to enter platelets [550].
In patients with HIV-1 infection, increased plasma levels of PF4, increased plateletleukocyte aggregates as well as increased sCD40L levels, all suggest platelet
activation [551]. HIV-1 trans-activator of transcription protein (Tat) directly activates
platelets to release sCD40L in a CCR3 and β3 integrin-dependent manner [552].
Various soluble endothelial activation markers like sVCAM-1, sICAM-1, and von
Willebrand Factor levels are higher in HIV-1 infected patients [544].
Anti-retroviral therapies have been successful in lessening deaths caused due to AIDS.
This has also led to a decreased severity in thrombocytopenia by containing the bone
marrow damage caused by HIV-1 replication, reduction in pro-inflammatory
cytokines and festering of opportunistic infections [553]. Highly active anti-retroviral
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therapies (HAART) have also reduced markers of endothelial and platelet activation
such as P-selectin and CD40L levels in HIV-infected patients [554].
HIV-1 infects platelets and megakaryocytes. Yet how it enters and much of what it
does upon entry remains unclear. The bigger questions remain whether infection of
platelets is beneficial or detrimental to HIV viral dissemination. Do platelets
encounter the virus at the early stages of infection or does it occur, when the
infection is truly systemic and widespread in the circulation? Do platelet responses
to the virus facilitate immune clearance by allowing detection of virus-containing
platelets by the macrophages, monocytes, dendritic cells, T-cell populations etc.?
Conversely, do platelet responses to the virus exacerbate the process of viral
infection? Further studies will help answer some of these questions.
Hepatitis C Virus (HCV)
Like HIV-1 infections, HCV infections also cause thrombocytopenia in addition to
hepatic complications like liver cirrhosis [555]. Hepatitis C virus is a small enveloped
positive-sense, single-stranded RNA virus belonging to the Flaviviridae family and is
known to cause Hepatitis C infections as well as some liver cancers such as
hepatocellular carcinoma, although the mechanisms are unclear. Thrombocytopenia
in Hepatitis C patients strongly correlates with hepatic dysfunction, HCV viral load
(HCV RNA) and severity of cirrhosis and is thought to be a consequence of bone
marrow damage, inhibition of thrombopoietin production by the liver, coupled with
autoimmune activation that leads to increased platelet clearance [555-556]. Platelets
bind to HCV via their envelope-residing glycoprotein E2, in a CD81-independent
manner [557]. The E2 glycoprotein of HCV has been known to bind CD81 to allow
viral attachment and entry to a target cell [558]. CD81-lacking platelets still seem to
bind HCV, although the mechanisms of viral attachment and entry remain unclear.
The presence of HCV-bound platelets isolated from HCV patients indicates that there
are other potential receptors that could perhaps mediate HCV binding; what those
may remain to be seen. Liver sequestration of HCV-bound platelets has been thought
to be a way by which HCV evades the immune system, facilitating viral dissemination
and persistence in the body [557]. Further studies are required to fully understand
how HCV binds platelets and modulates platelet functions in causing
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thrombocytopenia, in an effort to develop antiviral strategies to combat this
infection.
Dengue Virus
Another member of the positive-sense, single-stranded RNA virus of the Flaviviridae
family, is Dengue virus, which causes dengue hemorrhagic fever. Thrombocytopenia
and platelet dysfunction go hand-in-hand with dengue viral infection and are related
to the clinical outcomes of this disease [559, 563]. Platelets isolated from dengue
hemorrhagic fever (DHF) have increased levels of P-selectin expression, lysosomal
CD63 expression, and αIIbβ3 activation compared to healthy control platelets [561]. In
dengue patient platelets, the intrinsic pathway of apoptosis is activated with
concomitant elevation in phosphatidylserine exposure, mitochondrial depolarization,
and activation of caspase-3 and caspase-9. This phenotype is strongly correlated with
increased platelet activation. Studies have further shown that increased platelet
activation during DHF leads to increased production of pro-inflammatory cytokines
as well as increased vascular permeability [560]. In vitro exposure to dengue virus
caused increased expression of the pro-inflammatory cytokine, IL-1β, in platelets, a
phenotype mimicking in vivo analyses of platelets and platelet-like microparticles
isolated from DHF patients that showed elevated levels of IL-1β synthesis. The
nucleotide-binding domain leucine-rich repeat containing protein (NLRP3)
inflammasomes, which are present in platelets, are turned on by dengue virus
infection. NLRP3 activation leads to caspase-1 activation that mediates secretion of
IL-1β from platelets [560]. Dengue virus infects human dendritic cells via DC-SIGN
(CD209) receptor [562]; dengue virus also uses DC-SIGN to infect platelets [561].
Dengue virus has been shown to replicate inside the platelet cytosol producing
infectious viral particles, upon DC-SIGN and heparan sulfate proteoglycan-mediated
viral binding and entry [565]. qRT-PCR and ELISA assays confirmed the presence of
newly synthesized ssRNA as well as presence of the highly antigenic viral NS1 protein,
with copies of about 800 viruses bound per platelet, when platelets were incubated
with dengue virus in vitro at 37°C. This was the first report to describe an active
process of viral replication inside platelets. This replicative ability becomes a serious
issue while storing platelet transfusion units, which might be already unknowingly
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(due to lack of testing) infected with the dengue virus. Dengue virus can persist and
replicate, albeit at a much lower level in these storage units. Upon entering a new
host, during platelet transfusion, dengue virus can then infect the host and
disseminate in circulation to cause dengue fever [566].
Dengue hemorrhagic fever is commonly associated with elevated plasma levels of
pro-inflammatory cytokines such as MIP-1β, RANTES, IL-7, IL-12, IL-5, and PDGF,
caused due to increased platelet activation [564]. Clearly, DHF caused by dengue
virus leads to a complex disease etiology, that oversees a dynamic interplay between
dengue virus, platelets and other participating immune cells and future studies will
aim to better understand how to ameliorate some of the platelet-related
dysfunctions prevalent in dengue viral infections.
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Thesis overview
Ever since their discovery, platelets have almost exclusively been studied in
the context of hemostasis and thrombosis. Recent research over this past decade
has challenged this canonical view of platelets and has provided insights into how
platelet functions extend beyond hemostasis and thrombosis. Platelets have been
shown to be important for immune and inflammatory responses, wound healing,
angiogenesis, tumor progression and cancer metastasis among others. Platelet
activation and exocytosis remain the cornerstone for mediating platelets’ functions
in hemostasis and thrombosis. Endocytosis, on the other hand, has been shown to
be involved in granule cargo loading (e.g., fibrinogen and VEGF), receptor trafficking
of integrins (αIIbβ3, αvβ3) and purinergic receptors (P2Y1, P2Y12), and thereby for
normal platelet function. However, platelet endocytosis could potentially be critical
for actively sensing changes in vascular microenvironments and responding
accordingly to vascular damage and exogenous substances that are being taken up
by platelets (i.e. pathogens, PAMPS and DAMPS). We posit that endocytosis confers
platelets with the ability to become vascular sentries providing active and dynamic
“immune surveillance” against circulating pathogens and “hemostatic surveillance”
against prothrombotic vascular damage. The mechanistic underpinnings of
endocytosis, its importance in platelets, and the molecular machinery required and
possible trafficking routes are however understudied, in part due to a lack of
experimental tools. The work presented here puts forth new players that regulate
endocytosis and mediate cargo loading and hemostasis as well as provides a novel
mechanistic understanding of how endocytosis allows platelets to act as immune
cells and become the first responders to pathogens in the vasculature.
Work presented in the first part of the thesis identifies a v-SNARE protein called
Cellubrevin/VAMP-3 as a key mediator of endocytosis in modulating platelet
functions. Together with another previously identified endocytic regulator, Arf6, a
small GTPase that mediates cargo uptake and integrin trafficking in platelets, we
probe the varied roles of endocytosis in mediating the innate immune responses of
platelets to circulating pathogens in the bloodstream, in the second part of the thesis.
Taken together, we uncover novel mechanistic understandings of how endocytosis is
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important for platelet functions, shedding light on some of the critical regulators of
the process, in general, and how it allows platelets to act as effector immune cells.
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Chapter Two: Reagents and methods
Reagents and antibodies
Rabbit anti-cellubrevin/VAMP-3 antibody (Ab) was obtained from Novus Biologicals
(Littleton, CO). FITC-anti-CD41/61, PE-anti-Jon/A, FITC-P-selectin, PE-LAMP1 Abs
were from Emfret Analytics (Eibelstadt, Germany). Rabbit anti-Integrin β3, anti-βactin Ab, rabbit anti-Akt, rabbit anti-phospho-Akt (Ser32), rabbit anti-TLR7, rabbit
anti-TLR9, mouse anti-IRAK4 were from Cell Signaling (Danvers, MA). Rabbit antifibrinogen Ab was from Dako (Glostrup, Denmark). Rabbit anti-vitronectin Ab was
from Molecular Innovation (Novi, MI); mouse anti-fibronectin and rabbit anti-TPOR
Abs were from Abcam (Cambridge, MA). Anti-rab4, anti-rab11, anti-dynamin 2, and
anti-clathrin heavy chain Abs were from BD Transduction Laboratories (San Jose, CA).
Anti-JAK2 and anti-phospho (Tyr 1007/1008) JAK2 Abs were from EMD Millipore
(Darmstadt, Germany). Rabbit anti-murine PF4 Ab, ELISA kit for mouse PF4 detection
and thrombopoietin were from R&D Systems (Minneapolis, MN). Rabbit antiRabGDI-Ab was generated by our laboratory using recombinant RabGDIα as antigen
and described in [202]. The anti-SNAP-23 antibody was used as described in [202].
Anti-SNAP-23-pSer95 antibody that specifically recognizes phosphorylation at the
Ser95 site in mouse SNAP-23 was previously characterized [457] and was generously
gifted to us by Dr. Paul Roche (NCI). Rabbit Anti-Arf6 serum was homemade as
described before [360]. FITC-Fibrinogen, Dextran (10,000 MW) Oregon Green 488,
Alexa 647-Fibrinogen were obtained from Molecular Probes, Invitrogen (Carlsbad,
CA). Prolong Diamond Antifade Reagent was from Invitrogen (Carlsbad, CA). Human
fibrinogen, fibronectin, poly-D-lysine, hirudin, ammonium chloride and apyrase were
all from Sigma (St. Louis, MO). Thrombin, collagen, and ADP were from Chrono-log
(Havertown, PA). Prostacyclin (PGI2) was from Cayman Chemicals (Ann Arbor, MI).
Trypan Blue was from Thermo Scientific (Waltham, MA). [3H]-tryptamine was from
Perkin Elmer (Waltham, MA). RGDS peptide was from Anaspec (San Jose, CA).
Apyrase, human fibrinogen, poly-D-lysine, hirudin, paraformaldehyde, and
proteinase K were from Sigma (St. Louis, MO). Thrombin, Collagen, ADP, and
CHRONO-LUME reagent were from Chrono-log (Havertown, PA). U46619 and
prostaglandin I2 (PGI2) was from Cayman (Ann Arbor, MI). A23187 was from
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Calbiochem (San Diego, CA). Convulxin was from Centerchem (Norwalk, CT).
PAR1/PAR4-peptide was from Bachem (Bubendorf, Switzerland). Fibronectin-free
fibrinogen was from Enzyme Research Laboratory (South Bend, IN). DNA ligation Kit
was from Enzymax (Lexington, KY). Fura-2/acetoxymethyl ester (AM) was from
Molecular Probes (Eugene, OR). Calcein-AM was from BD Biosciences (San Jose, CA).
Complete, EDTA-free protease inhibitor cocktail was from Roche (Indianapolis, IL).
Acid citrate dextrose (ACD) blood collection tubes were from BD Diagnostics (Sparks,
MD). All other reagents used were of analytical grade.
Mice
The following mice were used for the experiments enlisted in this thesis. All work
with animals was under the supervision of the University of Kentucky Institutional
Animal Care and Use Committee (IACUC) as described in the approved protocol
884M2005.
WT mice (C57BL/6 background), initially purchased from Jackson Laboratory and
bred in our animal vivarium.
IKKβfl/fl/PF4-Cre+ and IKKβfl/fl generated by Dr. Zubair Karim in our lab [242].
Polymerase Chain Reaction (PCR)-based genotyping was performed using genomic
DNA isolated from tail tip of an individual mouse. For IKKβ gene, the PCR analysis
was carried out using following primer set:
Forward primer, (MB1F) 5’-ATGTCTTGTGCCCTCTGGAAAGA-3’,
Reverse primer, (IKK49 antisense) 5’- TCCTCTCCTCGTCATCCTTCG-3’.
The PCR yields a 436 bp DNA product for WT allele and a 533 bp one for floxed allele.
The PCR conditions for IKKβ reactions were: 94°C for 7 min for 1 cycle, followed by
40 cycles of 94°C for 30 sec, 60°C for 30 sec and 72°C for 1 min, and lastly 72°C for 10
min for 1 cycle.
Global VAMP-3 KO mice were bred and genotyped as described [202].
Forward primer, (3F) 5’-CACAGGCACTCTGTTGCATT-3’,
Reverse primer, (6R) 5’-CCACACAGGCTCCTGATCTT-3’,
Neo primer, (mutant allele) 5’-GAGCAGCCGATTGTCTGTTG-3’.
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The PCR reactions were run for WT (with 3F WT and 6R reverse) and for KO (with
Neo and 6R reverse). The PCR yields a 500 bp DNA product for WT allele and a 750
bp one for the mutant allele.
The PCR conditions for VAMP-3 reactions were: 94°C for 7 min for 1 cycle, followed
by 30 cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 90 sec, and lastly 72°C for
10 min for 1 cycle.
Arf6fl/fl/PF4-Cre+ and Arf6fl/fl was generated in our lab by Dr. Yunjie Huang [19]. For
Arf6 gene, the PCR analysis was carried out using following primer set:
Forward primer, 5’-GACCCCATGAGTGTTGTCAC-3’,
Reverse primer, 5’-GGGATACATAGAGAAACCTTGTCTCAGG-3’.
The PCR yields a 240 bp DNA product for WT allele and a 270 bp one for floxed allele.
The PCR analysis for the Cre transgene was carried out using the following primer set:
For the wild-type allele,
Forward primer 5’-CCCATACAGCACACCTTTTG-3’,
Reverse primer 5’-GAAACAACAGGCCCAGAAGC-3’;
For the Cre allele,
Forward primer 5’-CCCATACAGCACACCTTTTG-3’,
Reverse primer 5’-TGCACAGTCAGCAGGTT-3’.
PCR yielding a 450 bp DNA product indicates the presence of PF4-Cre gene.
PCR conditions for both Arf6 gene and PF4-Cre gene are 94°C for 10 min for 1 cycle,
followed by 30 cycles of 94°C for 1 min, 54°C for 45 sec and 68°C for 30 sec, and
lastly 68°C for 7 min for 1 cycle.
Global TLR23479-KO mice were a generous gift from Dr. Jayakrishna Ambati,
University of Virginia, VA.
Genomic DNA isolation from mouse tail tip
Mouse tail tips (3-5 mm) were digested overnight (O/N) at 55°C in 400 µl tail lysis
buffer (50 µM Tris/HCl, pH 7.5, 100 µM EDTA, 100 µM NaCl, and 1% SDS after
autoclave) containing 20 µl 10 mg/ml proteinase K., Protein/peptide was
precipitated by mixing with 200 µl saturated 6 M NaCl and centrifuged at 13,000 x g
for 30 min at room temperature (RT). The supernatant containing DNA was
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harvested and mixed with equal volume of 100% ethanol. After incubation for 10
min at RT, DNA was pellet down by centrifuge at 13,000 x g for 10 min. DNA pellets
were washed once with 1 ml 70% ethanol and then dried in a vacuum centrifuge for
around 20 min. Genomic DNA was finally dissolved in 100 µl autoclaved ddH2O.
Whole blood count
Blood was drawn via cardiac puncture from VAMP-3 KO and control WT littermates
and whole blood counts were performed using a Hemavet (Drew Scientific, Dallas,
TX). Mean Platelet Volume (MPV) measurements were taken using the Z2 Coulter
Counter (Beckman Coulter, Inc., Miami, FL). Statistical analyses were done using the
statistical software program in SigmaPlot (v13.0).
Preparation of mouse platelets
Mouse blood was harvested via cardiac puncture into 0.38% sodium citrate (final)
and diluted (1:1 v/v) in PBS, incubated with 0.2 U/mL apyrase and 10 ng/mL
prostacyclin (PGI2) and centrifuged at 237 x g at room temperature (RT). Platelet-rich
plasma (PRP) was recovered and platelets were pelleted at 657 x g. The pelleted
platelets were resuspended in HEPES Tyrode buffer (pH 6.5, 20 mM HEPES/KOH, 128
mM NaCl, 2.8 mM KCl, 1 mM MgCl2, 5 mM D‐glucose, 12 mM NaHCO3, and 0.4 mM
NaH2PO4), supplemented with apyrase, PGI2, and 1 mM EGTA, and recovered by
centrifugation at 657 x g. Pelleted platelets were finally resuspended in HEPES
Tyrode buffer (pH 7.4) and concentrations were measured using Z2 Counter
(Beckman Coulter, Inc., Miami, FL).
Preparation of fresh human platelets
Fresh whole blood was drawn from an informed healthy donor using acid citrate
dextrose (ACD) collection tubes (BD Biosciences). Whole blood was diluted in HEPES
Tyrode buffer (pH 6.5) with 1:1 ratio in the presence of 0.2 U/ml apyrase and 10
ng/ml PGI2. After centrifugation at 215 x g for 20 min at RT, the supernatant (PRP)
was harvested. To remove residual red blood cells and white blood cells, PRP was
subjected to centrifugation at 155 x g for 10 min at RT. Platelets were recovered
from the resulting PRP by centrifugation at 750 x g for 13 min at RT and then
resuspended in HEPES Tyrode buffer (pH 6.5) in the presence of 0.2 U/ml apyrase, 10
ng/ml PGI2 and 1 mM EGTA. Platelets suspensions were subjected to centrifugation
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again at 750 x g for 13 min at RT and the resulting pellet was resuspended in HEPES
Tyrode Buffer (pH 7.4) supplemented with 1 mM CaCl2. Platelet concentrations were
determined by using Z2 Counter (Beckman Coulter, Inc., Miami, FL) and adjusted to 4
X 108/ml with HEPES Tyrode buffer (pH 7.4) unless otherwise indicated. Platelets
were incubated at RT for 30 min before use.
Platelet aggregometry and ATP release from dense granules
Washed platelets were freshly prepared and adjusted to the desired concentration
with HEPES Tyrode buffer (pH 7.4) containing 1 mM CaCl2. Platelets suspensions (250
or 500 µl) in a siliconized glass cuvette (Chrono-log, Havertown, PA) was warmed to
37°C under stirring conditions (1200 rpm) for 2-3 min in a Model 460Vs Lumi-dual
aggregometer (Chrono-log). After pretreatment with the indicated reagents,
platelets were stimulated with the indicated agonists to initiate platelet aggregation.
A model 810 Aggro/Link computer interface and Aggro/Link software (Chrono-log)
were used to monitoring platelet aggregation traces. Buffer alone had been used to
set baselines.
ATP release from platelets dense-core granules was monitored using Chrono-Lume
reagents (Chrono-log) while measuring platelet aggregation. Chrono-Lume reagents
containing luciferin and luciferase enzyme were pre-incubated with platelet
suspension (1:20 ratio) for 1 min prior to addition of agonists. Luminescence traces
were recorded using the same interface and software as platelet aggregation.
Graphs of platelet aggregation and ATP release was processed and assembled into
figures using Adobe Photoshop CS5 (Adobe Inc. San Jose, CA).
Platelet lysate preparation and western blotting
Platelet lysates were prepared in SDS-PAGE sample buffer supplemented with 2 mM
Na3VO4, 2 mM PMSF, protease inhibitor cocktail, and phosphatase inhibitor cocktail
(PhosStop, Roche). Platelet proteins were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Immobilon-P PVDF
membranes (Millipore Corp., Bedford, MA). Transferred proteins were probed with
suitable primary Abs and visualized using appropriate alkaline phosphataseconjugated secondary Abs and AmershamTM enhanced chemifluorescence (ECF)
substrate (GE Healthcare Life Sciences, Piscataway, NJ). Images were recovered with
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a Typhoon 9500 Variable Mode Imager and quantified using ImageQuantTL software
(GE Healthcare Life Sciences, Piscataway, NJ).
Flow cytometry analysis
To measure the surface levels of total and activated GPIIb/IIIa, washed platelets (5 x
107/mL) were either kept resting or stimulated with 0. 1 U/mL thrombin for 1 min.
The reactions were stopped with hirudin (2-fold excess) and incubated with FITC‐
anti‐CD41/61 antibody and PE‐Jon/A antibody. The mixture was analyzed by flow
cytometry and geometric mean fluorescence intensity (GMFI) was measured.
Washed platelets from WT and KO mice were freshly prepared and adjusted to 5 X
107/ml in HEPES Tyrode buffer (pH 7.4) in the presence of 1 mM CaCl2. Platelets (20
µl) were either kept resting or stimulated with 0.1 U/ml thrombin for 1 min or with
any of the TLR agonists (Loxoribine, CpG ODN2395, LPS, Pam3CSK4 or HIV-1
pseudovirions (HIVpp)). The reactions were stopped by adding a 2-fold excess of
hirudin or HT pH 6.5 wash buffer in the case of TLR and HIVpp agonists. Samples
were then incubated with fluorophore-conjugated antibodies (2.5 µl each) for 15
min at RT. FITC-anti-CD62 antibody and PE-anti-LAMP1 antibody were used to
measure P-selectin and LAMP1. The mixture was transferred to polystyrene FalconTM
tubes (BD Biosciences, San Jose, CA) containing 200 µl HEPES Tyrode buffer (pH 6.5).
Unlabeled platelets were used as background controls. Samples were analyzed at the
flow cytometry facility at the University of Kentucky. Flow cytometry analysis was
performed using FACScanTM flow cytometer (BD Biosciences). Platelet populations
were determined by a combination of forward light scattering (FSC) and side light
scattering (SSC). CellQuestTM (BD Biosciences) was used to monitor platelet
fluorescent intensities. A total of 10,000-20,000 platelet events were analyzed and
the geometric mean of the fluorescent intensity was determined and analyzed using
the SigmaPlot (v13.0) statistical software.
To measure steady-state FITC‐fibrinogen binding, platelets (1.0 x 109/mL) were
incubated on ice for 20 min, and then with 0.06 or 0.12 mg/mL FITC‐fibrinogen for an
additional 20 min. Platelets were fixed with 2% paraformaldehyde (PFA) and
analyzed by flow cytometry. The difference of geometric mean fluorescence
intensity (GMFI) before and after 0.04% Trypan Blue addition was used to assess
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surface fibrinogen binding (0.04% Trypan Blue quenched >95% of free FITC‐
fibrinogen [19]).
To study activated state FITC‐fibrinogen endocytosis, washed platelets (1.0 x 109/mL)
were incubated with or without ADP (10 µM) in the presence of 0.12 mg/mL FITC‐
fibrinogen at 37°C for 30 min. The platelets were then put on ice for 20 min, fixed
with 2% PFA (final conc.), and GMFI measurements were taken by flow cytometry
before and after addition of 0.04% Trypan Blue.
Whole blood platelet-leukocyte aggregation assay
Whole blood (in ACD) was pre-treated for 10 min with an anti-mouse CD16/CD32
antibody (Biolegend, San Diego, CA) to block the FcγRIII/II receptors on immune cells
to prevent antibody-antigen immune complexes. This antibody was a generous gift
from Dr. Ahmad Al-Attar, University of Kentucky. After pretreatment with the
indicated reagents, platelets were kept quiescent or stimulated with the indicated
agonists (Loxoribine, CpG ODN2395, LPS, Pam3CSK4, HIV-1 pseudovirions or
thrombin) to initiate platelet-leukocyte aggregation. To 50 µL of whole blood in a
polystyrene FalconTM tubes (BD Biosciences, San Jose, CA), add 5 µL each of antiplatelet CD41-FITC conjugated antibody, anti-neutrophil Ly6G-APC/PE-conjugated
antibody or anti-monocyte CD14-PE conjugated antibody and vortex gently while
incubating for 15-30 min in the dark at RT. Add 500-1000 µL of 1X BD FACS/Lyse
Solution (BD Biosciences Cat No. 349202) and vortex gently while incubating for 10
min in the dark at RT. Centrifuge the tube contents at 500 x g for 7 min to remove
the supernatant. This removes all the lysed red blood cells. Finally, samples were
resuspended in 500 µL of 1X PBS pH 7.4 and take the tubes for FACS analysis.
Samples were run on the BD LSRII machine and 500,000 events were captured per
sample with gating around 50,000 granulocytes. Data was then analyzed using the
FlowJo software (v7.6.5) and plotted and analyzed using the SigmaPlot (v13.0)
statistical software.
Static platelet adhesion
Washed platelets (4 x 108/mL), labeled with 10 μM calcein AM (BD Bioscience) and
0.2% of Pluronic F‐127 (Invitrogen), were seeded onto 96‐well opaque plates, pre‐
coated with either 50 μg/mL human fibrinogen or 5% bovine serum albumin (BSA) in
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buffer (25 mM Tris, 137 mM NaCl, pH 7.4). After incubation for 1 hr at 37°C, the
wells were washed thrice with HEPES Tyrode Buffer (pH 7.4) and adherent platelets
were

measured

by

fluorescence

using

a

SpectraMax

plate

reader

(excitation/emission/cutoff: 485/538/515 nm). Standard curves were generated
using labeled WT and KO platelets.
Platelet spreading
Fibrinogen-coated slides were prepared by incubating human fibrinogen (50 µg/ml in
PBS) in the wells of a Nunc Lab-Tek II chamber slide (Thermo Scientific) overnight at
4°C. WT and KO platelets (2 X 107/mL) were suspended in HEPES Tyrode buffer (pH
7.4) containing 1 mM CaCl2, seeded into the fibrinogen-coated wells, and incubated
at 37°C for the indicated times. Unbound platelets were removed by washing and
the adherent platelets were fixed with 2% PFA overnight at 4°C. Images of spread
platelets were taken using DIC microscopy and quantified with ImageJ software
(v1.48, NIH).
Clot retraction
Acrylamide pads (polymerized 10% solution) were added to siliconized cuvettes and
washed thrice with HEPES Tyrode buffer pH 7.4. Thrombin (0.05 U/mL) was used to
stimulate clot formation and retraction in washed WT and KO platelets (500 µL; 3 x
108/mL) supplemented with 1 mM CaCl2 in the presence of human fibrinogen (0.5
mg/mL; Sigma). Images were taken at increasing times and clot sizes were measured
using ImageJ software (v1.48, NIH). The percent of clot sizes relative to initial
suspension volumes were determined and analyzed using SigmaPlot (v13.0).
Plate assay to measure endocytosis
Opaque/black 96 well polystyrene plates (Corning, USA) were coated with 5% bovine
serum albumin (BSA) in Phosphate Buffered Saline (PBS) overnight at RT. Wild-type
(WT) and knockout (KO) washed platelets (100 µL; 5 X 107/mL), pre-incubated with 1
mM CaCl2 for 5 min, were added to each well and either incubated with varying
concentrations of FITC-Fg or low molecular weight (10 kDa) Oregon Green 488dextran for increasing times at 37°C. Fluorescence intensities were measured using a
SpectraMax plate reader (Molecular Devices; excitation/emission: 495/520 nm)
before and after addition of 0.04% Trypan Blue (0.04% Trypan Blue quenched >95%
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of Oregon green 488-dextran, data not shown) to stop reactions at various time
points. Standard curves were generated using serial dilutions of FITC-Fg or Oregon
Green 488-dextran.
Cargo uptake ex vivo
Washed platelets (1 X 109/mL) from WT and KO mice were incubated with FITC-Fg
and Oregon Green 488-dextran (1 µM each) at 37°C for increasing times up to 30 min.
Platelets were fixed with 2% PFA and mixed with 0.1% Trypan Blue prior to imaging.
Platelets were visualized using epifluorescence and Differential Interference Contrast
(DIC) microscopy on a Nikon Eclipse E600 microscope (Nikon, Melville, NY) fitted
with an AxioCam MR camera (Zeiss, Germany) and processed using the Zen 2011
Digital Imaging software (blue edition, Zeiss). The number of FITC-positive or Oregon
Green 488-positive puncta per platelet in both WT and KO samples were counted
and plotted using SigmaPlot software (v13.0).
Cargo uptake in vivo
WT and KO mice (n= 3, each) were injected with Alexa 647-Fg and Oregon Green
488-dextran (2 µM each) through the retro-orbital sinus and, 24 hr post-injection,
mice were euthanized and blood was drawn directly into fixative (0.38% sodium
citrate containing 2% PFA and 0.05% glutaraldehyde). Platelets were harvested,
refixed with 2% PFA, and prepared for imaging.
3D-SIM super-resolution microscopy (3D-SIM)
Washed WT and KO platelets (1.0 x 109/mL) were incubated ex vivo with Alexa 647Fg and Oregon Green 488-dextran (1 µM each) at 37°C, then fixed with PFA.
Centrifugation (700 x g for 5 min) was used to remove fixative and platelet pellets
were re-suspended in PBS. The platelets were fixed a second time and then allowed
to settle onto poly-D-lysine (0.1mg/mL) coated coverslips for >90 min at RT in a
humid chamber. To quench fixative, coverslips were incubated cell-side down in 50
mM NH4Cl in PBS for 30 min at RT. Coverslips were washed and mounted in Prolong
Diamond Antifade Mounting medium and cured for 2 days at RT in the dark.
For in vivo experiments, 24 hr post-injection of Alexa 647-Fg and Oregon Green 488dextran, mice were euthanized and platelets were directly fixed during the blood
draw. Platelets were then isolated and allowed to settle onto poly-D-lysine coated
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coverslips. Imaging was done using the Nikon Ti-E N-STORM/N-SIM super-resolution
microscope at the University of Kentucky Imaging Core. Images were processed using
NIS-Elements v3.2 N-SIM/STORM software.
TPO-induced JAK2 signaling
Washed WT and KO platelets (4 X 108/mL) were pre-incubated with 1 mM CaCl2 and
then with 50 ng/mL of thrombopoietin (TPO; R&D Systems) for 0 to 30 min at 37°C.
Platelet extracts were prepared in SDS-PAGE sample buffer (supplemented with
protease inhibitors) and analyzed by western blotting using anti-JAK2 and antiphospho JAK2 (Tyr 1007/1008) and anti-TPOR antibodies.
Measurement of platelet granule cargo release (secretion assays)
Platelet-rich plasma (PRP) from WT and KO mice were prepared and labelled with 0.4
µCi/mL [3H]5-HT (serotonin, Perkin Elmer, Waltham, MA) for 30 min at 37°C. After
washing, platelets were resuspended in HT buffer pH 7.4 fortified with 0.7mM CaCl2
for 5 min prior to stimulation with thrombin or TLR agonists (LPS, Pam3CSK4,
Loxoribine, CpG ODN) for indicated times or doses. 2X Hirudin was added to stop the
reaction for thrombin-treated samples while centrifugation at 13, 800 x g for 2 min
was done to stop the TLR agonist reactions. For each time point or dose reaction,
samples were prepared in triplicates. The supernatant and pellet was separated
post-centrifugation, kept on ice and the pellets were lysed with 1% Triton X-100
solution in 1X PBS on ice for about 45 min. The supernatant and pellet samples were
vortexed and centrifuged one final time (13, 800 x g for 1 min) before doing the
individual granule assays.
For dense granule assay, 25 µL of supernatant or pellet is added to 3 mL of
scintillation cocktail (Econo-safeTM, Research Products International Corp, Mt.
Prospect, IL) and the radioactivity is read as counts per minute using a Tri-Carb
2100TR liquid scintillation analyzer (Beckman, Fullerton, CA). For alpha granule assay,
sandwich enzyme-linked immunosorbent assay (ELISA) is used to detect the release
of platelet-specific alpha granule cargo, Platelet Factor 4, PF4, a chemokine, in the
supernatant and pellet fractions of resting and activated platelets. The assay is
performed according to the manufacturer’s instructions (R&D Systems, Minneapolis,
MN). For lysosomal secretion, a colorimetric assay to measure the release of β89

hexosaminidase in the pellet and supernatant fractions is measured by analyzing its
enzymatic activity on its substrate p-nitrophenyl-N-acetyl-β-D-glucosaminide (Sigma).
Optical density from each sample (pellet and supernatant) is measured at 405 nm
using a Biotek Elx808 plate reader and data is collected using the Softmax Pro 6
software (Molecular Devices, Sunnyvale, CA). The percent release for each marker at
each data point was calculated by using the supernatant fraction measurements
divided by the total measurements (supernatant + pellet values) multiplied by 100.
TLR activation of platelets
Washed WT and KO platelets or freshly isolated human platelets (4 X 108/mL) were
pre-incubated with 1 mM CaCl2 and then with increasing times or increasing
concentrations of various TLR compounds such as TLR2 agonist (Pam3CSK4), or TLR4
agonist (LPS O111:B4), or TLR7 agonist (Loxoribine) or TLR9 agonist (CpG ODN2395
Class C) at 37°C. In some instances, platelets were either pre-treated with
ammonium chloride or Dynasore (to inhibit endocytosis) prior to TLR stimulation.
Platelet extracts were prepared in SDS-PAGE sample buffer (supplemented with
protease inhibitors) and analyzed by western blotting using anti-Akt, anti-phosphoAkt (Ser473), anti-SNAP-23, anti-phospho-SNAP-23 (Ser95), anti-IRAK4, antiphospho-IRAK4 (Thr345) (Abbomax), anti-IκBα and anti-phospho-IκBα (Ser32/36)
antibodies (in the case of human platelets).
Preparation of HIV-1 pseudovirions
Plasmids
Viral vectors to make the HIV-1 pseudovirions were a generous gift from Dr. Gregory
Melikyan, Emory University. These were: (i) A chimeric Ecph-TM expressing vector
containing the ecliptic pHluorin, derived from the original ecliptic pHluorin construct
[455] and transmembrane (TM) domain of ICAM-1 (intercellular adhesion molecule
1). The pCDM8 ICAM-1 vector (Addgene) was used as the template for the TM
domain of ICAM-1 while the MLV (murine leukemia virus) Gag-EcpH-expression
vector was used as a template for the EcpH [456]. (ii) The HIV-1 Gag-mCherry
expression vector was constructed by cloning the Gag fragment of the
p96ZM651gag-opt vector [National Institutes of Health ARRRP (AIDS Research and
Reference Reagent Program)] into pcDNA3.1zeo (+) plasmid (Invitrogen) together
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with the mCherry fragment, which was obtained from pRSET-BmCherry (from Dr. R.
Tsein, University of California, San Diego). The other two vectors were (iii) HIV pR8
delta Env and (iv) pCAGGS.HXB2 Env.
Pseudovirion Preps
The vectors were first amplified in E. coli expression systems by Midi-Prep. Viral
preps were made by Dr. Gabriel J. Popa and Dr. Michael D. Mendenhall at the
University of Kentucky Genetic Core. Pseudovirions were then prepared by
transfecting 293-LTV cell lines with all four viral vectors in the following proportions
[HIV pR8 delta Env (30%), HIV-Gag-mCherry (12.5%), 3x FLAG-EcpH-ICAM (12.5%)
and pCAGGS.HXB2 Env (45%)] using polyethyleneimine (PEI). Cells were transfected
and after 5-6 hrs, the transfection medium was withdrawn and fresh medium
(DMEM+ fortified with 10% FBS) was added. Cells were grown for 48-72 hrs
depending on GFP and mCherry expression. Viruses were then harvested and
concentrated by centrifugation at 4°C over a 20% sucrose cushion. Viral titers in the
concentrates were quantified by measuring amount of p24 using the ZeptoMetrix
HIV-1 p24 antigen ELISA kit (Cat No. 0801111) (ZeptoMetrix, Franklin, MA).
Ex vivo uptake of HIV-1 pseudovirions
Washed WT and KO platelets were resuspended at concentrations of 1 X 109/ml in
supernatants from the 293-LTV cells (containing the HIV-1 pseudovirions) or in
HPEPS Tyrode Buffer containing 1% BSA and 1 mM CaCl2 that was supplemented
with 100X concentrated pseudovirions. Platelets (100 µl) were incubated for varying
times at 37°C in the CO2 incubator. Aliquots were drawn at different intervals and
fixed with 2% paraformaldehyde at 4°C overnight. Platelets were recovered by mild
centrifugation and resuspended in 15 µl HEPES Tyrode buffer. Microscopic slides
with 5 µl platelets mixed with 1 µl Trypan Blue (stock 4%) were prepared and
visualized using Nikon Eclipse E600 microscope (Nikon, Melville, NY) with a
100X/1.40 numeric aperture DIC H oil objective lens (Nikon). Images were taken
using Zeiss camera (AxioCam MR, Germany). Images were processed using Zen 2011
(blue edition, Zeiss). As a metric of viral uptake, the number of GFP-mCherry doublepositive puncta per platelet was counted. To eliminate non-specific fluorescence
signal from the EcpH-TM-labelled particles that are probably membrane vesicles
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lacking the Gag-mCherry, only the double-positive virions were counted. The
presence of double-positive pseudovirions within the platelets should thus reflect
virus internalization.
In vivo uptake of HIV-1 pseudovirions
Mice from WT and KO groups (age-matched and sex-matched) were anesthetized
under isoflurane inhalation and HIV-1 pseudovirions were injected using a 27G
needle (BD Biosciences) through the retro-orbital sinus. 24-hr post-injection, mice
were euthanized, blood was drawn directly into fixative and platelets isolated as
previously described. Microscopic slides with 5 µl platelets mixed with 1 µl Trypan
Blue (stock 4%) were prepared and visualized using Nikon Eclipse E600 microscope
(Nikon, Melville, NY) with a 100X/1.40 numeric aperture DIC H oil objective lens
(Nikon). Images were taken using Zeiss camera (AxioCam MR, Germany). Images
were processed using Zen 2011 (blue edition, Zeiss). As a metric of viral uptake, the
number of GFP-mCherry double-positive puncta per platelet was counted.
HIV-1 pseudovirion activation of human and mouse platelets
Washed WT and KO platelets or freshly isolated human platelets (4 X 108/mL) were
pre-incubated with 1 mM CaCl2 and then with increasing times or increasing
concentrations of HIV-1 pseudovirions at 37°C. In some instances, platelets were
either pre-treated with ammonium chloride or Dynasore (to inhibit endocytosis)
prior to HIV-1 pseudovirion stimulation. Platelet extracts were prepared in SDS-PAGE
sample buffer (supplemented with protease inhibitors) and analyzed by western
blotting using anti-Akt, anti-phospho-Akt (Ser473), anti-SNAP-23, anti-phosphoSNAP-23 (Ser95), anti-IRAK4, anti-phospho-IRAK4 (Thr345) (Abbomax), anti-IκBα and
anti-phospho-IκBα (Ser32/36) antibodies (in the case of human platelets).
Study approval
All animal procedures were done under an approved protocol (884M2005) from the
University of Kentucky Institutional Animal Care and Use Committee (IACUC). Human
blood drawn from healthy donors was obtained at the Kentucky Clinic Lab by a
phlebotomist.
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Statistics
Where appropriate, Student’s t-test or Mann-Whitney U test (from the SigmaPlot
statistical software) were used to determine statistical significance. The data from
secretion assays and FACS-based experiments were analyzed by two-way ANOVA. A
one-tailed Student’s t-test was used to analyze the properties of platelets from KO
mice. In all cases, the p values are indicated.
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Chapter Three: VAMP-3-mediated endocytosis and trafficking regulate platelet
functions
Introduction
Blood platelets respond to repair vascular damage via activation and subsequent
granule exocytosis [458]. Platelet endocytosis is essential for cargo packaging (e.g.,
fibrinogen (Fg)) [14, 9, 340]. However, platelet endocytosis could be critical for
actively sensing changes in vascular microenvironments and responding accordingly
to what is being taken up. This is a more dynamic view of platelets as active
surveyors of the vasculature; extending the importance of platelet endocytosis
beyond granule biogenesis and perhaps even hemostasis. The mechanistic
underpinnings of endocytosis and its importance in platelets are however
understudied, in part due to a lack of experimental tools.
Endocytosis refers to cargo uptake and receptor trafficking to and from the plasma
membrane through distinct membrane-bound compartments. Seminal studies, from
the 1980s, provided the first glimpses into the presence of an active endomembrane
system in platelets. Platelets have clathrin-coated vesicles [326, 331]; can
endocytose several plasma proteins (e.g., albumin, IgG, Fg, von Willebrand Factor
(vWF), fibronectin) and translocate them to α-granules [340, 15-17, 328-330]. Both
clathrin-mediated and clathrin-independent endocytosis has been reported in
platelets [327]. Additionally, several platelet surface receptors such as integrin αIIbβ3
and glycoprotein Ib are internalized and then recycled back to the plasma membrane
[334, 336-337]. Platelet CLEC-2 is internalized in a Syk-independent manner whereas
Arrestin and Arf6 have been shown to be crucial to endocytic trafficking of the P2Y12
receptors [21, 459]. ADP and thrombin stimulation leads to translocation of internal
pools of receptors and surface re-distribution [333, 335-336, 338-339]. Consistent
with these reports of platelet endocytosis, platelets do contain key endocytic
proteins and regulators including the vesicle scission-inducing large GTPase,
Dynamin, Dynamin-related protein 1 (Drp1), and adaptor proteins such as Disabled-2
(Dab-2) [22, 344, 347, 351, 356-357]. Recently, we highlighted the role of ADPribosylation factor 6 (Arf6), a small GTP-binding protein, that specifically regulates
αIIbβ3-mediated Fg uptake/storage and hence modulates acute platelet functions
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such as clot retraction and spreading [19]. These studies are supported by “omics”
analyses [200, 343] that highlight the burgeoning importance and complexity of
endocytosis in platelets.
Here we describe a role for Cellubrevin/Vesicle-Associated Membrane Protein-3
(VAMP-3) in mediating endocytosis and trafficking in platelets. This v-SNARE has
been reported to be localized to intracellular punctate structures within platelets
[30]. Using a knockout (KO) mouse, with normal hemostasis and whose platelets had
no aggregation or secretion defects [202], we determined that VAMP-3 plays a role
in Fg uptake and governs platelet endocytosis. VAMP-3 deletion caused defective
αIIbβ3-mediated Fg uptake and accumulation while fluid phase pinocytosis, as
monitored by dextran uptake, was marginally affected, both in vivo and ex vivo.
Platelet spreading on Fg and thrombin-stimulated clot retraction was faster in the
VAMP-3 KO platelets. Additionally, we demonstrate that platelets sort endocytosed
cargo into discrete compartments in vivo and ex vivo. Taken together, our work
presents VAMP-3 as a regulator of platelet endocytosis and this knockout mouse
adds to the repertoire of tools for studying endocytic trafficking in platelets while
maintaining normal exocytosis and hemostasis.
VAMP-3 KO platelets were fibrinogen-deficient
Given past reports of fibrinogen (Fg) endocytosis by platelets [340, 329] and the
intracellular localization of VAMP-3 [205], we asked if VAMP-3 played a role in Fg
uptake and/or accumulation. In Figure 1A-B, VAMP-3 KO platelets, isolated from 3
individual mice, had less associated Fg (~40% less, p≤ 0.001) than their
corresponding WT littermate controls, indicating a defect in uptake and/or
accumulation of Fg. Plasma Fg levels were unchanged suggesting that loss of VAMP-3
did not affect Fg production (Figure 7). The major platelet integrin that binds Fg
[337], αIIbβ3, was also unaffected by loss of VAMP-3 as evidenced by the unchanged
levels of β3 in the KO platelets (Figure 3C). Ligands for other platelet integrins, e.g.,
fibronectin (binding to α5β1 and αvβ3) and vitronectin (binding to αvβ3), were either
unchanged or slightly elevated in KO platelets (Figure 3D). Of note, vitronectin levels
were also slightly increased in the Arf6 KO platelets as compared to WT [19]. Since
VAMP-3 is thought to localize on both early and recycling endosomes [403, 458],
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Rab4 (early) and Rab11 (recycling) levels were measured and found to be unchanged
in KO platelets (Figure 3C-D). Other platelet endocytic markers e.g., Dynamin-2,
Clathrin Heavy Chain and Disabled-2 (Dab2) were also unchanged (Figure 3C-D).
Levels of de novo synthesized cargo such as platelet factor 4 (PF4) and other platelet
SNARE proteins were unaltered in the VAMP-3 KO platelets, consistent with normal
granule secretion [202]. Defective Fg endocytosis did not alter the gross morphology
of VAMP-3 KO platelets. Moreover, the KO mice had normal platelet, RBC and WBC
counts (See Table 2), although their platelet size was ~5% smaller than age-matched
WT littermate controls. Thus the reduced intra-platelet Fg observed in KO platelets
was not due to alterations in any endocytic proteins and regulators or due to
decreased levels of β3 integrins and circulating plasma Fg, suggesting that VAMP-3 is
essential for uptake and/or accumulation of Fg in platelets.
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Figure 3
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Figure 3 VAMP-3 KO platelets had lower fibrinogen levels. (A) Fg levels in washed
platelet extracts from 3 WT and KO mice were measured by western blotting. β-actin
was used as loading control. (B) Quantification of Fg levels in (A) was done using
ImageQuantTL and plotted with SigmaPLot (v 13.0). (C) Comparison of protein levels
by Western blotting between WT and KO platelets. Washed platelet extracts (5 X
107platelets/lane) were loaded, and the indicated proteins were probed by western
blotting. (D) Quantification of protein levels was done using ImageQuantTL and data
was plotted as the ratio of KO over WT. The dashed line represents the ratio 1 of
KO/WT protein levels. Statistical analysis was done using Student’s t-test where ***
represents p-value of ≤0.001. Data for (C) and (D) is representative of platelets
pooled from 2-3 mice in at least 2 independent experiments.
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Surface αIIbβ3 levels and Fg-binding was unchanged on the VAMP-3 KO platelets
Reduced levels of internalized Fg could be due to decreased surface and/or activated
αIIbβ3. By flow cytometric analysis, levels of surface αIIbβ3, under resting conditions,
were unchanged in the KO platelets (Figure 4A i-iii). As expected [19], thrombininduced activation mobilized an internal pool of αIIbβ3 integrins. We observed a ~25%
increase in the total surface αIIbβ3 levels upon stimulation. While this ~25% increase
was noted in both WT and KO platelets, there was no significant difference between
the two. Similarly, in Figure 4B (i-iii), levels of activated αIIbβ3, as measured by JonA
binding, were unchanged in VAMP-3 KO platelets, consistent with normal
aggregation [202]. Defective Fg uptake, despite normal levels of αIIbβ3, could be
attributed to defective surface-binding of Fg to αIIbβ3. Under steady-state conditions,
FITC-Fg binding at two different concentrations (0.06 and 0.12 mg/mL) was
unaffected in the VAMP-3 KO platelets (Figure 4C). Taken together, these results
indicated that the lower Fg levels in KO platelets were not due to defective binding
or reduced surface levels of αIIbβ3.
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Figure 4
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Figure 4. Total surface and activated αIIbβ3 and fibrinogen-binding were unchanged
in VAMP-3 KO platelets. (A) Using FITC-anti-CD41/61 antibody, surface levels of total
αIIbβ3 between WT (dark gray, solid lines) and KO platelets (light gray, dotted lines) (5
X 107 platelets/mL) and (B) Using PE-Jon/A antibody, activated αIIbβ3, in resting state
(i) or thrombin-stimulated (ii) were compared using flow cytometry. Unlabeled
platelets (black, solid lines) were used as background controls. (iii) Quantification of
data shown in Ai or Bi and Aii or Bii expressed as geometric mean fluorescence
intensity (GMFI) was plotted. WT is depicted in black while KO is depicted in gray. (C)
Fg-binding to αIIbβ3 between WT (black) and KO (gray) platelets was compared.
Washed platelets (1 X 109 platelets/mL) were held on ice for 20 min, and then
incubated with FITC-Fg (0.06 mg/mL and 0.12 mg/mL) for a further 20 min on ice.
Platelets were fixed with 2% PFA and analyzed using flow cytometry. Data expressed
as GMFI was quantified as shown. Data shown here is representative of at least 3
independent experiments (mean ± SEM) for (A), (B) and (C).
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VAMP-3 KO platelets had defective Fg uptake
ADP-stimulation enhances internalization of Fg-bound αIIbβ3 into platelets [333, 335].
We verified this observation using flow cytometric analysis to measure FITC-Fg
uptake in resting and ADP-stimulated WT and VAMP-3 KO platelets. Similar to Huang
et al. 2016 [19], we used 0.04% Trypan Blue (TB) to quench external FITC
fluorescence (including the fluorescence that is trapped within the open canalicular
system) and measured TB-resistant fluorescence of internalized cargo as a metric of
endocytosis. Platelets were incubated with FITC-Fg, either in the presence or
absence of ADP, at 37°C, and then chilled on ice to arrest further endocytosis, fixed
with 2% PFA, analyzed using flow cytometry prior to (darker bars) and after (lighter
bars) addition of TB. In the absence of TB, geometric mean fluorescence intensity
(GMFI) measurements represent the total fluorescence intensity of FITC-Fg present
both inside the platelet and on the surface. In Figure 5A, under resting conditions,
the total fluorescence intensity prior to the addition of TB was equivalent between
WT and KO platelets, confirming equal amounts of FITC-Fg bound in each sample.
Post-TB quenching, KO platelets had ~50% less FITC-Fg signal (p≤ 0.03 at 0.06 mg/mL
and p≤ 0.006 at 0.12 mg/mL) indicating that under steady-state conditions, VAMP-3
loss affected platelet internal accumulation of Fg. In Figure 5B, activation by ADP (10
µM) stimulation increased overall net fluorescence for both WT and VAMP-3 KO
platelets by ~30 fold, indicative of αIIbβ3 activation caused by ADP receptor signaling
[333, 335]. Although VAMP-3 KO platelets had enhanced Fg association comparable
to WT, less FITC-Fg was resistant to TB addition, consistent with a ~50% deficit in
internalized FITC-Fg (p≤ 0.039 at 0.06 mg/mL and p≤ 0.023 at 0.12 mg/mL).
Collectively, these data suggest that VAMP-3 deletion leads to impaired endocytic
uptake and/or accumulation of Fg into platelets in both resting and activated states.
Endocytosis defects in VAMP-3 KO platelets: receptor-mediated vs. fluid-phase
endocytosis
Platelets can endocytose diverse cargo e.g., VEGF [459], bacteria, and viruses [[263]
and Banerjee, et al. (in preparation)] etc., thus we asked whether loss of VAMP-3
affected other cargo. Uptake of fluorescently tagged, receptor-mediated cargo (Fg)
and fluid-phase pinocytosis cargo (low mol. wt. dextran) was tracked in a plate-based
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assay using TB as a quencher of external fluorescence. In Figure 5C and 5E, WT
platelets internalized FITC-Fg in a time-dependent manner (up to 60 min) and dosedependent manner (up to 5 μM) respectively while VAMP-3 KO platelets showed a
robust defect in both time- and dose-dependent Fg uptake. Arf6 KO platelets were
also defective in FITC-Fg uptake (Figure 10A, C) confirming our earlier studies [19].
Based on these data, Fg internalization within platelets exhibited time- and dosedependence that appears to saturate. This was indicative of a receptor-mediated
endocytosis process.
Unsurprisingly, fluid phase endocytosis/pinocytosis occurs constitutively in WT
platelets and showed a linear increase in dextran uptake with time (Figure 5D) and
concentration (Figure 5F). Loss of either VAMP-3 or Arf6 renders platelets nominally
defective in dextran uptake, but there was still a time- and dose-dependence similar
to WT. Our data agrees with reports of normal pinocytosis of small molecules such as
horseradish peroxidase in VAMP-3 KO mouse embryonic fibroblasts (MEFs) when
compared to wildtype MEFs [419-420]. Interestingly, from a quantitative perspective,
more of the fluid phase marker (dextran) was endocytosed than Fg (1018 vs. 1015
molecules/platelet over 60 min). These data were consistent with fluid phase
pinocytosis having a higher overall capacity than receptor-mediated uptake. Arf6 KO
platelets had only a modest decrease in dextran uptake as compared to WT (Figure
10B, D). Collectively, our data suggests that both VAMP-3 and Arf6 are more
important for receptor-mediated uptake of Fg in platelets than for fluid-phase
pinocytosis.
We used fluorescence microscopy to further confirm these results. WT and VAMP-3
KO platelets were incubated with 1 µM of FITC-Fg for 30 min, fixed, treated with 0.04%
TB to quench external fluorescence, and imaged by epifluorescence. WT platelets
had more FITC-Fg+ puncta than VAMP-3 KO platelets after 30 min (Figure 5G).
Quantification of total fluorescent puncta present per platelet showed that over 80%
of VAMP-3 KO platelets (vs ~30% in WT) had no puncta consistent with defective Fg
uptake (Figure 5H; overall p≤ 0.01). Only WT platelets had ≥ 3 puncta compared to 2
or less in KO platelets. Consistent with our ex vivo plate-based assay, quantification
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of dextran+ fluorescent puncta (indicative of dextran uptake) in WT and VAMP-3 KO
platelets showed no significant differences (Figure 11A-B).
Collectively, these data show that Fg uptake and/or accumulation is dramatically
reduced in the VAMP-3 KO platelets and comparatively more affected than dextran
uptake and/or accumulation. Since αIIbβ3 activation and Fg-binding to αIIbβ3 remained
unaffected in the VAMP-3 KO platelets, it appears that VAMP-3 could be mediating
membrane trafficking step(s) that are downstream of Fg binding and internalization
but required for accumulation of Fg inside platelets.
Platelets sorted different classes of endocytic cargo
In VAMP-3 and Arf6 KO mice, Fg uptake and/or accumulation was more affected
than dextran uptake. This suggested that VAMP-3 and Arf6 are more important for
receptor-mediated uptake of Fg than for fluid-phase pinocytosis of dextran. Could
the two different cargos be endocytosed differently and access different
compartments

upon

internalization?

We

used

3D-Structured

Illumination

Microscopy (3D-SIM) to address this question. Ex vivo platelets were co-incubated
with equimolar concentrations of Alexa 647-Fg and Oregon Green 488-dextran and
imaged over time. In Figure 6A, at 1 min, Fg (depicted in magenta) was found on the
platelet plasma membrane (possibly via binding to αIIbβ3), while dextran (depicted in
green) already appeared to be internalized within punctate structures inside the
platelet. Surface staining for dextran was minimal; most likely because no specific
dextran receptor is present on platelets. At 5 min, while surface staining was still
visible, Fg+ puncta started to appear, with a concomitant increase in dextran+ puncta.
By 30 min, more Fg-positive puncta appeared, and the surface localization was
minimal. Strikingly, Fg and dextran puncta did overlap but in a very limited way,
suggesting that the two cargo might be in distinct compartments. This implies that
platelets can distinguish and perhaps sort their internalized cargo. Consistently,
VAMP-3 KO platelets have fewer Fg puncta compared to WT while dextran uptake
was less affected. Loss of VAMP-3, however, did not completely compromise cargo
sorting as discrete punctate localization of Fg and dextran was still seen in the KO
platelets, similar to WT.
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To further confirm the defects in the accumulation of Fg and dextran in the VAMP-3
KO platelets in vivo, equimolar amounts of Alexa 647-Fg and Oregon Green 488dextran were injected via the retro-orbital sinus of WT and VAMP-3 KO mice.
Platelets were harvested 24 hr post-injection and imaged by 3D-SIM. In both WT and
VAMP-3 KO platelets, Fg and dextran were localized to distinct compartments
(Figure 6B). VAMP-3 KO platelets had a robust defect in Fg accumulation with very
few fluorescent puncta visible. Surprisingly, dextran+ puncta were also diminished in
KO platelets, suggesting that loss of VAMP-3 may have a greater effect on
accumulation over longer incubation times (24 hr; i.e., when in circulation), than
during acute uptake at shorter times (up to 60 min). This would argue that VAMP-3 is
essential for both acute uptake and long-term accumulation/storage of receptormediated cargo (Fg) whereas it preferentially affects accumulation/storage over
acute uptake of fluid-phase pinocytic cargo. The integrity of the fluorescently-tagged
dextran was not evaluated so its degradation could also explain our findings.
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Figure 5
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Figure 5 VAMP-3 KO platelets had defective fibrinogen uptake. WT and KO platelets
(1.0 x 109/mL) were either kept resting (A) or stimulated with ADP (10 µM) (B), then
incubated with FITC-Fg (0.06 mg/mL or 0.12 mg/mL) at 37°C for 30 min. The platelets
were then put on ice for 20 min, fixed with 2% PFA and GMFI measurements were
taken by flow cytometry before and after addition of 0.04% Trypan Blue (TB).
Quantification of data shows both GMFI measurements before addition of TB
(WT/KO –TB) which gives the total fluorescence and after addition of TB (WT/KO +
TB) which gives the measure of internal fluorescence. As explained in “Methods”
under plate assay to measure endocytosis, WT and KO platelets were added to each
well and either incubated with FITC-Fg (0.1-5 µM) (E) or low mol. wt. (10 kDa)
dextran-Oregon green 488 (1-100 µM) (F) or for times 0 to 60 min (C-D) at 37°C.
Reactions were stopped at given time points and fluorescence was measured before
and after addition of 0.04% TB. Data were plotted using SigmaPlot (v13.0) and
graphed as number of molecules of Fg or dextran endocytosed per platelet. (G)
Washed WT and KO platelets (1 X 109/mL) were incubated with FITC-Fg at final
concentrations of 1 µM at 37°C for increasing times up to 30 min. Platelets were
fixed with 2% PFA (final conc.) and mixed with 0.1 % TB prior to imaging. Platelets
were visualized as in the Methods section. Exposure times for DIC were 100 msec
while for FITC laser were 500 msec. Scale bars are 5 µM. (H) Quantification of the
number of FITC+ puncta/platelet in both WT and KO samples and plotted using Sigma
Plot software (v13.0). Statistical significance (**) denoted by p-value ≤0.01. Data is
representative of 3 independent experiments (mean ± SEM) for all.
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Figure 6
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Figure 6 Platelets sorted endocytosed cargo. (A) Washed WT and KO platelets (1.0 x
109/mL) were incubated ex vivo with Alexa 647-Fg and Oregon green 488-dextran at
final concentrations of 1 µM each and incubated at 37°C for 1 min to 30 min and
prepared for 3D-SIM imaging as described in ”Methods”. (B) WT and KO mice were
injected with Alexa 647-Fg and Oregon Green 488-dextran, at a concentration of 2
µM each, through the retro-orbital sinus. 24 hours post-injection, platelets were
harvested and prepared for 3D-SIM analysis. Slides from (A) and (B) were then
imaged using the Nikon Ti-E N-STORM/N-SIM super-resolution microscope and
images were processed using the NIS-Elements v3.2 N-SIM/STORM suite software.
Scale bars are 5 µm. Data is representative of at least 2 independent experiments.
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Table 2 Characteristics of blood Cells from WT and KO mice

WT (n= 10)

KO (n=10)

P value

WBC (K/µL)

9.79 ± 1.9

9.54 ± 1.59

0.57

RBC (M/µL)

7.68 ± 1.72

7.57 ± 1.59

0.695

878.62 ±

945.8 ± 496.1

0.74

4.18 ± 0.19

0.014

Platelets (K/µL)

520.7
Mean Platelet

4.36 ± 0.32

Volume (fL)

110

Loss of VAMP-3 caused faster platelet spreading on Fg and enhanced clot
retraction
VAMP-3 has been shown to modulate β1 integrin-dependent cell adhesion and
migration in epithelial cell lines [426-427]. We asked whether VAMP-3 plays a similar
role in αIIbβ3-mediated platelet spreading. Consistent with our data in Figure 4C
where there was no change in Fg-binding to αIIbβ3 in the VAMP-3 KO platelets, there
was no statistically significant difference in static adhesion to Fg between WT and KO
platelets (Figure 7C). To determine whether VAMP-3 loss affected platelet spreading,
we monitored WT and KO platelet spreading on Fg-coated surfaces from 0 to 120
min at 37°C. VAMP-3 deletion caused faster spreading on Fg-coated surfaces with
significantly larger platelet surface areas covered in as early as 30 min (p≤ 0.05), and
continuing to later time points [45 min (p≤ 0.001), 60 min (p≤ 0.001) and 90 min (p≤
0.01)] (Figure 7A-B). The rate of spreading was 82% faster in the KO platelets (rate of
0.80 µm2/min for KO vs 0.44 µm2/min for WT; assuming spreading is a linear function
over time). Consistent with increased spreading, clot retraction was also faster in KO
platelets compared to WT (Figure 7D-E). Unlike spreading, which is a linear function,
clot retraction proceeded exponentially over time, with the decay constant for WT
being 0.011 % of initial clot size/min and that for KO is 0.015 % of initial clot size/min.
This led to a 36% enhancement in the rate of clot retraction in the KO platelets as
early as 30 min (p≤ 0.05) and continued at 60 min (p≤ 0.05) and 120 min (p≤ 0.05).
Note that exogenous Fg was added in excess and was not limiting in these assays.
Thus, loss of VAMP-3 led to enhanced platelet spreading and clot retraction. These
alterations, however, do not affect platelet aggregation and hemostasis on a global
scale, as both were normal in the VAMP-3 null mice which also have no bleeding
diathesis [202].
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Figure 7
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Figure 7 VAMP-3 KO platelets spread faster on Fg and had enhanced clot retraction.
(A) Representative images of WT and KO platelets allowed to spread for 60 min are
shown. Images of spread platelets were taken using DIC Microscopy as described in
“Methods”. Exposure times for DIC images were 100 msec. (B) Quantification of
platelet surface area from WT and KO Fg-spread platelets for indicated times. Data is
representative of 2 independent experiments (mean ± SEM). (C) Quantification of
static adhesion on 50 μg/mL human Fg and 5% BSA-coated surfaces for WT and KO
calcein-labeled platelets harvested from 3 different KO and WT mice. Adherent
platelets were measured by fluorescence using a SpectraMax plate reader. Data was
plotted using SigmaPlot (v13.0). (D) Representative images of thrombin-stimulated
(0.05U/mL; denoted by +) clot retraction in WT and KO platelets at increasing times.
(E) Clot sizes were measured and the percent of clot size relative to initial suspension
volume (measured at time 0 and set as 100%) were determined and plotted. Three
different KO and corresponding WT littermate controls were used in this experiment.
Statistical significance (*) denoted by p-value ≤0.05, (**) denoted by p-value ≤0.01,
(***) denoted by p-value ≤0.001, and n.s stands for not significant.
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Loss of VAMP-3 led to increased JAK2 phosphorylation downstream of TPOR/Mpl
receptor
Since VAMP-3 mediates trafficking of several transmembrane receptors such as the
Transferrin receptor in other cell types [404], we asked what other platelet receptors
could rely on VAMP-3-dependent trafficking step(s). Thrombopoietin (TPO) binding
to its receptor Thrombopoietin Receptor (TPOR/Mpl) induces internalization of the
receptor in a Dynamin-2 and clathrin-mediated process that initiates signaling via
Janus Kinase 2 (JAK2) phosphorylation [22, 460]. We asked whether VAMP-3
contributes to this process. In contrast to Dynamin-2 KO platelets, VAMP-3 KO
platelets did not exhibit constitutive JAK2 phosphorylation. Instead, they showed a
time-dependent increase in phospho-JAK2 levels similar to WT. However, at each
time point, phospho-JAK2 levels were markedly elevated in VAMP-3 KO vs. in WT
platelets (Figure 8A-B) with statistically significant differences at 15 min (p≤ 0.05)
and at 30 min (p≤ 0.05). The levels of total JAK2 appeared to be lower in the VAMP-3
KO platelets compared to WT and the levels of total TPOR were unchanged (Figure
8A). Our data suggests that while TPOR levels may be unaffected, there exists a
VAMP-3-mediated membrane trafficking step(s) that occurs upon TPO-bound TPOR
internalization, which affects JAK2 phosphorylation. Given that Arf6 is important for
integrin trafficking, we asked whether it could play a role in signaling through the
TPOR-JAK2 axis. Arf6 KO platelets demonstrated normal JAK2 phosphorylation upon
TPO induction similar to WT platelets, with no change in TPOR levels (Figure 12A-B).
Arf6, thus, may be less important than VAMP-3 or Dynamin-2 in regulating
TPOR/Mpl-JAK2 signaling.
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Figure 8
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Figure 8 Loss of VAMP-3 led to increased JAK2 phosphorylation downstream of
TPOR/Mpl receptor. (A) Platelet extracts were prepared from washed WT and KO
platelets (4 X 108/mL) were incubated with 50 ng/mL of thrombopoietin (TPO) for 0
to 30 min at 37°C. Western blotting was performed using anti-JAK2 and anti-phospho
JAK2 (Tyr 1007/1008) and anti-TPOR antibodies. Images were taken on a Typhoon
9500 Variable Mode Imager and quantified using the ImageQuantTL software. (B)
Volumetric quantification of phospho-JAK2 levels over total JAK2 levels was plotted
as a ratio of pJAK2/JAK2 (arbitrary units) over time of TPO incubation. Statistical
significance (*) denoted by p-value ≤0.05 and is representative of at least 3
independent experiments (mean ± SEM).
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Figure 9
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Figure 9 Plasma Fg levels were unaffected in VAMP-3 KO mice.
Western Blotting showing levels of plasma Fg from 2 different VAMP-3 KO and
corresponding WT littermate controls. Equal amounts of protein 30 µg/lane,
quantified by protein BCA assay, were loaded.
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Figure 10
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Figure 10 Arf6 KO platelets had a greater negative defect in Fg uptake than in
dextran uptake.
100 µL of WT and Arf6 KO washed platelets (5 X 107/mL), pre-incubated with 1 mM
CaCl2 for 5 min, were added to each well in a 96-well black opaque plate and either
incubated for increasing times (0-60 min) (A-B) or with varying concentrations of
FITC-Fg (0.1-5 µM) (C) or low mol. wt. (10,000 MW) dextran-Oregon green 488 (1100 µM) (D) at 37°C. Reactions were stopped at given time points and fluorescence
intensity was measured using a SpectraMax plate reader (Molecular Devices;
excitation/emission at 495/520 nm) before and after addition of 0.04% Trypan Blue.
Data were plotted using SigmaPlot (v13.0) and plotted as number of molecules of Fg
or dextran endocytosed per platelet. Data are representative of at least 2
independent experiments.
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Figure 11
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Figure 11 VAMP-3 deletion did not affect dextran uptake. Washed platelets (1 X
109/mL) from WT and KO mice were incubated with Dextran-Oregon Green 488 at
final concentrations of 1 µM each at 37°C for increasing times up to 30 min. (A)
Representative images at 30 min are shown here. Platelets were fixed with 2% PFA
(final conc.) and mixed with 0.1 % Trypan Blue prior to imaging. Platelets were
visualized using the using Differential Interference Contrast Microscopy on a Nikon
Eclipse E600 microscope (Nikon, Melville, NY) fitted with an AxioCam MR camera
(Zeiss, Germany) and processed using the Zen 2011 Digital Imaging software (blue
edition, Zeiss). Exposure times for DIC was 100 ms while for FITC laser was 500 ms.
Scale bars are at 5 µM. (B) Quantification of the number of Oregon Green 488positive puncta per platelet in both WT and KO samples that were counted and
quantified using Sigma Plot software (v13.0). Data are representative of 2
independent experiments.
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Figure 12

123

Figure 12 Arf6 KO platelets had normal TPO-induced JAK2 phosphorylation. (A)
Washed WT and KO platelets (4 X 108/mL) were pre-incubated with 1 mM CaCl2 for 5
min and incubated with 50 ng/mL of Thrombopoietin (TPO; R&D Systems) for 0 to 30
min at 37°C. Platelet extracts were prepared in SDS-PAGE sample buffer
(supplemented with protease and phosphatase inhibitor cocktail mix). Western
blotting was performed using anti-JAK2 and anti-phospho JAK2 (Tyr 1007/1008) and
anti-TPOR antibodies. Images were taken on a Typhoon 9500 Variable Mode Imager
and quantified using ImageQuantTL software (GE Healthcare Life Sciences,
Piscataway, NJ). (B) Volumetric quantification of phospho-JAK2 levels over total JAK2
levels was plotted as a ratio of pJAK2/JAK2 (arbitrary units) over time of TPO
incubation. Data shown here are representative of 2 independent experiments
(mean ± SEM).
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Conclusions
Endocytosis is key to fibrinogen (Fg) uptake, receptor trafficking of integrins (αIIbβ3,
αvβ3) and purinergic receptors (P2Y1, P2Y12), and thereby for normal platelet function.
However, the molecular machinery required and possible trafficking routes are still
ill-defined. Using VAMP-3 KO mice, that are otherwise unaffected in their activation,
aggregation and secretion responses, we examined the role of a vesicle-residing
Soluble N-ethylmaleimide Factor Attachment Protein Receptor (v-SNARE) called
Cellubrevin/Vesicle-Associated Membrane Protein-3 (VAMP-3) in platelet function.
In this chapter, we explored the role of VAMP-3 in mediating endocytosis in platelets.
Platelets from VAMP-3 KO mice had less platelet-associated Fg, indicating a defect in
Fg uptake/storage. This defect was not attributed to any alterations of endocytic
machinery components, surface expression levels of αIIbβ3, or reduced plasma Fg
levels. Loss of VAMP-3 led to a defective uptake of fluorescently-tagged Fg and low
molecular dextran in platelets though it had a greater negative effect on receptormediated Fg uptake than on the fluid-phase marker uptake. Additionally, we
followed the time-dependent trafficking of Fg and dextran into platelets using 3DStructured Illumination Microscopy. Wild-type platelets endocytosed both cargoes
but quickly sorted them into distinct compartments with partial overlap occurring
only at early time points. This is the first demonstration of platelets being able to
sort cargo upon endocytosis. Sorting was unaffected in VAMP-3 KO platelets. The
VAMP-3 loss did affect some acute platelet functions leading to enhanced spreading
on Fg and faster clot retraction compared to wild-type, suggesting that VAMP-3 is
involved in endocytic trafficking of integrin αIIbβ3. Additionally, the rate of JAK2
phosphorylation, initiated through the thrombopoietin receptor (TPOR/Mpl)
activation, was affected in VAMP-3 KO platelets. Collectively, our studies show that
platelets are capable of a range of endocytosis steps with VAMP-3 being pivotal in
these processes. This is the first report of v-SNARE being involved in endocytic
trafficking in platelets. How VAMP-3-mediated endocytosis affects other platelet
functions will be explored in the next chapter.
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Chapter Four: Endocytosis mediates innate immune responses by platelets in the
vasculature
Introduction
How multifunctional platelets can act as immune cells, bridging the gap between
coagulation cascades and immune systems in the vasculature, has in recent years
become an active field of research [464]. Being the most abundant “responsive” cell
type in circulation, it is hardly surprising when studies showed that platelets are,
indeed, the first responders to trap bacteria and present them to leukocytes, even
before the professional immune cells encounter the pathogen [463]. In fact, studies
within activated high endothelial venules (HEVs) showed that neutrophils hone in on
inflammatory damage by actively seeking P-selectin-bearing activated platelets to
mediate responses [611].
Systemic viral and bacterial infections have long been associated with severe
thrombocytopenia especially in the cases of sepsis [465], viral hemorrhagic fevers
[466], hepatitis C virus infections [467], and human immunodeficiency virus-1
infections [468] among others. The severity of thrombocytopenia often predicts the
clinical outcomes of viremia and bacteremia. Platelets isolated from patients
infected with viruses such as HIV-1 [263], influenza [469], dengue virus [471] and
hepatitis C virus [470], have been shown to harbor viral particles, yet the molecular
machinery that is required for viral entry is unclear.
Platelets express several Toll-like Receptors (TLRs) that are pattern-recognition
receptors that can recognize viral and bacterial pathogen-associated molecular
patterns (PAMPS) or damage-associated molecular patterns (DAMPS) [437, 439-442].
Of the ones that are present in platelets, the plasma membrane-residing TLR2 and
TLR4 and the intracellular-residing TLR7 and TLR9 have been found to be functionally
relevant [411]. Recently, TLR7, which resides in an intracellular compartment and
recognizes single-stranded RNA, was found to be present in platelets [411, 437, 472];
and is required for mediating platelet counts and host survival in a mouse model of
encephalomyocarditis virus (EMCV) infection. Viruses such as EMCV, HIV-1, and
influenza virus as well as small guanosine analogs such as Loxoribine have been
shown to activate TLR7 signaling pathways [437]. In plasmacytoid dendritic cells,
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responses to HIV-1 are mediated by virus phagocytosis/endocytosis, degradation to
release Toll-like Receptor ligands, and subsequent receptor activation [473].
Whether all or some of this process is recapitulated in platelets is unknown.
Towards this direction, we queried the molecular machinery that is required for HIV1 entry into platelets and how does viral endocytosis affect platelets in determining
the clinical outcomes in these HIV-1+ patients. We first examined platelets’
responses to two specific nucleotide-based, TLR agonists, loxoribine (TLR7) and
unmethylated CpG oligonucleotides (TLR9). Using secretion assays to measure
release from all three classes of granules (alpha, dense and lysosomes), we found
that both TLR agonists elicited a small (compared to hemostatic agonists, i.e.,
thrombin) secretory response that was sufficient to form platelet-leukocyte
aggregates as measured by FACS. Additionally, both activated IKK and PI3K-Akt
pathways as measured by immunoblotting. Inhibitor studies (using known inhibitors
of endocytic trafficking such as Dynasore, ammonium chloride) and analysis of
platelets from two different endocytosis mutants (VAMP-3 KO and Arf6 KO)
demonstrated the importance of platelet endocytic trafficking in regulating
responses to these intracellular TLRs. To further understand this process, we used
HIV-1 pseudovirions that contain ssRNA which can be recognized by the endosomal
TLR7, showing that platelets did endocytose and degrade retroviral particles to
release TLR agonists, which initiate platelet activation and secretion. Fluorescence
micrographs showed uptake of HIV-1 pseudovirions in both in-vitro and in vivo
analyses of wild-type platelets. Consistently, HIV-1 uptake and subsequent activation
were abolished in endocytosis-deficient VAMP3 KO or Arf6 KO platelets.
Taken together, our data supports that platelets can act as early damage responders
by recognizing pathogenic viruses and mount an appropriate immune response to
them.
Platelets responded differentially to different stimuli: “immuno-activation” versus
“hemostatic activation”
Given that platelets express TLR7 (binds to ssRNA) and TLR9 (binds to DNA,
unmethylated CpG motifs) [472, 442], we asked how these TLRs activates platelets.
Using bioactive, pathogen-mimetics such as Loxoribine a guanosine analog that
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specifically activates TLR7 and CpG oligonucleotides Class C (CpG ODN2395) that
specifically turns on TLR9; we measured platelet secretion as an indicator of
activation. Wildtype platelets when stimulated with thrombin (0.05 U/mL), which is
the most potent activator of platelets, showed rapid and robust secretion that
reached maximum saturation levels within 3 min of stimulation, from all three types
of granules (Figure 13A i, ii, iii). When platelets were stimulated with TLR7 agonist
Loxoribine (1 mM) and TLR9 agonist CpG ODN2395 (5 µM), the kinetics of release
were much slower and lower in terms of percent secretion. Thrombin stimulation of
platelets causes 80-90% secretion of [3H]-serotonin from dense granules, 50-60%
secretion of platelet factor 4 (PF4) and 20-30% secretion of β-hexosaminidase from
lysosomes. Compared to that, both Loxoribine and CpG ODN2395 stimulated roughly
30-40% release of [3H]-serotonin from dense granules, 15-20% secretion of platelet
factor 4 (PF4) and hardly any secretion of β-hexosaminidase from lysosomes. It is to
be noted here that lysosome secretion is usually the weakest of the three granules.
This lower extent of release held true even for longer times of incubation with the
respective agonists. Thrombin reaches its maximum saturation within 3-5 mins while
it takes much longer for the TLR agonists to reach even half of thrombin’s maximum
release percentages.
P-selectin (CD62P), which is exteriorized by platelets upon exocytosis of alpha
granules during activation, functions as a cell adhesion molecule by binding to the
leukocyte receptor, P-selectin glycoprotein ligand-1 (PSGL-1) that are essential for
forming the platelet-leukocyte aggregates and serve as markers for thromboinflammation in the circulation [474]. We measured whether these TLR agonists
could stimulate P-selectin exteriorization from platelet alpha-granules. In Figure 13B,
Loxoribine at two different concentrations (0.1 mM and 1mM) and CpG-ODN (at 2.5
µM and 5 µM) stimulated platelets, when incubated for 30 min at 37°C, to exocytose
P-selectin, that was higher than resting levels (p values ≤ 0.05) but was markedly
lower than the P-selectin levels expressed by platelets upon thrombin stimulation
(0.1 U/mL for 3 min). TLR-stimulated P-selectin levels (at least in the case of
Loxoribine) were even lower than those exteriorized by sub-optimal doses of
thrombin (25 mU/mL for 3 min). Consequently, we measured platelet-neutrophil
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aggregates in whole blood using anti-CD42b antibodies (platelets) and anti-CD11b
antibodies (neutrophils and monocytes), in response to Loxoribine (1 mM) and CpG
ODN (5 µM) stimulated for 30 min and compared that with thrombin (0.1 U/mL)
stimulation for 3 min. As expected, TLR agonists stimulate low levels of CD11bCD42b aggregates compared to thrombin stimulation (Figure 13C). Taken together,
we show using three different assays, that platelets respond differently (slower and
lower levels of activation) to “immune agonists” than they do to “hemostatic
agonists” such as thrombin, where responses are extensive and robust.
Responses to endosomal TLRs required Dynamin-mediated endocytosis and acidic
compartments
TLRs 3, 7, 8, and 9 are present in intracellular compartments. Response to these
endosomal TLRs requires Dynamin-dependent endocytosis of their specific ligands,
followed by trafficking to an acidic endosomal compartment, where receptor binding
and signaling occurs [411]. We asked whether the response to these endosomal TLRs
also proceeds via similar endocytic trafficking routes in platelets. Washed platelets
were pre-incubated for 30 min, at 37°C, with either Dynasore (80 µM), a small
molecule Dynamin inhibitor [577], at concentrations that do not inhibit ATP
secretion from platelets [351] or with ammonium chloride (20 mM), which
neutralizes the pH of acidic compartments to determine whether activation-induced
signaling downstream of TLR7 and TLR9 was affected.

Loxoribine stimulation

activates PI3K-Akt pathways in platelets [472], while TLR9 stimulation also activates
PI3K

and

MAPK

pathways

in

platelets

[506].

IKK-β-mediated

SNAP-23

phosphorylation drives SNARE complex formation and granule secretion [242]. We
have a phospho-peptide specific antibody that detects SNAP-23 phosphorylation, at
Ser95, that allows us to measure SNAP-23 phosphorylation as a metric of secretion.
This antibody only works in mouse platelets [242]. In Figure 14A, Akt and SNAP-23
phosphorylation was measured in platelets in response to Loxoribine (1 mM) (TLR7),
CpG ODN2395 (5 µM) (TLR9) and HIV-1 pseudovirions (100x) (TLR7) stimulation,
incubated for 30 min, either in the presence or absence of NH4Cl (20 mM). In Figure
14B, Akt phosphorylation was reduced in the presence of NH4Cl, in response to
Loxoribine, CpG ODN and HIV-1 pseudovirions (HIVpp), suggesting the need for
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trafficking into acidic compartments for efficient TLR-induced signaling. In Figure
14C, SNAP-23 phosphorylation was affected in CpG ODN and HIVpp stimulated
platelets, while NH4Cl-mediated inhibition of Loxoribine-stimulated SNAP-23
phosphorylation appeared to be much weaker than the others. In a similar vein, we
monitored signaling responses to these TLR ligands in response to Dynasoremediated Dynamin inhibition. In Figure 15A, Akt and SNAP-23 phosphorylation was
measured in platelets in response to Loxoribine (1 mM) (TLR7), CpG ODN2395 (5 µM)
(TLR9) and HIV-1 pseudovirions (100x) (TLR7) stimulation, incubated for 30 min,
either in the presence or absence of Dynasore (80 µM).

In Figure 15B, Akt

phosphorylation was reduced in the presence of Dynasore, in response to Loxoribine,
CpG ODN and HIV-1 pseudovirions (HIVpp), suggesting the need for Dynamindependent endocytosis for efficient trafficking to TLR-containing compartments to
initiate TLR-induced signaling. In Figure 13C, SNAP-23 phosphorylation was also
affected in Loxoribine-, CpG ODN- and HIV-1pp-stimulated platelets. Collectively, our
data suggests that responses to endosomal TLRs proceed via Dynamin-mediated
pathways, followed by trafficking into acidic compartments, where engagement of
the TLR ligand with its receptor initiates downstream signaling responses. To
determine whether platelet activation by these TLR ligands indeed occurs through
the actions of TLRs, we probed platelet activation by measuring Akt and SNAP-23
phosphorylation in response to LPS (TLR4), Pam3CSK4 (TLR2), Loxoribine (TLR7) and
CpG ODN (TLR9) in TLR23479 mutants. In Figure 21, we see the loss of signaling (both
Akt and SNAP-23 phosphorylation) in response to each of these agonists in the
quintuple mutants, indicating that signaling through these ligands indeed proceeds
via their cognate TLR receptors. Of note, thrombin-induced responses are unchanged
in these mutants suggesting that defective Akt and SNAP-23 phosphorylation is due
to inability to induce signaling upon ligand binding and not due to any other
hemostatic or platelet activation defects.
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Figure 13
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Figure 13 Platelets responded differently to “hemostatic activation” vs “immunoactivation”. (A) Washed platelets (2.5 X 108 platelets/mL) were stimulated with
Loxoribine (1 mM), CpG ODN2395 (5 µM) and Thrombin (0.05 U/mL) for the
indicated times and percent secretion (i) [3H]-Serotonin from dense core granules, (ii)
PF4 from alpha granules and (iii) β-hexosaminidase from lysosomes was measured.
(B) anti-FITC-P-selectin antibody was added to platelets (5 X 107/mL) stimulated with
Loxoribine (0.1 mM and 1 mM), CpG ODN2395 (2.5 µM and 5 µM) for 30 min and
thrombin (0.025 U/mL and 0.1 U/mL) for 3 min and geo mean fluorescence intensity
was plotted for each condition. (C) Anti-APC-CD11b and anti-FITC-CD42b antibodies
were added to 50 µL of wildtype whole blood, stimulated with Loxoribine (1 mM),
CpG ODN2395 (5 µM) stimulated for 30 min and Thrombin (0.1 U/mL) for 3 min or
buffer control (for unstimulated) and samples with analyzed for double-positive
CD42b-CD11b stained conjugates using BD LSRII Flow Cytometer. Data was then
analyzed using FlowJo (v5.6.7 software) and plotted as percent of aggregate
formation. Data is representative of at least three independent experiments with
statistical significance represented by p≤0.05 (*).
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Figure 14
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Figure 14 Responses to endosomal TLR7, TLR9, and HIV-1 pseudovirions required
endosomal maturation. (A) Washed platelets (4 × 108 platelets/mL) were preincubated with or without NH4Cl (20 mM) for 30 min and then stimulated with
Loxoribine (1 mM), CpG ODN2395 (5µM), HIV-1 pseudovirions (HIV-1pp) for 30 min
at 37°C. Western blotting was performed using anti-phospho-Akt (Ser473), anti-Akt,
and anti-phospho-SNAP-23 (Ser95) and anti-SNAP-23 antibodies. Images were taken
on a Typhoon 9500 Variable Mode Imager and quantified using the ImageQuantTL
software. (B) Volumetric quantification of the percent of phospho-Akt relative to
total Akt and (C) of phospho-SNAP-23 over total SNAP-23. Statistical significance (*)
denoted by p-value ≤0.05, (**) denoted by p-value ≤0.01 and is representative of at
least 3 independent experiments (mean ± SEM).
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Responses to endosomal TLRs required VAMP-3 and Arf6-mediated endocytosis
Our data suggests that platelets utilize endocytosis to mediate responses to
endosomal TLR ligands. Using fibrinogen uptake as a metric for endocytosis, we have
identified two key endocytic regulators in platelets. Both Arf6 and VAMP-3 loss
causes a robust defect in fibrinogen uptake. Arf6, the Ras-like small GTPase, that is
involved in integrin trafficking and Fg uptake in platelets has also been shown to be
involved in the pathogenic invasion of various cell types [587-590]. Inhibition of Arf6
in RAW264.7 macrophages by siRNA knockdown or dominant-negative mutants,
show impaired uptake of CpG oligonucleotides, reduced PI3K/Akt signaling and
impaired TLR9-dependent immune responses [612]. On the other hand, data
presented in this thesis demonstrates VAMP-3 is critical for receptor-mediated
uptake of fibrinogen. VAMP-3/Cellubrevin has also been shown to be critical for
phagocytosis of pathogens and various particles [416-417]. However, the importance
of both Arf6 and VAMP-3 in mediating uptake of endosomal TLR ligands in platelets
remains to be determined. We queried whether platelets utilize a common
endocytic machinery to internalize granule cargo and pathogens or “immunogenic
cargo”.
Towards this direction, we incubated washed WT and VAMP-3 KO platelets with
either TLR7-Loxoribine (1 mM) or TLR9-CpG ODN2395 (5 µM) for 0 to 60 min at 37°C
and platelet lysates were prepared and probed for Akt and SNAP-23 phosphorylation
as metrics of activation. As shown in Figure 16, in WT platelets, both Loxoribine and
CpG ODN induced Akt and SNAP-23 phosphorylation in a time-dependent manner,
with the VAMP-3 KO platelets showing robust attenuation in Akt and SNAP-23
phosphorylation at each time point measured. There appears to be a lag in
generating appreciable phosphorylation (usually about 15 min) in platelets treated
with Loxoribine and CpG oligonucleotides, possibly due to the time taken by
respective ligands to internalize and traffic to the right compartment that has the
endosomal TLRs. Similarly, as shown in Figure 17, time-dependent Loxoribine and
CpG ODN stimulation were also affected in the Arf6 KO platelets. It would appear
that while both TLR7-Loxoribine and TLR9-CpG ODN signaling responses are
significantly affected in VAMP-3 KO platelets while as expected, TLR9-CpG ODN
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stimulation induced Akt and SNAP-23 phosphorylation is more affected in the Arf6
KO platelets than the TLR7-Loxoribine induced responses. This would suggest that
there exists some heterogeneity in endocytic regulator usage by these TLR ligands to
target them to their respective TLR-bearing endosomal compartment. VAMP-3 may
be more central in coordinating trafficking to both TLR7+ and TLR9+ endosomes,
while Arf6 may be preferred for trafficking cargo into TLR9+ endosomes and to a
lesser extent to TLR7+ endosomes. While this diversity in trafficking routes and
regulator usage is indeed interesting in platelets, at this point it is unclear whether
platelets have discrete TLR7+ and TLR9+ endosomes or whether both TLRs co-exist in
the same endosome. Immunofluorescence studies will shed more light on this
complex trafficking system. What other potential endocytic proteins and regulators
are involved in this process in platelets remains to be seen.
The observed reduction in Akt and SNAP-23 phosphorylation in response to TLR7 and
TLR9 stimulation in the Arf6 or VAMP-3 mutants could be due to loss of any or both
of the TLR, unstable receptors (prone to degradation) or some aberrant dysfunction
that could potentially explain the impaired signaling responses. To exclude this
possibility, we probed for both TLR7 and TLR9 in platelet extracts from the mutants
and compared them to littermate-matched controls. In nucleated cells, processing of
the endosomal TLRs (7, 9, etc.) occurs in the endoplasmic reticulum, where the fulllength receptor gets cleaved to generate the functional component of the TLR (that
which initiates ligand-binding and downstream activation) that gets trafficked into
the appropriate endosome [411]. Platelets, much like the nucleated cells, have both
the full-length and the cleaved ligand-binding functional form and western blotting
showed that the levels of both forms appear to be unchanged in the VAMP-3 and
Arf6 mutants (Figure 20A-B). This holds true for both TLR7 and TLR9. This argues that
the impairment of signaling in these mutants is possibly due to defective endocytosis
of ligands and not due to altered levels of the TLRs. However, the possibility of the
presence of both full-length and cleaved, but functionally inactive, forms of the TLR7
and TLR9 receptor in the VAMP-3 and Arf6 mutants, that could arguably give similar
defects in signaling responses, cannot be excluded at present. Further experiments
will need to confirm this possibility.
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Figure 15
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Figure 15 Responses to endosomal TLR7, TLR9, and HIV-1 pseudovirions required
Dynamin. (A) Washed platelets (4 × 108 platelets/mL) were pre-incubated with or
without Dynasore (80 µM) for 30 min and then stimulated with Loxoribine (1 mM),
CpG ODN2395 (5µM), HIV-1 pseudovirions (HIV-1pp) for 30 min at 37°C. Western
blotting was performed using anti-phospho-Akt (Ser473), anti-Akt, and anti-phosphoSNAP-23 (Ser95) and anti-SNAP-23 antibodies. Images were taken on a Typhoon
9500 Variable Mode Imager and quantified using the ImageQuantTL software. (B)
Volumetric quantification of % of phospho-Akt levels over total Akt levels and (C) of
phospho-SNAP-23 levels over total SNAP-23 levels. Statistical significance (*)
denoted by p-value ≤0.05, (**) denoted by p-value ≤0.01 and is representative of at
least 3 independent experiments (mean ± SEM).
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Endocytosis of HIV-1 pseudovirions required VAMP-3 and Arf6
Like the small bioactive TLR ligands, the more physiologically relevant agonist, HIV-1
pseudovirions also require endosomal uptake and processing to generate TLR ligands.
In plasmacytoid dendritic cells, Dynamin-dependent endocytosis internalizes HIV-1
virions upon CD4-mediated entry; virus gets trafficked through endosomal
compartments and eventually reaches the late endosomes and lysosomes, where it
gets degraded. We asked how much of this process is recapitulated in platelets.
Figure 14 and 15, indicates that response to HIV-1 pseudovirions requires dynaminmediated uptake and trafficking to acidic compartments, where the viral particles
get degraded to release TLR ligands that might then activate Akt and SNAP-23
phosphorylation. Additionally, Arf6 is also required for HIV-1 endocytosis in T-cells
[586]. Use of siRNA against Arf6, or inhibiting Arf6 function by using GDP-bound or
GTP-bound inactive mutants, led to a decrease in HIV-1 viral membrane fusion, entry
and infection of T lymphocytes. Furthermore, Arf6 inhibition impaired cell-to-cell
transmission of HIV-1 viral particles in CD4+-T lymphocytes. On the other hand,
VAMP-3/Cellubrevin has been critical for phagocytosis of pathogens and various
particles [416-417]. However, the importance of VAMP-3 in mediating HIV-1
endocytosis is unclear. We sought to determine, whether VAMP-3 and Arf6 play a
role in mediating viral uptake.
Using our plate assay to measure endocytosis as described in Methods, we
incubated WT, VAMP-3 KO and Arf6 KO platelets with two different concentrations
of FITC-conjugated CpG ODN2395 (5 µM and 10 µM) at 37°C for 30 min. Reactions
were stopped by addition of 0.04% Trypan Blue. Similar to Huang et al. 2016 [19], we
used 0.04% Trypan Blue (TB) to quench external FITC fluorescence (including the
fluorescence that is trapped within the open canalicular system) and measured TBresistant fluorescence of internalized cargo as a metric of endocytosis. In Figure 18A,
WT platelets internalized more CpG ODN in a dose-dependent manner, while VAMP3 KO and Arf6 KO platelets had robust defects in uptake. This argues that the
signaling that we measure in terms of Akt and SNAP-23 phosphorylation is caused
due to endocytosis of CpG ODN molecules and this response is significantly affected
in the endocytosis mutants. To determine whether the same holds true for the HIV-1
139

pseudovirions, we tested viral endocytosis in our plate assay. Figure 18B shows a
schematic of the HIV-1 pseudovirion construct that was obtained from Dr. Gregory
Melikyan’s lab [613]. These genetically modified non-infectious HIV-1 viral particles,
provisionally called “pseudovirions” retain most of the actual HIV-1 viral backbone,
with modifications introduced in the form of double fluorescent tags such that the
green fluorescent protein is fused to the plasma membrane-residing intercellular
adhesion molecule-1 (ICAM-1) and the viral core has an mCherry fluorescent tag
encoded with the viral Gag protein. Viral expression in 293-LTV (lentiviral derived)
cell lines generated red-green double-tagged pseudovirions that were produced by
the Genetics Core Facility, here at the UK. Pseudovirions obtained were incubated
with WT, VAMP-3 KO and Arf6 KO platelets at increasing concentrations (1x and 2x)
at 37°C for 30 min and Trypan Blue-resistant fluorescence intensities were measured.
In Figure 18C, WT platelets internalized more HIV-1pp in a dose-dependent manner,
while VAMP-3 KO and Arf6 KO platelets had robust defects in uptake. These data
provide the first indication that VAMP-3 and Arf6 may be involved in viral uptake.
We used fluorescence microscopy to further confirm these results. WT, VAMP-3 KO,
and Arf6 KO platelets were incubated with HIV- pseudovirions (100x concentrated)
at 37°C, for 0 to 6 hr, fixed with PFA, treated with 0.04% trypan blue to quench
external fluorescence, and imaged by epifluorescence. WT platelets had more GFPmCherry double positive puncta than either of the endocytosis mutants (Figure 16D).
Based on Miyauchi et al 2011 [613], the GFP-ICAM-1 molecule often gets
incorporated into the membrane to form membrane vesicles; these are not virions
and hence were excluded from measurements. Only double-positive red-green
viruses were considered whole virions and were counted to denote viral uptake
inside platelets. Quantification of total fluorescent puncta present per platelet
showed that over time, WT platelets accumulated more HIV-1 pseudovirions and the
number of red-green double-positive puncta increased, while the VAMP-3 KO and
Arf6 KO platelets failed to do to any great extent, even up to 6 hr of incubation with
HIV-1pp (Figure 18E), consistent with our ex vivo plate-based assay.
To further confirm the ex vivo defects in the endocytosis of HIV-1pp, age-matched
WT and VAMP-3 KO mice were intravenously injected with the pseudovirions (100X)
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via the retro-orbital sinus of the mice. Platelets were harvested 24 hr post-injection
and imaged by fluorescence microscopy. As shown in Figure 18F-G, quantification by
counting the number of double-positive viral particles in WT and VAMP-3 KO
platelets showed viral particles were present in WT platelets, even 24 hr postinjection while there were hardly any detectable viral particles within VAMP-3 KO
platelets. Our data indicates that VAMP-3 and Arf6 are not only involved in the acute
uptake of HIV-1pp (over shorter times) but also on chronic accumulation (24 hr; i.e.,
when in circulation) of the viral particles. In an essence, uptake of HIV-1pp in WT
platelets and its lack thereof in the endocytosis mutants mirrors that of Fg uptake in
both acute and chronic phases of endocytosis. Given that HIV-1pp requires a surface
receptor (CLEC-2, DC-SIGN or any other potential receptor) to internalize, it is hardly
surprising that its endocytosis proceeds in a similar fashion to αIIbβ3-mediated Fg
binding and uptake. Further experiments are in the works to clarify this theory.
Given that CLEC-2 and DC-SIGN are the potential HIV-1-binding receptors on
platelets (which lack CD4), defective endocytosis of the pseudovirions in the VAMP-3
and Arf6 mutants could be due to decreased levels of one or more of the receptors.
We, thus, probed for DC-SIGN levels in the VAMP-3 KO and Arf6 KO platelets. Only
15% of platelets express DC-SIGN [543] which explains the low levels of detection of
the protein by western blotting. However, the levels of DC-SIGN appear to be
unaltered in the mutants (Figure 18E). The other receptor, CLEC-2, remains unaltered
in the Arf6 KO platelets (Figure 18D). Surprisingly, VAMP-3 KO platelets showed
lower levels of CLEC-2 than WT platelets (Figure 18C). While this could partly explain,
why VAMP-3 platelets have such a severe phenotype in their ability to internalize the
virions; the fact that Arf6 KO platelets are still defective in viral uptake despite
expressing normal levels of CLEC-2, suggest that viral uptake by platelets may have
multiple components with viral-binding by CLEC-2 being one aspect of it. Low levels
of CLEC-2 on VAMP-3 KO platelets portend towards a biogenesis defect at the
megakaryocyte level. What this entails will require further experiments at probing
the role of VAMP-3 in platelet formation, cargo biogenesis and/or packaging in the
megakaryocytes.
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Collectively, these data show that HIV-1pp uptake and/or accumulation is
dramatically reduced in the VAMP-3 KO and Arf6 KO platelets suggesting the need
for endocytosis to internalize the virus. Our data provides the first mechanistic
understanding as to the molecular machinery required for HIV-1 endocytosis in
platelets.
Endocytosis of HIV-1 pseudovirions triggered platelet activation
What happens to the viral particles once it gets endocytosed within platelets? In
Figure 19A-B, washed WT, VAMP-3 KO, and Arf6 KO platelets were incubated with
HIV-1pp (100X) for 30 min at 37°C and probed for activation markers. HIV-1pp
stimulated Akt and SNAP-23 phosphorylation in the WT platelets but had a
significant loss of activation in the endocytosis mutants. This indicates that
endocytosis of the HIV-1 pseudovirions, mediated by VAMP-3 and Arf6, leads to
platelet activation.
Activation-induced signaling through PI3K/Akt pathway and IKKβ-mediated SNAP-23
phosphorylation converges to drive platelet granule secretion. We measured HIV1pp-induced platelet secretion by probing for P-selectin exteriorization by flow
cytometry, as a metric of alpha granule secretion. In Figure 19C, HIV-1pp caused Pselectin exteriorization from WT platelets. Loss of either VAMP-3 or Arf6 significantly
inhibited P-selectin exteriorization from platelets (p≤ 0.01). Similarly, Loxoribine (1
mM) and CpG ODN (5 µM) stimulated P-selectin from platelet alpha-granules and
this response was also impaired in the mutants. Consistent with the activationinduced Akt and SNAP-23 phosphorylation, defects in endocytosis leads to severe of
HIV-1pp-induced immune responses in platelets.
P-selectin exteriorization by activated platelets acts as a “beacon of damage” for
patrolling leukocytes, alerting them to existing inflammatory or immune-induced
damage in the circulation. As a result, these platelet-leukocyte aggregates serve as
“units of inflammation” and initiates host immune responses [611]. Patients with
active HIV-1 infection often have increased levels of platelet-leukocyte aggregates,
which strongly correlated with platelet activation [614]. Based on these reports, we
sought to determine whether endocytosis of HIV-1 pseudovirions triggers plateletleukocyte aggregate formation. In Figure 19D, while compared to unstimulated
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controls, thrombin-induced robust platelet(CD41/61)-neutrophil(Ly6G) aggregates,
as measured by flow cytometry, in whole blood and was unaffected in the VAMP-3
and Arf6 mutants (these mutants are not secretion-deficient to hemostatic agonists).
Loxoribine, CpG ODN and HIV-1pp all induced aggregate formation in WT, but
showed significant reductions in the mutants. Of note, the level of plateletneutrophil aggregate formation in response to thrombin (hemostatic activation) is
almost two-fold higher than all the other TLR ligands, including HIV-1pp activation
(immuno-activation). This harkens back to our initial findings that platelets do
interpret and respond differentially to “immune agonists” than they do to stronger
and more potent “hemostatic agonists”. While agonist potency drives rates and
extents of secretion [91], platelets appear to interpret between different classes of
agonists and respond accordingly. How this mechanism will warrant future studies to
parse the distinguishing signaling aspects that lead to variable activation patterns
observed in platelets. Conceivably, these platelet-neutrophil aggregates generated
by HIV-1pp, get recognized by professional phagocytes and are cleared from the
circulation, dropping platelet counts, which may, in part, explain the severe
thrombocytopenia observed in HIV-1+ patients.
Our studies provide a novel mechanistic understanding of how viral particles enter
platelets and why platelets from HIV-1+ patients with chronic HIV-1 infection show
signs of platelet activation.
To determine whether platelet activation by HIV-1 pseudovirions occurred through
the actions of TLR7, which is the physiological sensor for viral ssRNA, we probed
platelet activation by measuring Akt and SNAP-23 phosphorylation in response to
HIV-1pp in TLR23479 mutants. Unlike Loxoribine, which binds to TLR7 and shows loss
of signaling in the mutant platelets, HIV-1pp induced activation only shows a partial
loss of Akt and SNAP-23 phosphorylation, suggesting that there may be a TLRindependent component (in addition to a TLR-dependent component) of HIV-1ppinduced platelet activation (Figure 21). Other potential TLR ligands that may be
generated by viral degradation inside platelet endosomes, or activation by surface
binding to any surface TLR, such as TLR2, 4, 3 or 9 has been already excluded in these
mutants. As a result, we posit that viral activation may be through some other
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platelet receptor that leads to signaling responses. Once such receptor that binds to
HIV-1pp and can induce signaling downstream in platelets is the hem(ITAM)-receptor,
CLEC-2, that leads to activation of Syk and SFK, PLCγ and activates Akt and eventually
causes platelet secretion. Use of specific inhibitors such as PP2 (which inhibits Srcfamily kinases (SFK)) or Dasatinib, another Src family tyrosine kinase inhibitor, or use
of CLEC-2 null platelets, may be useful in determining whether this partial loss of
signaling is indeed due to CLEC-2 activation or not.
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Figure 16
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Figure 16 VAMP-3 was required for signaling through TLR7 and TLR9 in platelets. (A)
Washed platelets (4 × 108 platelets/mL) from WT and VAMP-3 KO mice were
incubated with TLR7-Loxoribine (1 mM) or TLR9-CpG ODN2395 (5 µM) for the
indicated time points at 37°C. Western blotting was performed using anti-phosphoAkt (Ser473), anti-Akt, and anti-phospho-SNAP-23 (Ser95) and anti-SNAP-23
antibodies. Images were taken on a Typhoon 9500 Variable Mode Imager and
quantified using the ImageQuantTL software. (Bi-ii) Volumetric quantification of % of
phospho-Akt levels over total Akt levels and of phospho-SNAP-23 levels over total
SNAP-23 levels in response to Loxoribine. (Ci-ii) Volumetric quantification of % of
phospho-Akt levels over total Akt levels and of phospho-SNAP-23 levels over total
SNAP-23 levels in response to CpG ODN2395. Statistical significance (*) denoted by
p-value ≤0.05, (**) denoted by p-value ≤0.01 and is representative of at least 3
independent experiments (mean ± SEM).
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Figure 17
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Figure 17 Arf6 was required for signaling through TLR7 and TLR9 in platelets. (A)
Washed platelets (4 × 108 platelets/mL) from WT and Arf6 KO mice were incubated
with TLR7-Loxoribine (1 mM) or TLR9-CpG ODN2395 (5 µM) for the indicated time
points at 37°C. Western blotting was performed using anti-phospho-Akt (Ser473),
anti-Akt, and anti-phospho-SNAP-23 (Ser95) and anti-SNAP-23 antibodies. Images
were taken on a Typhoon 9500 Variable Mode Imager and quantified using the
ImageQuantTL software. (Bi-ii) Volumetric quantification of % of phospho-Akt levels
over total Akt levels and of phospho-SNAP-23 levels over total SNAP-23 levels in
response to Loxoribine. (Ci-ii) Volumetric quantification of % of phospho-Akt levels
over total Akt levels and of phospho-SNAP-23 levels over total SNAP-23 levels in
response to CpG ODN2395. Statistical significance (*) denoted by p-value ≤0.05, (**)
denoted by p-value ≤0.01 and is representative of at least 3 independent
experiments (mean ± SEM).
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Endocytosis of HIV-1 pseudovirions in human platelets required Dynaminmediated internalization and trafficking to acidic compartments
Given that endocytosis of HIV-1pp causes platelet activation, we asked whether this
process occurs in human platelets. Freshly isolated human platelets, from healthy
donors, were prepared and stimulated with HIV-1pp, in the presence of Dynasore or
NH4Cl, to inhibit either Dynamin-mediated endocytosis or neutralize endosomal
maturation process required for normal processing and signaling. In Figure 22A,
human platelets endocytose viral particles, much in the same way as mouse platelets
do. Human platelets lack CD4; hence probable viral binding occurs through CLEC-2 or
DC-SIGN. In Figure 22B, use of Dynasore (80 µM) inhibits phosphorylation of IκBα,
that is used as a surrogate metric for IKK-β-mediated SNAP-23 phosphorylation and
hence platelet activation. NH4Cl (20 mM), also inhibited phosphorylation of IκBα. In
Figure 22C, formation of platelet (CD41/61)-neutrophil (Ly6G) aggregates in
response to HIV-1pp was also significantly inhibited in the presence of Dynasore and
NH4Cl. Taken together, our data suggests that Dynamin-dependent endocytosis,
targeting to acidic compartments and activation of signaling cascades, in response to
the HIV-1 pseudovirions, can be recapitulated in human platelets, indicating that
human platelets probably utilize similar VAMP-3 and Arf6-dependent pathways for
viral endocytosis and response.
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Figure 18
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Figure 18 Endocytosis of HIV-1 pseudovirions required VAMP-3 and Arf6. (A, C)
Washed WT, VAMP-3 KO and Arf6 KO platelets (5 x 107/mL) were incubated with
FITC-CpG ODN (5 µM or 10 µM) or with GFP-HIV-1pp (1X and 2 X concentrations) at
37°C for 30 min as described in the Methods section, under endocytosis plate-based
assay. (B) Schematic of the HIV-1pp viral constructs showing the GFP-fused ICAM-1
on the surface and mCherry-fused gag protein inside the viral core. (D)
Representative micrographs from washed WT, VAMP-3 KO, and Arf6 KO platelets (1
X 109/mL) that were incubated with red-green HIV-1pp (100X) for indicated time
points at 37°C. Platelets were fixed with 2% PFA (final conc.) and mixed with 0.1 %
Trypan Blue prior to imaging. Platelets were visualized as described in the Methods
section. Exposure times for DIC were 100 msec, for FITC laser were 1000 msec and
for the mCherry was 500msec. Scale bars are 5 µM. (E) Quantification of the number
of GFP+-mCherry+ puncta/platelet in WT, VAMP-3 KO, and Arf6 KO samples and were
plotted using Sigma Plot software (v13.0). Data is representative of 2 independent
experiments. (F) Age-matched WT and VAMP-3 KO mice were injected with HIV-1pp
(100X) through the retro-orbital sinus and platelets were harvested 24 hr postinjection, fixed and mixed with 0.1 % Trypan Blue prior to imaging. Platelets were
imaged using the Nikon E600 Eclipse fitted with a Zeiss Axiocam MR camera and
visualized under 100X oil-immersion lens. Representative micrographs show
endocytosed viral particles within platelets. (G) Quantification of the number of
GFP+-mCherry+ puncta/platelet in WT and VAMP-3 KO samples and were plotted
using Sigma Plot software (v13.0). 394 platelets (for WT) and 323 platelets (for
VAMP-3 KO) over 6 different fields were counted.
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Figure 19
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Figure 19 Endocytosis of HIV-1 pseudovirions triggered platelet activation. (A)
Washed platelets from WT, VAMP-3 KO, and Arf6 KO mice were either kept resting
or stimulated with HIV-1pp (100X) for 30 min at 37°C and lysates were prepared for
western blotting using anti-phospho-Akt (Ser473), anti-Akt, and anti-phospho-SNAP23 (Ser95) and anti-SNAP-23 antibodies. Images were taken on a Typhoon 9500
Variable Mode Imager and quantified using the ImageQuantTL software. (B)
Volumetric quantification of % of (i) phospho-Akt levels over total Akt levels and (ii)
of phospho-SNAP-23 levels over total SNAP-23 levels. (C)

Anti-FITC-P-selectin

antibody was added to WT, VAMP-3 KO and Arf6 KO platelets (5 X 107/mL)
stimulated with Loxoribine (1 mM), CpG ODN2395 (5 µM) or HIV-1pp (100X) for 30
min at 37°C and geo mean fluorescence intensity was plotted for each condition. (D)
Whole mouse blood from WT, VAMP-3 KO, and Arf6 KO mice was either kept
unstimulated or stimulated with thrombin (0.1 U/mL) for 3 min, Loxoribine (1 mM),
CpG ODN (5 µM), or HIV-1pp (100X) for 30 min. Using BD LSRII, platelet (FITCCD41/61)- neutrophil (PE-Ly6G) aggregates were acquired by gating around 50, 000
granulocytes and percentage of double-positive events were plotted over total
granulocytes. Data was analyzed using FlowJo (v.5.6.7). Statistical significance is
denoted by (*) p≤0.05, (**) p≤ 0.01. Data is representative of at least three
independent experiments.

153

Endocytosis of Eco-HIV required Dynamin-mediated internalization, trafficking to
acidic compartments and proteolytic degradation
Our overarching hypothesis is to determine how platelet endocytosis contributes to
viral dissemination and disease etiology in HIV-1 infections. Towards this goal, we
have acquired viral constructs that produce Eco-HIV virions from Dr. David Volsky at
Mt. Sinai Icahn School of Medicine. These chimeric viruses have the gp120 of HIV-1
replaced by the gp80 of the murine leukemia virus to render it infectious to rodents
only. The virus behaves similar to its human counterpart, infects mouse T cells,
generating viral infection with the production of pro-inflammatory cytokines [602].
The Eco-HIV virus is neuroinvasive and causes blood-brain barrier (BBB) disruption.
We have Preliminary studies performed with the virus was to determine, whether it
behaves like the pseudovirions and does viral endocytosis of Eco-HIV lead to platelet
activation.
In Figure 23A, Eco-HIV (100X) induced platelet activation by phosphorylating Akt and
SNAP-23, in a time-dependent manner. Dynasore treatment-, NH4Cl treatment- and
protease inhibitor cocktail treatment of mouse platelets, incubated with Eco-HIV
virions, showed robust inhibition. In Figure 23B-C, quantification of Akt and SNAP-23
phosphorylation shows that protease inhibition caused the most dramatic inhibition,
possibly due to the prohibition of degradative processing of the virus that is essential
for signaling. Dynasore and NH4Cl inhibition follow the pattern observed in mouse
platelets (and human platelets) in response to HIV-1pp. Taken together, our data
suggests that Eco-HIV virions get internalized by platelets using Dynamin, get
trafficked into acidic compartments where proteolytic processing of the virus leads
to activation-induced signaling in platelets.
In a future series of experiments, we will determine whether VAMP-3 and Arf6mediated endocytosis affect infection and neuroinvasiveness in mice infected with
Eco-HIV viruses.
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Figure 20
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Figure 20 Receptor levels of TLRs in VAMP-3 and Arf6 mutant platelets. Lysates
were prepared from platelets (4 x 108/mL) isolated from WT and VAMP-3 KO and
Arf6 KO mice and western blotted for the indicated protein using specific antibodies
(A) TLR7 levels in WT, VAMP-3 KO, and Arf6 KO platelets. β-actin was used as a
loading control. (B) TLR9 levels in WT, VAMP-3 KO, and Arf6 KO platelets. β-actin was
used as a loading control. (C) CLEC-2 levels WT and VAMP-3 KO platelets. RabGDI
was used as a loading control. (D) CLEC-2 levels WT and Arf6 KO platelets. RabGDI
was used as a loading control. (E) DC-SIGN (CD209) levels in WT, VAMP-3 KO and
Arf6 KO platelets with RabGDI as a loading control. Data is representative of at least
two independent experiments.
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Figure 21
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Figure 21 Response to Loxoribine, CpG ODN required TLR signaling. Washed
platelets (4 × 108 platelets/mL) were from WT and TLR23479 KO platelets were
either kept resting or stimulated with thrombin (0.1 U/mL), LPS (100 ng/mL),
Pam3CSk4 (10 µg/mL), Loxoribine (1 mM), CpG ODN2395 (5 µM), HIV-1pp (100X) for
30 min at 37°C. Lysates were prepared and western blotting was performed using
anti-phospho-Akt (Ser473), anti-Akt, and anti-phospho-SNAP-23 (Ser95) and antiSNAP-23 antibodies. Images were taken on a Typhoon 9500 Variable Mode Imager
and images were processed using the ImageQuantTL software.
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Figure 22
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Figure 22 Endocytosis of HIV-1 pseudovirions in human platelets required
Dynamin-mediated internalization and trafficking to acidic compartments. (A)
Representative fluorescent micrographs of washed human platelets containing redgreen HIV-1pp showing platelets with endocytosed pseudovirions (denoted by
arrows). (B) Human platelets were incubated with HIV-1pp for 30 min either in the
presence or absence of Dynasore (80 µM) or NH4Cl (20 mM) and lysates were
prepared for western blotting with anti-phospho-IκBα and anti-IκBα antibodies. (C)
Whole human blood was pre-incubated with either Dynasore (80 µM) or NH4Cl (20
mM) and stimulated with HIV-1pp for 30 min. Using BD LSRII, platelet (FITCCD41/61)- neutrophil (PE-Ly6G) aggregates were acquired by gating around 50, 000
granulocytes and percentage of double-positive events were plotted over total
granulocytes. Data was analyzed using FlowJo (v. 5.6.7). Statistical significance is
denoted by (*) p≤0.05, (**) p≤ 0.01. Data is representative of at least three
independent experiments.
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Figure 23
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Figure

23

Eco-HIV-stimulation

of

platelets

required

Dynamin-mediated

internalization, trafficking to acidic compartments and proteolytic degradation. (A)
Washed platelets (4 × 108 platelets/mL) were stimulated with Eco-HIV (100x) for the
indicated time points at 37°C or pre-incubated with Dynasore (80 µM), or NH4Cl (20
mM) or protease inhibitor cocktail mixture (PIC) (100X) for 30 min and then
stimulated with Eco-HIV (100X) for 30 min at 37°C. Western blotting was performed
using anti-phospho-Akt (Ser473), anti-Akt, and anti-phospho-SNAP-23 (Ser95) and
anti-SNAP-23 antibodies. Images were taken on a Typhoon 9500 Variable Mode
Imager and quantified using the ImageQuantTL software. (B) Volumetric
quantification of % of phospho-Akt levels over total Akt levels and (C) of phosphoSNAP-23 levels over total SNAP-23 levels. Data is representative of one experiment.
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Conclusions
It is becomingly increasingly clear that platelets bridge coagulation cascades with
inflammation. Platelets respond to changes in the vasculature and modulate their
response accordingly. Platelets also interact with pathogenic bacteria and viruses to
mediate immune responses against them. Infection-related platelet activation can be
strongly correlated with thrombocytopenia that leads to further cardiovascular
complications that can prove to be detrimental to prognosis and cure. Chronic viral
infections, e.g., HIV-1, severely increase the risk of acute myocardial infarction (MI),
possibly via some level of platelet activation, contributing to increased thrombotic
potential. Platelets do endocytose viruses and bacteria, but the molecular machinery
is ill-defined. In nucleated cells, responses to HIV-1 are mediated by virus
phagocytosis/endocytosis, degradation to release Toll-like Receptor ligands, and
subsequent receptor activation. Is this process recapitulated in platelets? Here we
show that platelets indeed use VAMP-3 and Arf6-dependent pathways to
endocytose HIV-1 virions, degrade retroviral particles to release TLR ligands, which
initiate platelet activation and secretion. HIV-1 uptake and subsequent activation are
abolished in VAMP-3 and Arf6 KO mice.
Collectively, our studies shed light on how platelets act at the early stage of
pathogen recognition and are able to process them to initiate an immune response.
Our overarching hypothesis is to determine how platelet endocytosis contributes to
viral dissemination and disease etiology in HIV-1 infections. Future experiments
planned with the Eco-HIV viruses in a mouse model of HIV infection using our
endocytosis mutants will go a long way in elucidating the relevance of platelet
endocytosis in mediating disease outcomes.
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Figure 24
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Figure 24 Model diagram showing the role of Dynamin-, VAMP-3- and Arf6mediated endocytosis of HIV-1 pseudovirions and TLR ligands in platelet activation.
Platelets can internalize bacterial and viral ligands via Dynamin-, VAMP-3- and Arf6dependent endocytosis. Viruses such as HIV-1 or TLR ligands such as unmethylated
CpG oligonucleotides, Loxoribine etc. can then be trafficked to an endosomal
compartment bearing their respective Toll-like receptors. Viruses require acidic
compartments to allow degradation of the viral capsid, releasing ssRNA or TLR
ligands, which can then bind to TLR7 and initiate a response. Receptor-ligand
interactions lead to the recruitment of the adaptor protein MyD88, which then
triggers downstream signaling through TRAF6, TAK1, and IRAK-1 activation,
phosphorylating IRAK-4. Concomitant PI3K activation also leads to Akt activation,
driving IKK activation. IKK then activates SNAP-23, which drives SNARE complex
formation and ultimately granule secretion. TLR and HIV-1 pseudovirion activation of
platelets leads to P-selectin exteriorization from alpha granules, which can then form
platelet-leukocyte aggregates with PSGL-1-bearing leukocytes in the circulation.
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Chapter Five: Endocytosis in platelet function: roles in hemostasis and innate
immunity
Through the work presented in this thesis, we have taken several key steps in
understanding how endocytosis modulates platelet functions in the context of
hemostasis and innate immunity. We have identified VAMP-3 to be a critical
regulator of fibrinogen (Fg) uptake in platelets. Loss of VAMP-3 causes defective
fibrinogen uptake, which manifests itself as dysfunctional integrin trafficking of αIIbβ3
that translates into increased platelet spreading and clot retraction. However, these
defects do not cause obvious alterations in thrombus formation or hemostasis.
Additionally, using 3D super-resolution microscopy, we present the first report of
differential sorting of receptor-mediated endocytic (fibrinogen) and fluid-phase
pinocytic (low mol. wt. dextran) cargos in platelets. Future research will determine
the intricacies of the different routes and endosomal compartments utilized by the
two kinds of cargos in platelets. How platelets respond to pathogenic viruses and
bacteria that determine the disease outcomes in viremia and bacteremia is still
unclear. Using both Arf6 KO and VAMP-3 KO mutants as tools to probe the
importance of endocytosis in platelets, we posited that platelet endocytosis could
potentially be critical for actively sensing pathogenic damage in the vascular
microenvironments and allowing platelets to act as immune cells. Using nonreplicative, genetically modified HIV-1 pseudovirions, we show that platelets
endocytose HIV-1 via VAMP-3 and Arf6-mediated endocytic pathways, degrade viral
particles, causing platelet activation, as measured by PI3K/Akt and IKKβ-mediated
SNAP-23 phosphorylation that drives secretion of P-selectin from alpha granules to
form platelet-neutrophil aggregates. HIV-1 uptake and subsequent activation are
abolished in VAMP-3 and Arf6 KO mice. This mechanism of viral endocytosis and
subsequent activation also occurs in human platelets and may, in part, explain some
of the platelet-associated phenotypes seen in HIV-1-infected individuals.
VAMP-3 is required for accumulation of fibrinogen in platelets
Fibrinogen, made by hepatocytes and not megakaryocytes [461], is an alpha-granule
cargo because it is taken up via a αIIbβ3-mediated process. VAMP-3 deletion results in
defective intra-platelet Fibrinogen accumulation (Figures 3A-B, 5). Data presented in
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this thesis is the first report of this v-SNARE protein being involved in internal
membrane trafficking steps in platelets. These trafficking steps are needed for αIIbβ3mediated Fg uptake, endocytic trafficking of cargo, platelet spreading, clot retraction,
and proper regulation of JAK2 phosphorylation downstream of TPOR. Global loss of
VAMP-3 did not affect the gross hematological profile of the mutant mice, with
whole blood counts unaltered in the KO (Table 2). Electron micrographs depicted
normal platelet ultrastructure in the VAMP-3 KO platelets [202]. Western blotting
analysis showed that loss of VAMP-3 did not cause overt defects in levels of other
endocytic cargo, endosomal markers, or proteins involved in endocytosis (Figure 3CD). Levels of total surface and activated αIIbβ3 were unaltered in resting and
thrombin-stimulated platelets (Figure 4A-B) as was the steady-state binding of Fg
(Figure 4C). ADP-stimulated WT platelets showed enhanced Fg-binding and increased
uptake of Fg; however, ADP-stimulation of VAMP-3 KO platelets was unable to
override the defect in Fg internalization (Figure 5A-B). In sum, the loss of VAMP-3
had no gross effects on many aspects of platelet function, yet it affected Fg
accumulation. Of note, the ~40% deficit in Fg seen in platelets from KO mice was not
sufficient to affect hemostasis [202].
Using TB as a quencher of external fluorescence of FITC/Alexa 488, we could monitor
cargo uptake by platelets. Our plate-based endocytosis assay allows more flexibility
for testing a variety of conditions and more sensitivity than flow cytometry-based
assays. Using this assay, we showed that Fg internalization reached saturation in WT
platelets and demonstrated classical receptor-ligand saturation kinetics over the
range of concentrations tested (Figure 5C, E). Conversely, uptake of small molecules
usually occurs via fluid-phase pinocytosis and is generally a non-specific process. In
platelets, dextran uptake appeared to occur constitutively and rapidly. In as early as
1 min, dextran uptake was detected and it linearly increased over time and dose
(Figure 5D, F). In platelets, dextran uptake had at least a 1,000-fold higher capacity
(as measured by total molecules internalized) than Fg uptake. This argues that fluidphase pinocytosis is more efficient in platelets, but further studies with other cargo
are needed to strengthen that conclusion. Fluorescence micrographs depicting
endocytosed FITC-Fg showed that VAMP-3 KO platelets indeed had a robust defect in
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Fg uptake/accumulation. The number of fluorescent puncta was significantly lower in
the KO platelets (Figure 5G-H). Dextran uptake, alternatively, did not show any
robust differences between WT and VAMP-3 KO platelets, both in the plate-based
endocytosis assay (Figure 5D, F) and in the fluorescence images (Figure 11). This
argues that, in platelets, VAMP-3 is important for an endocytic trafficking step(s) that
is part of the path taken by Fg bound to αIIbβ3; more so than cargo internalized by
constitutive pinocytosis. However, whether VAMP-3 is involved in mediating uptake
of cargo via other types of platelet endocytosis processes remains to be determined.
Platelets can sort different kinds of endocytic cargo
Can platelets decipher and sort endocytosed cargo or is it passively internalized via a
common endocytic route? Using 3D-SIM microscopy, we demonstrated that platelets
actively sort endocytosed cargo, exhibiting a more complex endocytic system than
previously imagined. Fg binds to surface αIIbβ3, at initial time points and then
proceeds to accumulate inside platelets as discrete puncta within 30 min. At this
time, surface binding was less apparent (Figure 6A). Fg is thought to enter platelets,
transit through two classes of multi-vesicular bodies, and end up in α-granules [41].
Platelets contain roughly 50-80 α-granules [34-35], yet we did not see equivalent
numbers of Fg puncta at 30 min or even after the overnight incubation in vivo (Figure
6B). The global distribution of Fg into α-granules, seen in recent immuno-electron
microscopy studies, would seem at odds with our data [55]. While unclear at present,
our observations could mean that only specific α-granules are readily loaded with
endocytosed cargo during circulation and that most cargo loading occurs at the
megakaryocyte stage. Our previous studies are not totally consistent with that
scenario since we failed to observe FITC-Fg in bone marrow megakaryocytes, 24 hr
post injection [19]. Alternatively, our data could imply the Fg loading into all αgranules requires more time, perhaps the lifetime of a platelet. It is equally possible
that larger amounts of FITC-Fg are needed to fully label all the granules. In contrast,
dextran uptake occurred very quickly and platelets accumulate more dextran+
puncta than Fg+ puncta over time (Figure 6A-B). Both cargoes showed partial overlap
at early time points but mostly existed as discrete puncta. VAMP-3 deletion did not
compromise the platelets’ ability to sort cargo but did affect their ability to
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accumulate it. Surprisingly, when dextran was injected for an overnight period, less
dextran accumulated in the VAMP-3 KO platelets (Figure 6B) compared to WT. This
was in contrast to Figure 6A, where no clear defect in dextran uptake was seen in the
VAMP-3 KO platelets up to 30 min of incubation and in the plate-based endocytosis
assay (Figure 5D). This could indicate that loss of VAMP-3 causes a defect in chronic
accumulation of cargo, irrespective of the initial endocytic pathway employed.
Potential role of VAMP-3 in integrin αIIbβ3 endocytic trafficking in platelets
Our previous studies of Arf6 KO platelets suggested that Fg uptake and integrin
recycling are important for some acute platelet functions e.g., clot retraction and
spreading [19]. VAMP-3 KO platelets had a similar phenotype. VAMP-3 is important
for epithelial cell migration, particularly mediating trafficking at the lamellipodia and
it also localizes to focal adhesions [426-427]. Tetanus toxin-mediated cleavage of
VAMP-3 reduced epithelial cell migration but enhanced adhesion to collagen,
laminin, and fibronectin; perhaps due to impaired recycling of β1 integrins [427]. In
Figure 7A-B, the rate of platelet spreading on immobilized Fg was faster in VAMP-3
KO than in WT platelets. This, together with the Arf6 KO phenotype, reinforces the
notion that altered αIIbβ3 trafficking affects platelet spreading. Unlike epithelial cells
where migration is directional, platelet spreading on coated surfaces is not vectorial
but seems to occur in all directions. In our assays, loss of VAMP-3 enhanced platelet
spreading. If VAMP-3 controls spatially-specific membrane fusion steps that facilitate
vectorial platelet spreading in a thrombus, its loss could make random,
multidirectional fusion more efficient leading to enhanced spreading in all directions
on a coated surface. Alternatively, loss of VAMP-7, a key v-SNARE in platelets, leads
to granule exocytosis defects and reduced spreading [203]. VAMP-3 KO platelets had
no defect in exocytosis; however, its deletion causes a modest secretion rate
enhancement [202]. Given that VAMP-7-mediated exocytosis is important for
spreading, enhanced secretion could enhance spreading. Loss of VAMP-3, which
could be acting as an inhibitory SNARE (i-SNARE) and competing with VAMP-7 [462],
could increase the efficacy of exocytic SNARE complex formation (containing VAMP7, or -8, Syntaxin-8 or -11, and SNAP-23) and thus increase the fusion needed for
spreading. These two potential mechanistic explanations for our phenotypes are
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difficult to distinguish; but, comparing platelets from VAMP-3 and VAMP-7 KO mice
will be invaluable in understanding how membrane trafficking affects platelet
spreading. The enhanced spreading and clot retraction phenotype is subtle and
might be expected to predispose these mice towards a more pro-thrombotic
phenotype. However, that was not detected in the tail-bleeding or FeCl3-injury [[19]
and Joshi, et al. in preparation] models that we have tested nor was an effect seen
with the VAMP-7 KO mice [203]. More refined assays will be needed to parse the
biological ramifications of these observations. Additionally, Fg deficiency causes
bleeding diathesis in both mouse and humans [607-608]. Both VAMP-3 and Arf6 KO
mice have about 50% defect in Fg levels, yet have normal hemostasis with no
bleeding defects. Thus it is not clear whether platelet-derived Fg is functionally
important for physiological processes or not; and if it's, how much Fg do platelets
contribute to form the fibrinous thrombus at the site of injury.
“Immuno” versus “hemostatic” stimulation of platelets: differential kinetics and
extent of responses
How platelets respond to “immune agonists” such as those tested in this thesis as
well as in previously published reports, have challenged the canonical view of
platelets being “all-or-none” type responders to vascular damage. Platelets need to
be able to respond to hemostatic damage rapidly in order to contain blood loss. This
is usually achieved via rapid degranulation of the already docked dense core
granules, which secrete ADP and ATP that allow paracrine activation of additional
platelet to form the platelet plug. The dense core granules are the first to secrete
their granular contents [91]. Agonist potency determines the extent and rate of
cargo release, stronger agonists such as thrombin and collagen prompted rapid
release that was extensive and maximal compared to weaker agonists such as PAR4peptide that elicited a lower degree of release. Agonist-induced secretion was
random and heterogeneous in nature bearing no thematic pattern in the distribution
of cargo within the releasates [91]. However, reports explaining the differential
release of proangiogenic and antiangiogenic factors in response to specific agonists
suggest that the observed platelet release heterogeneity could be a function of
partial platelet activation [567-569]. Platelet stimulation by the “immune agonists”
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such as the Toll-like receptor ligands and HIV-1 pseudovirions, are markedly slower
in their kinetics and have a less extensive release, irrespective of the dose of agonist
or time of stimulation, a phenomenon that could be attributed to partial platelet
activation. Our findings are corroborated by previous reports showing differential
activation of signaling pathways, differences in alpha granule release, and unique
protein-protein interactions when platelets were stimulated with thrombin versus
when they were stimulated with Pam3CSK4, a TLR2-specific agonist [447].
Additionally, bacteria-induced platelet aggregation proceeds after a lag time,
dependent on the bacterial density that lasts between 3-20 min, as compared to
thrombin or ADP-mediated hemostatic responses which reach maximal activation in
less than 3 min [538]. Taken together, these data suggest that platelets can interpret
between various kinds of activating stimuli and respond accordingly. While we have
not yet tested the platelet “secretome” in response to TLR/HIV-1 agonists using
antibody arrays similar to the ones used in [91], it could be possible that response to
“immuno-agonists” elicits differential releasates compared to hemostatic agoniststimulated releasates. While hemostatic-stimulation gives rise to factors and
mediators that allow containment of vascular damage by sealing the breached
endothelial vessel walls, thereby initiating a cascade of responses that lead to
hemostasis and thrombus formation; immune-stimulation may elicit platelets to
release immunomodulators that either allow platelets to directly annul the
pathogenic threat (ways how these works have been explained in the introduction
under platelet-bacterial/viral interactions) or alert the surveilling professional
immune cells to eliminate the infectious damage. A low-grade of activation may be
sufficient to generate an “immunomodulatory phenotype” for platelets, while at the
same time preserving its inherent hemostatic activities. This feature harkens back to
the evolutionary nature of platelets, having been descended from the primordial
hemocytes that were capable of hemostasis, coagulation and immune functions
[435]. How this differential response works, in terms of what signaling pathways it
activates, potential differences in calcium transients (which effectively determine
agonist potency in mediating aggregation and eventual thrombus formation [570])
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etc, are some of the potential future questions that will help uncover the basis of this
differential response.
Differential usage of the SNARE-machinery may provide useful insights into
differential responses of the platelet release reaction to “immune” versus
“hemostatic” stimuli. Major SNAREs that are essential for release from all three
classes of granules are VAMP-8 [201], SNAP-23 [39, 198, 210-212] and syntaxin 11
[209]. Loss of VAMP-3 does not affect platelet secretion [202] while the loss of
VAMP-7 preferentially affects alpha granule release [203]. Loss of VAMP-8 has less
effect on dense core granule but profoundly affects alpha granule and lysosomal
secretion [201]. Loss of syntaxin 11 affects serotonin release from dense granules
and PF4 release from alpha granules more than it affects β-hexosaminidase release
from lysosomes [209]. Loss of SNARE regulator, Munc18b, has a similar phenotype to
syntaxin 11 [216]. These differences in affecting release reactions from the three
granules suggest heterogeneity between fusogenic SNARE complexes. While other
SNAREs can participate in forming fusogenic SNARE complexes, the efficacy of
secretion is maximal when VAMP-8/SNAP-23/syntaxin 11 complexes are formed. Can
platelets utilize different SNARE complexes to mediate differential secretion in
response to different secretagogues (“immune” versus “hemostatic”)? Future
investigations will be required to answer this question in greater details.
Platelets endocytose HIV-1 using Dynamin, VAMP-3, and Arf6-mediated pathways
Platelets and megakaryocytes have been shown to endocytose HIV-1 viruses [542,
263] into an endosomal-like vacuole, thought to be part of the OCS in platelets [263].
Megakaryocytes utilize CD4 to bind to HIV-1 [547] whereas platelets, which lack CD4,
utilize CLEC-2 and DC-SIGN to bind the virus [550]. However, the molecular
machinery required to mediate viral endocytosis is unknown in platelets. Data
presented in this thesis provides the first report on the elements of the platelet
endocytic machinery that mediate HIV-1 uptake in platelets. Our studies show that
Dynamin, VAMP-3, and Arf6 are at least some of the proteins that mediate viral
endocytosis.
Enveloped viruses, such as HIV-1, require endocytosis for entry into cells. Surface
viral glycoproteins such as Env (gp120), interact with CD4 and coreceptors such as
172

CCR5 or CXCR4 to allow initial binding [571]. Except for CD4, platelets express
members of the CXCR family including CXCR4 [549]. Following binding, it is thought
that HIV viruses fuse with endosomes and macropinosomes [572-573]. Clathrinmediated endocytosis is thought to play a role in viral uptake as inhibition of this
route of endocytosis reduces the efficacy of viral fusion and infection in HeLaderived cells [574]. Use of dynasore, the small molecule inhibitor that blocks
Dynamin activity [577], inhibits HIV-1 uptake, fusion, and infection in TZM-bl cells
[575]. Using similar conditions as in Miyauchi et al. 2009 [613], we treated mouse
platelets with Dynasore (80 µM) to determine the effects on HIV-1 mediated platelet
activation. It is to be noted here, Dynasore concentrations were selected so as to not
affect platelet granule secretion [351 and data not shown]. Dynasore treatment
inhibited HIV-1 pseudovirion-mediated activation of platelets, leading to a reduction
in levels of phospho-Akt and phospho-SNAP-23. This result indicates that, like
monocytes and T-cells, HIV-1 requires Dynamin-mediated activity to enter platelets,
possibly via clathrin-mediated endocytosis. Dynamin2 has been specifically shown to
be required for the enhancement of HIV-1 infection by directly interacting with HIV-1
virulence factor Nef [585]. Inhibition of Dynamin2 activity, using either dominantnegative DNM2 or siRNA against DNM2, inhibited Nef-mediated HIV-1 infectivity of
293T cells. Incidentally, Dynamin2 is rather abundant in mouse platelets and also
present in human platelets [343], hence it could very easily play a role in HIV-1
endocytosis in platelets and possibly contribute to subsequent activation.
Plasmacytoid dendritic cells utilize a similar Dynamin-dependent endocytosis to
uptake HIV-1 virions and upon CD4-mediated entry; virus gets trafficked through
endosomal compartments that stained positive for EEA1, Rab5, Rab7, Rab9 and
LAMP-1 [576]. A study in plasmacytoid dendritic cells shows time-dependent
trafficking of the virions starting from the early endosomes (EEA1-positive and Rab5positive compartments) to late endosomes (Rab7-positive and Rab9-positive
compartments) and eventually to lysosomes (LAMP-1-positive) [576]. HIV-1mediated plasmacytoid dendritic cell activation as measured by interferon-α
production was significantly reduced upon dynasore treatment. It is thought that
HIV-1 viral particles get trafficked to the late endosomes and lysosomes, where it
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gets degraded. As a result, blocking lysosomal degradation and/or endosomal
acidification process leads to increased viral infection and concomitant IFN-α
production [473, 578-582]. Viral particles colocalize with Rab7 and Rab9 and LAMP-1,
indicating endolysosomal compartments, where the virus gets degraded, releases
viral nucleic acids (in this case ssRNA) that can then interact with endosomal Toll-like
receptors like TLR7 [473, 583, 584, 580].
How much of this process occurs in platelets? Platelets contain various RabGTPase
markers such as Rab4, Rab11, Rab7, and Rab5 among others. We have shown the
presence of two distinct endosomal populations, Rab4+ early endosomes and Rab11+
recycling endosomes [19]. TLR7 is present in platelets [472]. Treatment of platelets
with ammonium chloride, which inhibits the acidification of endosomes, leads to a
reduction in Akt and SNAP-23 phosphorylation in mouse platelets and a reduction in
IκB phosphorylation and subsequent platelet-neutrophil aggregate formation in
human platelets and human whole blood respectively. Given that most of the
endocytic machinery and signaling components required for HIV-1 entry and
subsequent IFN-α production in plasmacytoid dendritic cells are present in platelets,
ongoing and future experiments will determine whether HIV-1 follows a similar route
of endocytosis in platelets or not.
Arf6, the Ras-like small GTPase, which is involved in integrin trafficking and
fibrinogen uptake in platelets has also been shown to be involved in the pathogenic
invasion of various cell types [587-590]. Arf6 is also required for HIV-1 endocytosis in
T-cells [586]. Use of siRNA against Arf6, or inhibiting Arf6 function by using GDPbound or GTP-bound inactive mutants, led to a decrease in HIV-1 viral membrane
fusion, entry and infection of T lymphocytes. Furthermore, Arf6 inhibition impaired
cell-to-cell transmission of HIV-1 viral particles in CD4+-T lymphocytes. On the other
hand, VAMP-3/Cellubrevin has been critical for phagocytosis of pathogens and
various particles [416-417]. However, the importance of VAMP-3 in mediating HIV-1
endocytosis is unclear.
In our ex vivo assay, endocytosis of HIV-1 pseudovirions is dramatically impaired in
both VAMP-3 and Arf6 KO platelets. This is the first report to show the importance of
two critical endocytic regulators in platelets that drive pathogen internalization. Wild
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type platelets endocytose more pseudovirions in a time-dependent manner. On the
other hand, KO platelets have hardly any pseudovirions in them and viral endocytosis
remains impaired even over prolonged periods of time. Consistently, when HIV-1
pseudovirions were intravenously injected through the retro-orbital sinus of VAMP-3
KO mice, a severe defect in viral uptake was noted in these platelets even after 24
hours post-injection. Taken together, our data suggests that both VAMP-3 and Arf6
are required for HIV-1 entry into platelets.
Since HIV-1 binds to CLEC-2 and DC-SIGN on platelets and requires Dynamindependent clathrin-mediated endocytosis, we posit that HIV-1 entry utilizes similar
receptor-mediated endocytic routes that Fg uses in platelets and thereby could
colocalize with Fg. In fact, preliminary data obtained from 3D super-resolution
microscopy confirms this hypothesis (data not shown). Colocalization of HIV-1
pseudovirions with Fg increases over time while colocalization with low mol. wt.
dextran (fluid-phase pinocytosis marker) is very limited, corroborating our earlier
observations of differential sorting of receptor-mediated and fluid-phase cargos.
However, immunofluorescence experiments to demonstrate colocalization with
endosomal and platelet granule markers still need to be performed to pinpoint
specific endocytic routes of HIV-1 in platelets. It is interesting to note, that platelets
somehow can interpret between two different physiological cargos and respond
accordingly, despite using a similar route of endocytosis. For example, Fg enters
platelets and eventually traffics through the early endosomes, to multivesicular
bodies and ends up in alpha granules. Fg uptake does not activate platelets or cause
any overt physiological changes, yet HIV-1 endocytosis activates platelets enough to
cause Akt and SNAP-23 phosphorylation and mediate granule secretion in the form
of P-selectin exteriorization. How platelets make this distinction, pose an interesting
question, and add to the budding complexity of the platelet endomembrane system,
than previously imagined.
Mechanisms of platelet activation upon HIV-1 endocytosis
Patients with HIV-1 infections show up in the clinics with severe thrombocytopenia
that is commonly associated with increased plasma markers of platelet activation
[468], including increased plasma levels of PF4, increased platelet-leukocyte
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aggregates, and increased sCD40L levels [551]. HIV-1 trans-activator of transcription
protein (Tat) directly activates platelets to release sCD40L in a CCR3 and β3 integrindependent manner [552]. Various soluble endothelial activation markers like sVCAM1, sICAM-1, and von Willebrand Factor levels are higher in HIV-1 infected patients
[544]. In a simian immunodeficiency virus (SIV)/macaque model, acute SIV infection
causes

increased

surface

expression

of

P-selectin,

CD40L,

and

major

histocompatibility complex class I [591], with a drop in circulating platelet counts.
Acute infection led to an increase in monocyte counts, which led to increased
platelet-monocyte aggregates in the bloodstream, contributing to the observed
thrombocytopenia. Infection with HIV-1 is associated with a 50% increase in risk of
acute myocardial infarction in a Veterans Aging Cohort Study Virtual Cohort of 82,
459 participants that were HIV-1+, beyond that explained by all standard
Framingham risk factors such as HIV status, age, sex, race/ethnicity, hypertension,
diabetes, dyslipidemia, smoking, hepatitis C infection, body mass index, renal disease,
anemia, substance use, CD4 cell count, HIV-1 RNA, antiretroviral therapy, and
incidence of acute myocardial infarction (MI) [592]. Given that platelet hyperactivity
contributes to acute MI, this study provided important insights into how prolific
platelet hyperactivation is in chronically infected HIV-1 patients. In essence, as antiretroviral therapies prolong lifespans of HIV-1+ patients, it makes them increasingly
susceptible to cardiovascular-related ailments such as acute MI. The severity of HIV1 infection strongly correlates with thrombocytopenia and platelet activation, yet
the molecular mechanisms of how this activation occurs remain unclear.
In nucleated immune cells such as plasmacytoid dendritic cells, responses to HIV-1
are mediated by virus phagocytosis/endocytosis, degradation to release ssRNA (in
the case of HIV-1), and subsequent TLR7 receptor activation. While platelets use
more or less similar strategies to endocytose and respond to the viral particles, much
to our surprise, ablating TLR7, only causes a partial reduction in platelet activation.
Clearly, HIV-1 activation of platelets utilizes both TLR-dependent and TLRindependent pathways. A possible explanation for this partial reduction in platelet
activation, as measured by Akt and SNAP-23 phosphorylation, could be due to
activation of the CLEC-2 receptor and its downstream signaling pathways, that in and
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of itself, are potent platelet activation receptors. HIV-1 binding to CLEC-2 could
activate

these

pathways

leading

to

Akt

phosphorylation

and

SNAP-23

phosphorylation [593]. DC-SIGN, the other HIV-1 binding receptor on platelets, does
not induce any downstream activation signals [543]. The CXCR family of coreceptors
that can bind to HIV-1 and are present on platelets do not elicit any platelet
activation responses either [549]. There could be some other signaling cascade being
turned on by HIV-1 endocytosis in platelets that we do not know of, as yet. However,
it does indicate that HIV-1-mediated activation of platelets is indeed, a complex
interplay of multiple signaling pathways. This poses as a double-edged sword
because, on one hand, therapeutic interventions to target one signaling pathway
over another allows partial disruption of activation, thereby dampening levels of
platelet activation markers while preserving some normal functions of platelets; this
is advantageous. However, the flipside to this problem is the challenge to design
drugs that do not have any adverse side-effects on other cell types, which perhaps
need those signaling pathways to function properly.
Role of autophagy in mediating platelet activation upon HIV-1 endocytosis
Platelets have been shown to contain autophagosomal structures and autophagy
plays vital roles in mediating proper platelet function and hemostasis [240].
Autophagy is induced upon platelet activation. Agonists such as thrombin, convulxin
initiate platelet signaling cascades that lead to loss of autophagy marker LC3II and
requires proteolytic degradation, endosomal acidification and SNARE-membrane
fusion (involvement of VAMP-2, VAMP-3, and VAMP-8) [240].
Several recent reports have shown autophagy induction upon TLR stimulation [594598]. LPS causes TLR4-mediated autophagy induction in mouse macrophages as
demonstrated by the GFP-LC3 puncta formation, with LPS inducing an increased
amount of lipidated LC3II in these cells [597]. TLR7 stimulation by ssRNA and
imiquimod also induced autophagy in RAW264.7 macrophages, leading to increased
puncta formation (denoting autophagosomes) and LC3II formation in the presence of
pH-tropic drugs like Bafilomycin A (that blocks autophagosomal maturation by
inhibiting LC3II degradation) [595]. TLR7-mediated autophagic induction requires
MyD88 and is thought to utilize Beclin-1, a critical regulator of autophagy, (and is
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present in platelets) [595]. It is thought that TLR7-mediated autophagic induction
proceeds in a similar fashion to starvation-, rapamycin- or LRG47-induced autophagy
[599]. In HeLa cells and plasmacytoid dendritic cells infected with HIV-1, autophagy
was induced as measured by LC3II formation, upon binding of ssRNA to TLR7 [595,
598]. The speculative model is that viral PAMPs (HIV-1 ssRNA) are introduced to
TLR7+-endosomes via autophagic degradation of the viral nucleocapsid. Once TLR7
binds to ssRNA, it signals through MyD88 and IRF7 to trigger activation of type I IFN
and other cytokine genes, which play critical roles in innate immunity and
pathogenesis of HIV-1 [498, 600].
How much of this process recapitulates in platelets remains to be seen? Whether
platelets utilize the autophagosomal machinery to respond to HIV-1 also remains to
be seen. Ongoing experiments are investigating whether HIV-1 viral particles, upon
endocytosis, gets trafficked to autophagosomes and colocalize with GFP-LC3 puncta.
Does HIV-1 stimulation of platelets cause an induction of autophagy, leading to more
GFP-LC3 puncta and formation of LC3II? Does TLR7 stimulation (by Loxoribine and
Imiquimod) of platelets leads to increased LC3II levels and increased puncta
formation? Using GFP-LC3 mice, we can answer these questions.
In mouse platelets, preliminary studies show that Loxoribine (TLR7) and CpG ODN
(TLR9)-mediated activation leads to a time-dependent phosphorylation of Akt and
SNAP-23 and loss of Atg7 or Beclin-1 had no effect on these activation profiles,
whereas HIV-1 pseudovirion stimulation of Atg7 KO platelets led to a partial
reduction in Akt and SNAP-23 phosphorylation. While LC3II levels were not yet
measured in these assays, these results suggest that viral degradation in platelets
possibly require autophagosomal machinery but some of the other TLR7 ligands
might not. Is this due to the differential sorting of cargo? Small molecules like
Loxoribine and Imiquimod could utilize the fluid-phase endocytic pathway in
platelets to reach TLR7+-endosomes for active signaling and thus may bypass
trafficking through autophagosomes. Contrary to that, HIV-1 pseudovirions use the
receptor-mediated pathway and require some degree of degradation in order to
generate functional ligands for signaling in TLR7+-endosomes and hence are directed
to the autophagosomes? Further investigation using immunolocalization studies will
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help answer these questions. Whatever might be the case, these results will further
shed light on how complex endocytic trafficking and cargo sorting might be in
platelets.
Global importance of platelet endocytosis in HIV-1 infection
Our current work clearly suggests that HIV-1-mediated activation of platelets
requires endocytosis. Using endocytosis mutants (VAMP-3 and Arf6 KO) that are
affected by one or more steps of endocytic uptake and trafficking in platelets, we
demonstrate for the first time that endocytosis of physiological cargo leads to
activation of platelet signaling cascades that cause granule secretion and formation
of platelet-leukocyte aggregates, considered to be a marker of active inflammation
in the bloodstream. Since activation-induced platelet sequestration from circulation
leads to thrombocytopenia, a common occurrence in HIV-1 infections, it stresses the
importance of endocytosis in mediating platelet responses to HIV-1 infection. Our
studies would indicate that platelets come into play in the initial stages of viral
infection, required for early detection of the viral particles in the bloodstream via
their surveillance mechanisms. This could happen when HIV-1 enters a new host
through blood transfusions, sharing needles with HIV-1 infected individuals etc.
Platelets take up the virus when they encounter it and process it to initiate a
response. This response may simply be manifested by P-selectin exteriorization on its
surface, which acts as a “beacon of damage” and alerts patrolling immune cells. It is
the immune cells e.g., T cells, dendritic cells, macrophages, monocytes and
neutrophils (or cells that express the cognate PSGL-1) that detect P-selectin-bearing
platelets and do the bulk of the immune responses. As a result, platelet endocytosis
may be an essential necessity for mounting appropriate immune responses against
the virus. Viruses such as HIV-1 often develop strategies to avoid interactions with
endolysosomes, where viral degradation occurs to initiate responses, by hijacking
components of the endocytic machinery and trapping themselves inside endosomal
organelles to evade immune-mediated detection and killing [601]. Viruses hiding
within endosomes may then utilize the host cell as a “Trojan Horse” to facilitate cellto-cell transmission and viral dissemination throughout the vasculature. This
portends that viral endocytosis may have deleterious effects and devise ways to
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interrupt endocytosis may have beneficial effects in mitigating viral spread and
infection. Whether the same occurs in platelets is unclear, but our endocytosis
mutants may provide some useful insights into the global importance of platelet
endocytosis in HIV-1 viremia and infections.
A mouse model of HIV-1 infection that mimics most of the viral etiology and disease
progression in humans has become increasingly beneficial in understanding HIV-1
infection, viral replication, control and pathogenesis [602]. These murine HIV-1
viruses, called Eco-HIV viruses can be made to target mouse cells by replacing the
coding region of gp120 in HIV-1/NL4-3 viruses with that of gp80 from the ecotropic
murine leukemia virus, a ssRNA-bearing retrovirus that targets only mice and rats
[602]. This chimeric Eco-HIV virus was shown to infect mouse lymphocytes only and
replication within mouse cells led to the production of infectious viruses that caused
neuroinvasiveness by breaching blood-brain barrier (BBB). Eco-HIV viruses are
detected in spleen and brain as early as 3 weeks post-inoculation of the virus into
mice and lead to expression of pro-inflammatory infectious response genes such as
MCP-1, STAT-1, and IL-1β etc. Co-incidentally, studies done by Jones et al. [603]
showed that mice infected with Eco-HIV showed increased blood-brain barrier
permeability as early as 2 weeks post-injection. These mice also had increased
plasma levels of sCD40L and PF4, both signs of platelet activation. Inhibiting platelet
function using eptifibatide (that antagonizes normal αIIbβ3 function), restored BBB
permeability, sCD40L, PF4 levels and P-selectin expression, indicating platelet
activation is important for the neuroinflammatory phenotype and breach of BBB in
Eco-HIV infected mice. These studies will be the basis for our planned future
experiments to answer whether platelet endocytosis of Eco-HIV is beneficial or
exacerbates viral infection and neuroinvasiveness.
We have obtained the Eco-HIV viral constructs from Dr. Volsky’s group and have
prepared the Eco-HIV viruses. We seek to determine the effects of Eco-HIV infection
in our VAMP-3 and Arf6 KO mice. We will inject Eco-HIV viruses into VAMP-3 and
Arf6 and littermate controls and probe for platelet activation markers (plasma PF4
and inflammatory cytokine levels, platelet-leukocyte aggregates), BBB permeability
(using fluorescent tracers such as sodium fluorescein), signs of viral replication (via
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measuring p24 antigen levels) in plasma and tissues, platelet counts to determine
thrombocytopenia at different timed intervals (24 hr, 2 weeks, 4 weeks and 6 weeks).
At the end, survival measurements will also be done. Preliminary ex vivo analyses
show that Eco-HIV infects mouse platelets and activates them. Eco-HIV induced Akt
and SNAP-23 phosphorylation in a time-dependent manner similar to HIV-1
pseudovirions. This phosphorylation was also inhibited by Dynasore-, ammonium
chloride-, and protease inhibitor cocktail, suggesting that activation responses to
Eco-HIV require Dynamin-dependent endocytosis, trafficking to acidic compartments
and some sort of proteolytic degradation to break down the viral capsid to release
ssRNA, which then activates platelets. So far, Eco-HIV behaves in a similar fashion to
HIV-1 pseudovirions, at least in the ex vivo analyses. Our proposed studies will,
therefore, be instrumental in answering the global importance of platelet
endocytosis in HIV-1 viral infection. The Arf6 KO mice are of special importance in
these assays because they are platelet-specific mutants and hence will be useful in
isolating the platelet endocytosis contribution to the HIV-1 disease progression and
outcomes.
Given that chronic HIV-1 infection increases risk of acute MI [592], it would be
interesting to test the Eco-HIV infected VAMP-3 and Arf6 KO mice and their wildtype
counterparts, in various models of arterial thrombosis (FeCl3-induced carotid artery
injury model, laser-induced vessel wall injury model) and coronary artery ligation
models to induce MI [604], to determine whether chronic viral infection leads to a
prothrombotic state and whether modulating endocytosis alters the experimental
outcomes.
Targeting platelet endocytosis for therapeutic interventions
Jones et al. 2016 [603] have shown that use of the antiplatelet drug, eptifibatide
(marketed commercially as Integrilin) reduces platelet activation associated
outcomes in Eco-HIV infection in mice. This would indicate that antiplatelet drugs
ameliorate the disease outcomes in HIV-1 infections. However, if platelets are
involved in the initial recognition of HIV-1 viruses in the bloodstream and help the
other immune cells in mediating immune responses to the virus, inactivating platelet
function might be imprudent. This becomes a challenge, especially in patients with a
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chronic HIV-1 infection that show an increased propensity to acute MI or stroke,
where administration of antiplatelet and antithrombotic drugs is necessary. Suffice
to say, role in platelets in HIV-1 infection is complex and our current intervention
strategies to mitigate aberrant platelet activation should be re-evaluated.
While anti-retroviral therapies (HAART) have been successful in reducing markers of
endothelial and platelet activation such as P-selectin and CD40L levels in HIVinfected patients [554], in some instances it has been shown to cause bleeding
problems in patients, in part, due to aberrant dysfunction of platelets by some of the
nucleosidase reverse transcriptase inhibitors (NRTIs) type anti-retroviral drugs [468].
For example, NRTI drugs, like Abacavir, which bear structural similarities with
endogenous purine bases, induce platelet adhesion to endothelial cells by directly
affecting the ATP-binding P2X7 purinergic receptors on endothelial cells. Abacavir
activates endothelial cells and causes endothelial cell ICAM-1 to bind to surfaceexpressed αIIbβ3, GPIbα and also with P-selectin on platelets. This helps in recruiting
more platelets, facilitating adhesion and aggregation [610]. These studies indicate
that drug-induced platelet-endothelium dysfunctions may exacerbate cardiovascular
complications in HIV-1 patients on ART. Platelets in these patients already have a
heightened state of activation with a predisposition to thrombosis-related problems
such as MI and stroke. Hence, care must be taken to determine drug side-effects in
HIV-1 patients to prevent platelet-related cardiovascular complications.
pH-tropic drugs like chloroquine have proven to be beneficial in ameliorating
systemic T-cell

immune

activation [605]. When hydroxychloroquine

was

administered to 20 HIV-1 infected patients, it reduced immune activation,
production of pro-inflammatory cytokines (IL-6 and TNF-α) and helped increase Tregulatory cell counts and CD4+ T cell counts [606]. Chloroquine is not thought to
adversely affect platelet functions, except for inhibiting acidification of endosomal
compartments and autophagosomes [240]. Thus, if platelet endocytosis of HIV-1
virus exacerbates the severity of infection, treating platelets with chloroquine
provides a useful strategy to modulate immune responses targeted towards HIV-1,
without affecting the hemostatic functions of platelets.
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Finally, understanding how platelet endocytosis works will prove to be beneficial in
uncovering strategies for novel therapeutics. Current antiplatelet and antithrombotic
therapies dampen platelet function in general; it is unclear whether the use of these
drugs is also dampening platelets’ role in other normal and essential aspects of
platelet functions, namely immune-related functions. Both arms of platelet vesicle
trafficking, endocytosis, and exocytosis, is important for platelet function. Exocytosis
is more important for hemostasis and thrombosis while it appears that endocytosis is
more crucial in mediating non-hemostatic functions of platelets, such as immunerelated and cargo trafficking functions. However, designing therapeutics that
specifically affect one arm of trafficking without affecting the other might prove to
be beneficial in modulating cardiovascular diseases. Thus, understanding the
mechanisms and routes of platelet endocytosis enables us with an alternative
approach to load platelets with therapeutic cargos that can then modulate platelet
responses paving the way to effectively treat cardiovascular diseases.
Final comments
While platelet endocytosis has been known to be important for granule cargo
loading since the 1980s, other physiological functions have not been clearly defined.
Work presented here shows for the first time, that platelets actively endocytose
physiological cargo (Fg) and pathogens such as HIV-1 viruses, interpret and sort
between different classes of cargos and can then mount appropriate responses.
Whether other viruses or bacteria can utilize VAMP-3 and Arf6-mediated
endocytosis to infect platelets remains to be seen. It has been known for decades
that certain cargo molecules in platelet granules are internalized and packed in
platelets through either receptor-mediated endocytosis (e.g. fibrinogen), or
pinocytosis (e.g. immunoglobulin, albumin). Therefore, endocytosis is a key
mechanism for modulating platelet granule content and thus may be important for
other platelets functions. How important endocytosis is in mediating platelet
activities in wound healing, tumor metastasis, and cancer, angiogenesis etc. also
remains to be seen.
Endocytosis is a multi-step process that utilizes several routes of entry-transit-exit of
cargo. Our data suggests that many of these paths are present and active in platelets.
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Clearly, VAMP-3 and Arf6 mediate some, but not all of the key steps that facilitate
αIIbβ3-mediated Fg uptake, integrin trafficking, and the dynamic processes that affect
contact-based signaling i.e., spreading and clot retraction. Endocytosis may also
allow platelets to actively interact with their environment and interpret damage
signals in the form of circulating pathogens and infectious agents. VAMP-3 and Arf6,
both appear to be critical for mediating these responses. Platelets’ ability to
endocytose and sort between different kinds of cargos provides them with the ability
to differentially respond to them. In essence, platelets act as the “vacuum cleaners”
of the vasculature, surveilling for damage (physiological and pathological) and
respond in a graded manner, much like a rheostat. There is clearly a robust fluidphase pinocytosis activity in platelets for taking in a host of small molecules. Future
studies will uncover even more kinds of cargo molecules that platelets can
internalize. Future studies will also uncover other potential endocytic regulators in
platelets that modulate platelet functions.
Our studies provide unique mechanisms of how platelets utilize endocytosis as a tool
to monitor their micro-environments. Platelet endocytosis for acute physiological
functions, i.e., detecting pathogenic bacteria and viruses, damage molecules (DAMPs)
champions novel functions of platelets that extend beyond cargo packaging and
granule biogenesis and perhaps even hemostasis. Endocytosis may be a way for
platelets to communicate not just with other cells in the circulation viz. neutrophils,
monocytes, macrophages, T and B lymphocytes but also with its parental
megakaryocytes, to modulate thrombopoiesis and megakaryocyte functions. The
VAMP-3 KO mice described here and the Arf6 described previously [19] offers us
means to answer some of these questions and allows us to parse the complexity of
platelet endocytosis and to define its physiological relevance.
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Appendices
ABBREVIATIONS

ADP

Adenosine diphosphate

Arf6

ADP-ribosylation factor 6

ATP

Adenosine triphosphate

CLEC-2

C-type Lectin domain family member-2

DAB-2

Disabled-2

DAMP

Damage-associated molecular pattern

EC

Endothelial cells

ECM

Extracellular matrix

EE

Early endosome

ER

Endoplasmic reticulum

ERC

Endocytic recycling compartment

Fg

Fibrinogen

FAK

Focal adhesion kinase

GAP

GTPase-activating protein

GDP

Guanosine diphosphate

GEF

Guanine nucleotide exchange factor

GPCR

G protein-coupled receptor

GPI

Glycosylphosphatidylinositol

GPVI

Glycoprotein VI

GSK

G protein-coupled receptor kinase

GT

Glanzmann thrombasthenia

GTP

Guanosine triphosphate

HIV-1

Human Immunodeficiency Virus-1

ITIM

Immunoreceptor tyrosine-based inhibitory motif
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ITAM

Immunoreceptor tyrosine-based activation motif

LPS

Lipopolysaccharide

LC3

Microtubule-associated protein 1A/1B-Light Chain 3 (LC3)

LC3II

LC3-Phosphatidylethanolamine conjugate (LC3II)

MAPK

Mitogen-activated protein kinase

MHC

Major Histocompatibility Complex

MVB

Multivesicular bodies

MI

Myocardial Infarction

NETs

Neutrophil extracellular DNA traps

NSF

N-ethylmaleimide-sensitive factor

OCS

Open Canalicular System

PAMP

Pathogen-associated molecular pattern

Pam3CSk4

Palmitoylated (tri)CysSerLys4

PDGF

Platelet-derived grow factor

PF4

Platelet factor 4

PGI2

Prostacyclin I2

PI(4,5)P2

Phosphatidylinositol 4,5-bisphosphate

PI3K

Phosphoinositide 3-kinase

PIP5K

Phosphatidylinositol 4-phosphate 5 kinase

PKC

Protein Kinase C

PKD

Protein kinase D

PLC

Phospholipase C

PLD

Phospholipase D

PNRC

Perinuclear recycling compartment

PPP

Platelet poor plasma

PRP

Platelet rich plasma
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RBC

Red blood cells

RGDS

Arginine-glycine-asparagine-serine acid

RANTES
secreted

Regulated on activation, normal T cell expressed and

SFK

Src family kinase

SH2

Src homology 2

SNAP

Soluble NSF attachment proteins

SNARE

Soluble N-ethylmaleimide-sensitive fusion protein
attachment receptor

SNPs

Single nucleotide polymorphism

TLR

Toll-like Receptor

TNF-α

Tumor Necrosis Factor-alpha

TfR

Transferrin receptor

TPOR

Thrombopoietin receptor

TXA2

Thromboxane A2

VAMP

Vesicle-associated membrane protein

VEGF

Vascular endothelial growth factor

vWF

von Willebrand Factor

WBC

White blood cells

3D-SIM
complex

3-dimensional structured illumination microscopy regulatory
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